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Introduction
Paraneoplastic neurological syndromes (PNS) are remote effects of cancer that are 
neither caused by invasion of the tumor or its metastasis, nor by infection, ischemia, 
metabolic and nutritional deficits, surgery or other forms of tumor treatment.1 PNS 
cause severe neurological disability and carry a poor prognosis. In PNS patients, vari-
ous antibodies (Abs) have been found directed at neuronal antigens that are also ex-
pressed by the associated tumors in most cases. In 2004, the term ‘well characterized 
onconeural Ab’ was defined based on (1) Abs for which there are recognisable patterns 
on routine immunohistochemistry and for which immunoblotting on recombinant 
proteins must be used to confirm their specificities; (2) the number of cases reported 
associated with tumours; (3) the description of well characterised neurological syn-
dromes associated with the antibodies; (4) the unambiguous identification of the Abs 
among different studies, and (5) the frequency of these Abs in patients without cancer.2 
These ‘well-characterized’ onconeural Abs are by definition almost exclusively found 
in patients with cancer and include anti-Hu, Yo, CV2, Ri, Ma2 and amphiphysin.2 
Recently, the anti-Tr antigen has been identified as the transmembrane protein Delta/
Notch-like epidermal growth factor-related receptor (DNER). Anti-DNER is thightly 
associated with Hodgkin lymphoma, and can therefore be considered a ‘well-char-
acterized’ onconeural Ab, although DNER is not expressed by Hodgkin lymphoma.3 
Anti-Hu is the most frequent well characterized onconeural Ab and usually associated 
with paraneoplastic encephalomyelitis and sensory neuronopathy.4 This thesis will 
focus on the immunopathogenesis of PNS with well-characterized onconeural Abs, in 
particular those with anti-Hu Abs (Hu-PNS).
IMMUNOPATHOGENESIS OF HU-PNS
Anti-Hu Abs are directed at a family of RNA-binding proteins (HuD, HuC, Hel-N1 
and HuR).5 Three of these proteins (HuD, HuC and Hel-N1) are exclusively expressed 
by neurons, and antibody titers against these three proteins are much higher than 
those against HuR indicating that the immunoreactivity against HuR represents 
cross-reactive antibody specificities directed against conserved sequences in the fam-
ily.6 In addition, only HuD and Hel-N1 are expressed by small cell lung cancer and 
small cell lung cancer cell lines.5,7 The presence of high titers of anti-Hu Abs in the 
blood and cerebrospinal fluid of Hu-PNS patients led to the hypothesis that Hu-PNS 
are caused by an immune response triggered by Hu expression in tumor cells that is 
subsequently also directed at Hu-expressing neurons.8 Additional evidence for this 
immune response is found in HLA-associations9, intrathecal antibody production10, 
cerebrospinal fluid (CSF) pleocytosis11, and infiltrates of oligoclonal cytotoxic T cells 
around damaged neurons at autopsy.12-15 Since immunization of animals against HuD 
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did result in high titer anti-Hu antibodies but no disease, it was hypothesized that 
the anti-Hu antibodies were not pathogenic.16 Furthermore, these studies showed 
that anti-Hu antibodies did not enter neurons and bind the intracellular Hu-proteins, 
suggesting that the observed intraneuronal IgG accumulation in autopsy studies in 
humans may have resulted from a postmortem artefact.16 Hence, it seems more likely 
that cytotoxic CD8+ T cells are responsible for neuronal destruction in Hu-PNS, as 
supported by the CD8+ T cell infiltrates around damaged neurons found at autopsy.16,17
DETECTION OF HUD-SPECIFIC T LYMPHOCYTES
The intracellular localization of HuD makes it inaccessible to autoantibodies, and 
therefore it is more likely that neuronal destruction in Hu-PNS is caused by HuD-
specific cytotoxic T cells. Previous studies that aimed to detect circulating HuD-specific 
T cells showed different, often conflicting results.18-25 First, it is uncertain whether or 
not HuD can elicit a specific T cell response. One study in healthy subjects and mice 
reported that the HuD protein can elicit a T cell response,22 whereas another study 
in mice reported tolerance to the HuD protein.23 Second, it is unclear which epitopes 
within the HuD protein are the targets of the hypothetical T cell response. Previously, 
we24,25 could not confirm T cell responses to T cell epitopes that were identified by 
others.18,22 More recently, Roberts et al.21 reported T cell responses to the HuD-derived 
T cell epitopes Hu133 and Hu157 that have not been confirmed by others until now. 
Third, it is unclear which cytokines are produced by HuD-specific T cells. Previously, 
classical IFN-γ producing CD8+ T cells were described,18 whereas Roberts et al. also 
reported ‘type 2’ CD8+ T cells that secreted robust amounts of the type 2 cytokines 
IL-4, IL-5 and IL-13.21 The detection and further characterization of any HuD-specific T 
cells is potentially relevant to patients with Hu-PNS, since these cells could serve as 
a target for specific therapies. Detection of HuD-specific T cells could additionally be 
relevant to cancer patients. If we would be able to dissect the properties of the T cells 
that are involved in the effective antitumor immune response from the properties of 
T cells involved in the harmful antineuronal immune response, these insights could 
ultimately contribute to more effective anticancer immunotherapies.
CELLULAR COMPOSITION OF CEREBROSPINAL FLUID IN HU-PNS
In 93% of of Hu-PNS patients, signs of inflammation are present in the CSF includ-
ing pleocytosis (38%), elevated protein levels (80%), or HuD-specific oligoclonal bands 
(59%).10,26 Previously, we showed that CSF of Hu-PNS patients contained five times 
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higher numbers of CD4+ T cells and CD8+ T cells. The B cell numbers were 20 times 
higher than in non-cancer controls and cancer patients without PNS,11 which is in line 
with the intrathecal antibody-production found in these patients.10 In other neurologi-
cal inflammatory diseases, it has been shown that lymphocytes in CSF might search 
for their specific antigen and migrate to the nervous tissue to fulfil their effector func-
tions or return to the lymph nodes, depending on whether or not they have encoun-
tered their antigen.27,28 Additionally, dendritic cells (DC) were shown to be present in 
CSF and might play a role by presententation of antigens from the CNS in the CSF, 
or transport these antigens further to the deep cervical lymph nodes.29,30 Therefore, 
the CSF of Hu-PNS patients offers an opportunity to study the CNS inflammation early 
in the disease without the need for nervous tissue biopsies. Analysis of the cellular 
composition of the CSF may help to identify immune cells that are involved in disease 
pathogenesis.
TREATMENT OF HU-PNS
In patients with Hu-PNS, detection and treatment of the underlying tumor offers the 
best chance to stabilize their PNS.31 However, even after tumor treatment, only 3-6% 
of Hu-PNS patients improve one point or more on the modified Rankin scale, while 
30% deteriorate.4,31 Median survival for Hu-PNS patients is 12 months, and 60% of the 
patients die from progression of their PNS, not of their tumor.4 Hence, in addition to 
anti-tumor therapy, there is a clear need for immunotherapies to suppress the harm-
ful auto-immune response in PNS and prevent further progression of neurological dis-
ability and death. There is evidence that SCLC patients with low titers of anti-Hu Abs 
without PNS have a better tumor prognosis32 and spontaneous tumor regressions have 
been reported in Hu-PNS patients.33 These findings indicate that the immune response 
against Hu may control tumor growth and that immunotherapy may potentially sup-
press this beneficial immune response against the associated tumor.33 However, in a 
series of 51 Hu-PNS patients, no negative effect was seen of immunotherapy on the 
outcome of anti-tumor therapy.31 Hence, the severity of PNS and the poor functional 
outcome after tumor treatment alone indicate that there is a need for effective im-
munotherapy in PNS.
SCOPE OF THIS THESIS
In this thesis, we aim to further unravel the immunopathogenesis of Hu-PNS in order 
to contribute to the development of an effective immunotherapy for Hu-PNS, and 
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probably other PNS with well characterized onconeural Abs. In chapter 2, we search 
for the presence of HuD-specific T lymphocytes, using techniques especially suited 
to detect rare antigen-specific T lymphocytes, and CD8+ T lymphocytes with a ‘type 
2’ phenotype. In chapter 3 and 4, we review the use of flow cytometry to study the 
cellular composition of CSF, and investigate the role of CMV carrier status on the 
distribution of T lymphocyte subsets in CSF. These chapters provide the knowledge 
needed for the study of T lymphocyte subsets, B lymphocyte subsets and dendritic 
cells in the CSF of Hu-PNS patients (chapter 5). In chapter 6, we report our efforts to 
further enhance the possibilities of CSF flow cytometry by investigating the useful-
ness of a novel CSF-stabilizing agent. In chapter 7, we review the available evidence 
on immunotherapies in Hu-PNS and other PNS with well characterized onconeural 
Abs. Subsequently, we report the results of a clinical trial in which we treat Hu-PNS 
patients with sirolimus, an inhibitor of activated T lymphocytes (chapter 8). The main 
findings of this thesis are summarized and discussed in chapter 9.
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ABSTRACT
Anti-Hu antibody-associated paraneoplastic neurological syndromes (Hu-PNS) are 
severe and often precede the detection of a malignancy, usually small-cell lung cancer 
(SCLC). In Hu-PNS, it is hypothesized that neuronal cells are destroyed by T cells tar-
geted against HuD, a protein expressed by small-cell lung cancer cells and neurons. 
There is only limited evidence for the existence of HuD-specific T cells. To detect these 
T cells in the blood of Hu-PNS patients we employed 3 highly sensitive assays that in-
cluded T cell stimulation with dendritic cells (DCs) to specifically expand the number 
of any HuD-specific T cells. A total of 17 Hu-PNS patients were tested with 1 or more of 
the following 3 assays: (1) tetramer staining after stimulation of T cells with conven-
tionally generated dendritic cells (cDCs) (n=9), (2) interleukin (IL)-13 enzyme-linked 
immunosorbent spot (ELISpot; n=3), IL-4 and IL-5 and interferon (IFN)-γ multiplex 
cytokine bead array (n=2) to assay cytokine production by T cells after stimulation 
with cDCs, and (3) IFN-γ ELISpot and tetramer staining after T cell stimulation with 
accelerated co-cultured DCs (acDCs, n=11). No circulating HuD-specific T cells were 
found. We suggest that either autoaggressive T cells in Hu-PNS are not targeted against 
HuD, or that their numbers in the blood are too low for detection by highly sensitive 
techniques.
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INTRODUCTION
Anti-Hu antibody (Hu-Ab)-associated paraneoplastic neurological syndromes (Hu-PNS) 
are severe, have no effective treatment, and often precede the detection of a malig-
nancy, usually small-cell lung cancer (SCLC)1. Hu-PNSs are thought to be caused by 
an immune response against the HuD protein that is normally exclusively expressed 
by neuronal cells and is aberrantly expressed by SCLC cells.2 Although patients with 
Hu-PNS have high titers of autoantibodies against the HuD protein, there is no evi-
dence that these autoantibodies directly cause neuronal damage.3 The intracellular 
localization of HuD makes it inaccessible to autoantibodies, and therefore it is likely 
that neuronal destruction in Hu-PNS is caused by HuD-specific cytotoxic T cells. The 
hypothesis that these T cells cause neuronal damage is supported by autopsy studies 
that show the presence of cytotoxic T cells around neurons in the nervous tissue of 
Hu-PNS patients.4,5
Previous studies that aimed to detect circulating HuD-specific T cells showed different, 
often conflicting results.6-13 First, it is uncertain whether the HuD protein is immuno-
genic. One study reported that the HuD protein can elicit a T cell response in healthy 
subjects and mice10, whereas another study in mice demonstrated tolerance to the 
HuD protein.11 Second, it is unclear which epitopes within the HuD protein are the 
targets of this hypothetical T cell response. Previously, we12,13 could not confirm T cell 
responses to T cell epitopes that were identified by others.6,10 More recently, Roberts et 
al.9 described in 3 patients T cell responses to the HuD-derived T cell epitopes Hu133 
and Hu157 that have not been confirmed by others until now. Third, it is unclear 
which cytokines are produced by HuD-specific T cells. Previously, classical CD8+ T cells 
producing interferon (IFN)-γ were described,6 whereas Roberts et al. also reported 
‘type 2’ CD8+ T cells that secreted robust amounts of the type 2 cytokines interleukin 
(IL)-4, IL-5 and IL-13.9 The detection and further characterization of any HuD-specific T 
cells potentially could help develop specific therapies for Hu-PNS.
In this study, we aimed to confirm the presence of HuD-specific T cells in a relatively 
large group of 17 Hu-PNS patients. We used HuD-peptide loaded tetramer staining 
to detect CD8+ T cells, a combination of IL-13 enzyme-linked immunosorbent spot 
(ELISpot) and a flow cytometric multiplex bead array to detect type 2 CD8+ T cells; and 
IFN-γ ELISpot to test for classical ‘type 1’ cytotoxic T cells. All procedures included the 
use of dendritic cells (DCs) to specifically expand the number of any HuD-specific T 
cells and to gain maximal sensitivity.
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MATERIALS AND METHODS
Sample Collection and Storage
Heparinized blood was drawn from 17 Hu-PNS patients who met the following cri-
teria: high-titer anti-Hu-Abs, a definite diagnosis of PNS14, and the presence of the 
human leukocyte antigen (HLA)-A*0201 and/or HLA-A*0301 restriction element. As 
procedural controls, three healthy subjects were tested who were cytomegalovirus 
(CMV) seropositive and HLA-A*0201 and/or HLA-A*0301 positive. Peripheral blood 
mononuclear cells (PBMCs) were isolated by Ficoll density-gradient centrifugation and 
cryopreserved in liquid nitrogen as described.15 Absolute numbers of lymphocytes in 
the blood (expressed as 109 cells/L) and distribution of T cell subsets (expressed as % 
of lymphocytes) were determined by flow cytometry using a whole-blood stain, lyse, 
no-wash method based on counting beads (all patients except no. 7, 10 and 14), or with 
a hematology analyzer and a flow cytometric method that included washing steps (the 
remaining 3 patients)16. The local ethical review committee approved the study and 
written informed consent was obtained from all participants.
Proteins and Peptides
Recombinant HuD and Yo proteins were produced in Escherichia Coli and purified 
using metal affinity chromatography, essentially as described before.3 Endotoxins 
were removed by Triton-X114 phase separation.17 A HuD protein-spanning peptide 
mix (HuDm) that consisted of 93 15-mers, with 11 amino acids overlap and a CMV 
phosphoprotein-65 (pp65) protein-spanning 15-mers mix (pp65m) were obtained from 
Jerini Peptide Technologies (Berlin, Germany). The single 9-mers Hu133 (NLYVSGLPK) 
and Hu157 (RIITSRILV), selected based on the observations of Roberts et al.,9 and NLVP-
MVATV (NLV, a CMV pp65-derived peptide) were obtained from Pepscan (Lelystad, the 
Netherlands). Tetanus toxoid (TTX) was kindly provided by Dr. R. Rappuoli (Novartis 
Vaccines, Siena, Italy).
Conventionally Generated DCs (cDCs)
After thawing the PBMC, we isolated CD14+ cells by magnetic separation (Miltenyi 
Biotec, Bergisch Gladbach, Germany) and cultured them in RPMI (Roswell Part Memo-
rial Institute) with GlutaMAX (Invitrogen, Carlsbad, CA), supplemented with 1% L-
Glutamine, 10% heat-inactivated human AB serum, 1% penicillin/streptomycin, 100U/
ml IL-4 (R&D systems, Minneapolis, MN) and 100U/ml of granulocyte-macrophage 
colony-stimulating factor (GM-CSF; Immunotools, Friesoythe, Germany).18 To induce 
DC maturation, 1µg/mL prostaglandin (PG)E2 and 50 ng/mL tumor necrosis factor 
(TNF)-α were added after six days (R&D systems). After 2 additional days of culture (day 
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8), these conventionally generated DCs (cDCs) were used for in vitro stimulation of 
CD8+ T cells.
In Vitro Stimulation of CD8+ T Cells with cDCs
In parallel with the generation of cDCs, the CD14- T cell fraction was cultured for 
8 days prior to stimulation using a feeder system, as described.13 CD8+ T cell were 
isolated from the CD14- fraction by magnetic separation (Miltenyi Biotec). Depending 
on the number available, cDCs were added to the CD8+ T cells at ratios of 1:10 to 1:30. 
The CD8+ T cells and cDCs were cultured in complete culture medium (RPMI1640 with 
4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid, 1% L-Glutamine, 10% human AB 
serum and 1% penicillin/streptomycin). Peptides (Hu133, Hu157 or NLV) were added at 
a final concentration of 10 µg/mL. One day after addition of cDCs and peptides, 10 IU/
mL IL-2 (R&D systems) was added to the cultures.
In-vitro Stimulation by Accelerated Co-cultured DCs
Thawed PBMCs were incubated for 24-48 h with peptides or proteins together with 
DC-activating agents to induce DCs and stimulate T cells as described.19,20 PBMCs were 
cultured in Adoptive Immunotherapy Media-Vero (AIM-V) medium (Invitrogen) with 
1000U/mL of GM-CSF and 500U/mL of IL-4 (R&D systems). Proteins (Yo, HuD) or peptide 
mixes (HuDm, pp65m) were added at 10 µg/mL or 2 µg/mL respectively. After 24 h, we 
added DC maturation stimuli (2000 U/ml TNF-α, 20 ng/ml IL-1ß (R&D systems) and 2 
µM PGE2 (Merck Calbiochem, Darmstadt, Germany)), 1ng/mL IL-7 (R&D systems) and 
single peptides (Hu133, Hu 157 or NLV) at 10 µg/mL. After 48 h, nonadherent cells 
were collected, washed and used for IFN-γ ELISpot and tetramer staining.
Tetramer Staining
Up to 2·106 cells were stained with phycoerythrin(PE)-conjugated tetramers, anti-CD3 
fluorescein isothiocyanate (FITC), anti-CD8 allophycocyanin (APC; Becton Dickinson, 
San Jose, CA) and 7-amino-actinomycin-D (7AAD; Sigma-Aldrich, St. Louis, MO) as de-
scribed.15 The tetramers Hu133 HLA-A*0301 and Hu157 HLA-A*0201that were selected 
based on the observations of Roberts et al.,9 and NLV HLA-A*0201, were obtained from 
Beckman Coulter (Marseille, France). Irrelevant tetramers loaded with glycoprotein 
(GP)100-derived peptides or HIV-derived peptides were obtained from Beckman Coulter 
or provided by Dr. W.A.F. Marijt (Leiden University Medical Center, the Netherlands). 
Listmode data were acquired on a FACSCalibur or FACSCanto flow cytometer (Becton 
Dickinson). We gated on viable T cells (7AAD-, CD3+ cells with appropriate side and for-
ward scatter properties). A positive response was defined as (1) a distinct population 
of CD8+ tetramer-positive cells and (2) a higher percentage of CD8+ tetramer-positive 
cells than irrelevant-tetramer-positive cells.
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IFN-γ ELISpot
After stimulation with accelerated co-cultured (ac)DCs, PBMCs were assayed for 6 h as 
described previously.19 Spots were counted with a Bioreader 3000 (BioSys, Karben, Ger-
many). A positive response was defined as (1) a weak response (3-4 SD above the mean 
number of spot-forming cells (SFC) in wells without peptide) that could be reproduced 
in a second experiment or (2) an intermediate to strong response (>4 SD above the 
mean number of SFC in wells without peptide). Previously, these cut-off values were 
shown to yield a high sensitivity (86.4%) and specificity (90.9%) for detecting auto-
reactive T cells in type 1 diabetes.21
Tests for the Detection of Type 2 CD8+ T cells
CD8+ T cells that were stimulated with cDCs for 8 days were plated in triplicates of 
100,000 cells/ 100µL/ well in polyvinylidene fluoride (PVDF) plates (Millipore, Billerica, 
MA) coated with anti-IL-13 Abs (Mabtech, Nacka Strand, Sweden). Subsequently, 25,000 
peptide-pulsed T2 cells in 100µL per well were added and incubated for 20 h. Culture 
supernatants were collected and stored at -80oC. ELISpot plates were processed accord-
ing to the manufacturer’s instructions (Mabtech). Cytokine concentrations of culture 
supernatants were determined with the Th1/2 cytometric bead array kit from Becton 
Dickinson, according to the manufacturer’s instructions. Since receiver-operator char-
acteristics data are not available for these methods under these specific conditions, 
we used a more stringent definition of a positive response than for the IFN-γ ELISpot 
assay: (1) a number of SFC or cytokine level >2× background level in wells with T2 cells 
but without peptides; and (2) an increase in the number of SFC or cytokine levels after 
stimulation with peptide-pulsed cDCs.
RESULTS AND DISCUSSION
Seventeen Hu-PNS patients were included who tested positive for the HLA-A*0201 
restriction element and/or the HLA-A*0301 restriction element (Table 1). The median 
age of the patients was 68 years (range, 46-77). In 14 patients an underlying tumor was 
detected, mostly SCLC (n=10). All but 3 patients (no. 2, 6 and 17) had progressive neu-
rological symptoms in the 4 weeks prior to study entry, indicating ongoing neuronal 
destruction. Most patients had not received immunomodulatory or cancer treatment 
prior to blood withdrawal, and showed normal numbers of lymphocytes in the blood. 
Two patients who had received chemotherapy showed subnormal lymphocyte counts 
(nos. 3 and 6, Table 1).
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First, we stimulated CD8+ T cells of 9 Hu-PNS patients (nos. 1-9) with cDCs pulsed 
with the HuD-derived HLA-A*0301-binding peptide Hu133 or the HLA-A*0201-binding 
peptide Hu157 and used HLA-peptide tetramers to reproduce the results of Roberts et 
al.9 Staining of CD8+ T cells from Hu-PNS patient no. 1 with Hu157-loaded tetramers 
after 2 cycles of stimulation with peptide-pulsed cDCs did not show any Hu157-specific 
T cells, whilst stimulation with the CMV pp65-derived positive control peptide NLV 
resulted in a dramatic increase in NLV-specific T cells from 0.01% to 25% of the T cells 
(Figure 1). The other 8 patients were stimulated for 1 cycle prior to tetramer staining, 
and did not show any Hu133- or Hu157-specific T cells (data not shown). Since the me-
dian number of acquired CD8+ T cells was 124,000 (range, 12,000-811,000) and a count 
of 100 tetramer-positive cells is needed for a reliable positive result,22 we reached a 
median sensitivity of 0.08% (range, 0.01-0.85%) of stimulated CD8+ T cells. Therefore, 
the sensitivity of our assay should have been sufficient to detect similar frequencies as 
reported by Roberts et al (i.e., 0.26-0.79%).
Since Roberts et al. also reported robust secretion of the type 2 cytokines IL-4, IL-5 and 
IL-13 in stimulated bulk CD8+ T cells, we additionally tested for the presence of these 
‘type 2’ CD8+ T cells in three patients (no. 7-9). Figure 2 shows the results of an IL-13 
Figure 1. Tetramer staining of T cells after stimulation with cDCs
Tetramer staining of T cells from patient 1 after 1 cycle (day 8) and 2 cycles (day 16) of stim-
ulation with cDCs. CD8-enriched T cells were stimulated with cDCs pulsed with Hu157, the 
CMV-pp65 derived peptide NLV, or no antigen (No Ag) as indicated in boldface, this indication 
applies to both rows of panels. Then, the stimulated T cells were stained with HLA-A*0201 tet-
ramers loaded with Hu157, NLV, or irrelevant peptide as indicated by the x-axis labels of each 
panel. The percentage of CD8+ NLV-tetramer-positive T cells (upper right quadrants) increased 
from 0.01% of the T cells (No Ag, day 8) to 25% of the T cells (NLV, day 16). The percentage 
of Hu157-tetramer-positive T cells remained similar to that of the negative control tetramer 
(Irrelevant A2).
Abbreviations: No Ag: no antigen added to cDCs, Hu157: cDCs pulsed with Hu157 peptide, NLV: 
cDCs pulsed with the CMV pp65-derived peptide NLV, Hu157 A2: HLA-A*0201 tetramer loaded 
with Hu157, NLV A2: HLA-A*0201 tetramer loaded with NLV, Irrelevant A2: tetramer loaded 
with irrelevant peptide.
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ELISpot and a IL-4, IL-5 and IFN-γ bead array after stimulation with cDCs in Hu-PNS 
patient no. 7 and a HLA-A*0201-positive CMV seropositive healthy control. CD8+ T 
cells of patient no. 7 did not show IL-13, IL-4, IL-5 or IFN-γ secretion in response to 
the Hu157 peptide. CD8+ T cells of the healthy control showed a significant increase 
in the number of IL-13 spot-forming cells (SFC) and IFN-γ concentration in culture 
supernatant in response to the NLV peptide. We additionally tested 2 Hu-PNS patients 
(patient 8 and 9) with IL-13 ELISpot and 1 of these patients (no. 9) also with the flow 
cytometric bead array and did not detect any type 2 HuD-specific T cells.
Because of these negative results, we decided to test 11 patients (no. 7-17) using an 
alternative approach based on methods that have been proven successful in detecting 
low numbers of circulating auto-reactive T cells in type 1 diabetes. This approach 
involved 48-h stimulation with acDCs and IFN-γ ELISpot with IL-7 co-stimulation. 
Advantages of these methods are reduction of culture time and number of manipula-
Figure 2. Secretion of type 2 cytokines and IFN-γ by CD8+ T cells after stimulation with cDCs
CD8+ T cells were tested for secretion of type 2 cytokines and IFN-γ in response to peptide-
pulsed T2 cells after stimulation with (i) peptide-pulsed cDCs (amplified, black bars) or (ii) cDCs 
without peptides (not amplified, grey bars). Upper panels (A) show the results of T cells ob-
tained from a CMV seropositive healthy donor, lower panels (B) show the results for Hu-PNS 
patient no. 7. CD8+ T cells were tested in medium, and against T2 cells (T2), T2 cells pulsed with 
the CMV pp65-derived peptide NLV, T2 cells pulsed with the HuD-derived peptide Hu157, or 
T2 cells that were added simultaneously with PMA plus ionomycin (PMA). Panels on the left 
show the numbers of IL-13 SFC/106 CD8+ T cells, the other panels show cytokine concentrations 
in culture supernatants (pg/mL) of IL-4, IL-5 and IFN-γ. The CD8+ T cells of the CMV seropositive 
healthy donor (upper panels) secreted both, IL-13 and IFN-γ. CD8+ T cells of Hu-PNS patient no. 
7 (lower panels) did neither secrete the type 2 cytokines IL-4, IL-5 and IL-13, nor IFN- γ.
Chapter 2
28
Figure 3. IFN-γ ELISpot of PBMCs after stimulation with acDCs
In panel A the numbers of IFN-γ SFC/106 PBMC are presented after stimulation with acDCs in 
Hu-PNS patient no. 8. Panel B shows the summary for all tested 11 patients as a relative value 
representing the mean number of SFC in wells with antigen minus the mean number of SFC 
in wells without antigen divided by the SD of wells without antigen. The cut-off value for a 
weakly-positive response (+3SD) is indicated by the dotted line. Responses to CMV antigens are 
shown for CMV seropositive patients only. Responses to peptides that are predicted to bind 
HLA-A*0201 or HLA-A*0301 molecules are shown for individuals with the corresponding HLA-
A phenotype only. Stimulation with positive control peptides (pp65m and NLV) and PMA with 
ionomycin (PMA) resulted in significantly higher number of IFN- γ spot-forming cells (>4SD) in 
CMV seropositive patients and other patients. Stimulation with HuD, or HuD-derived peptides 
(HuDm, Hu133 and Hu157) did result in either no respons (<3 SD), or weak responses (3-4SD) 
that could not be reproduced.
Abbreviations: No Ag: no antigen, Yo: Yo protein, HuD: HuD protein, HuDm: HuD 15-mers 
mix, Hu133: Hu133 peptide, Hu157: Hu157 peptide, pp65m: CMV-derived pp65 15-mers mix, 
NLV: CMV-derived NLV peptide, PMA: phorbol myristate acetate plus ionomycin, TTX: tetanus 
toxoid, ND: not determined.
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tions, which may therefore offer a better representation of the in vivo situation and a 
high sensitivity due to stimulation with acDCs, reduction of T cell background activity 
by using serum-free culture media and an increase in the amplitude of the antigen-
specific response by IL-7 co-stimulation.19 In order to test for other HuD-epitopes than 
Hu133 and Hu157, we also tested against the entire HuD protein and a HuD protein-
spanning 15-mers mix (HuDm). Figure 3 shows the results of the IFN-γ ELISpot assays 
after stimulation with acDCs in 11 Hu-PNS patients. Testing against the HuD protein, 
HuDm, Hu133 and Hu157 showed either negative results (<3 SD above background) 
or weak responses (3-4 SD above background) that could not be reproduced and were 
therefore considered negative. All 4 CMV-seropositive patients tested positive against 
the CMV-pp65 peptide mix (pp65m). Three of them were HLA-A*0201 and responded 
to the CMV pp65-derived HLA-A*0201-binding peptide NLV. In addition, we performed 
Hu133 and Hu157-loaded tetramer staining ex-vivo, and after 12 days of stimulation 
with acDCs. We acquired a median number of 147,000 (range, 15,000-645,000) T cells 
ex-vivo and 9,000 (range, 1,000-166,000) T cells after acDC stimulation, corresponding 
to median sensitivities of 0.07% (range, 0.02-0.67%) and 1.14% (range, 0.06-9.58%) of T 
cells respectively; no HuD-specific T cells were detected.
There are several possible explanations for our negative results, and the discrepancies 
between our results and those of Roberts et al. First, methodological differences could 
have been responsible. We tried to limit these differences by using exactly the same 
protocols for stimulation of CD8+ T cells with cDCs and using the same reagents for 
tetramer staining, IL-13 ELISpot and the multiplex bead array. However, Roberts et al. 
used separate vials for separated cryopreservation of monocytes and T cells, while we 
used single vials with PBMCs. Hence, we had to keep the T cells in culture for 8 addi-
tional days during the generation of cDCs. Theoretically, the numbers of HuD-specific 
T cells may have decreased during this period. However, we also used stimulation by 
acDCs as an alternative approach to reduce culture time and the number of manipula-
tions, and this approach did not result in detectable levels of any HuD-specific T cells.
Second, differences in patient characteristics between the two studies may exist. 
Theoretically, a delay in our patient inclusion could have resulted in more chroni-
cally ill patients with stable symptoms in whom certain auto-aggressive T cells may 
have disappeared. Of note, Roberts et al. could only detect Hu133-specific T cells in a 
single patient with progressive symptoms for 5 months, and not in two chronically ill 
patients who had symptoms for more than 10 months. However, since 14 of our 17 pa-
tients in this study had progressive neurological symptoms, and 13 of the 17 patients 
were included not later than 6 months after onset of their neurological symptoms, 
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we consider it unlikely that a delay in patient inclusion could have accounted for our 
negative results.
Third, the number of circulating HuD-specific T cells in our study may have been too 
low for detection with even the most sensitive techniques. HuD-specific T cells may 
be preferentially found in or around target tissues such as CNS, dorsal roots or SCLC 
rather than in peripheral blood.
Fourth, our negative results suggest that HuD itself might not be the target of the 
hypothetical auto-aggressive T cells in Hu-PNS. Although the high expression of HuD 
in both neurons and SCLC cells makes HuD an attractive target of the auto-aggressive 
T cells in Hu-PNS, other proteins may be involved. For example, another Hu-protein, 
HuB is also expressed by neurons and SCLC cells.23 Even proteins that do not belong to 
the family of Hu proteins may be involved, despite the presence of high titers of Hu-Ab 
in our patients. In celiac disease, for example, a B cell response targets the enzyme 
tissue transglutaminase itself, while T cell responses are target at the products of this 
enzyme.24
Finally, the high titers of immunoglobulin G1 anti-Hu-Abs in patients with Hu-PNS 
suggest the help of CD4+ T cells. In this paper, we focused on CD8+ T cells because 
these cells are believed to directly cause neuronal damage by the release of cytotoxins 
(classical CD8+ T cells) and because HuD-specific type 2 CD8+ T cells had been reported 
in the literature.9 Although we could also have detected CD4+ T cells with the third 
assay, further research is needed to specifically address the role of CD4+ T cells in 
Hu-PNS.
In summary, we propose either that auto-aggressive CD8+ T cells in Hu-PNS do not 
target HuD, but rather other antigens (e.g. HuB), or that these cells are extremely rare 
in the blood, which makes their detection not amenable to clinical application.
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ABSTRACT
Flow cytometry facilitates the detection of a large spectrum of cellular character-
istics on a per cell basis, determination of absolute cell numbers and detection of 
rare events with high sensitivity and specificity. White blood cell (WBC) counts in 
cerebrospinal fluid (CSF) are important for the diagnosis of many neurological disor-
ders. WBC counting and differential can be performed by microscopy, haematology 
analyzers or flow cytometry. Flow cytometry of CSF is increasingly being considered as 
the method of choice in patients suspected of leptomeningeal localization of haema-
tological malignancies. Additionally, in several neuro-inflammatory diseases such as 
multiple sclerosis (MS) and paraneoplastic neurological syndromes (PNS), flow cytom-
etry is commonly performed to obtain insight into the immunopathogenesis of these 
diseases. Technically, the low cellularity of CSF samples, combined with the rapidly 
declining WBC viability, makes CSF flow cytometry challenging. Comparison of flow 
cytometry with microscopic and molecular techniques shows that each technique has 
its own advantages and are ideally combined. We expect that increasing the number 
of flow cytometric parameters that can be simultaneously studied within one sample, 
will further refine the information on CSF cell subsets in low-cellular CSF samples and 
enable to define cell populations more accurately.
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INTRODUCTION
White blood cell (WBC) counts and their differential into mononuclear (MNC) and 
polymorphonuclear cells (PMN) in cerebrospinal fluid (CSF) are critical in the diagno-
sis of many infectious and inflammatory neurological disorders.1 In acute bacterial 
meningitis, WBC counts usually range between several hundred to more than 60,000/
µl, predominantly PMN (90%-95% of WBC count), although early in the disease WBC 
counts can be lower than 100 WBC/µL.2 In viral meningitis, cell counts are usually 
between 10 - 1,000 WBC/µL, but may exceed 1,000/µL. Here, MNC predominate, but in 
the very acute stages of disease PMN can account for more than 80% of leukocytes.2 
In multiple sclerosis (MS), two-thirds of patients have a normal CSF cell count and 
a low level of mononuclear pleocytosis is found in one-third of the cases.2 The CSF 
WBC count is usually normal (<5 leukocytes/µL) in patients with the Guillain-Barré 
syndrome, whereas in case of an increased WBC count other diagnoses should be 
considered.3 In paraneoplastic neurological syndromes (PNS), 47% of patients have a 
lymphocytic pleocytosis before the 3rd month after onset of the neurological symp-
toms, while after the 3rd month only 28% of patients have elevated cell counts.4 CSF 
WBC counts are also routinely determined in patients with suspected leptomeningeal 
metastases of solid or haematological malignancies and half of these patients have a 
lymphocytic pleocytosis.5,6
MICROSCOPY
Generally, cell counts and differential can be obtained by evaluating cell number and 
morphology in microscopic slides, by automatic counting based on cellular scatter 
properties or by flow cytometry in which antigen expression of cells is assessed in 
combination with light scatter properties. Specifically, microscopic counting of WBC 
and red blood cells (RBC) is performed using Neubauer or Fuchs-Rosenthal counting 
chambers, which contain a microscopically visible counting grid and are used with a 
fixed sample volume. Staining with Samson or Türk reagent may be added to the pro-
cedure to facilitate WBC counting and perform differential.6 However, in low-cellular 
CSF samples (<5 leukocytes/µL), differential by microscopy is not performed. When 
the WBC count is higher than the upper reference value, most laboratories perform 
cytospin centrifugation of the sample, followed by Wright or May-Grunwald-Giemsa 
staining to enable morphological differential of cells in CSF. This technique permits 
rapid differential between monocytes, lymphocytes and granulocytes, which is of 
utmost importance for patients with acute neurological disease.7 Counting of eryth-
rocytes is important to exclude traumatic bleeding as the cause of an elevated WBC 
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count.8 Although microscopic counting and differential has for a long time been used 
in routine CSF analysis, the clinical laboratory faces several challenges in perform-
ing it. First, the analysis is time-consuming and should ideally be performed within 
1 hour after lumbar puncture as CSF cell counts decrease rapidly after sampling.9 
Second, counting and differential results have relatively high intra- and interobserver 
variation8, as have other manual microscopic techniques. Furthermore, skilled and 
continuously trained technicians are required for this assay on a 24 hours/7 day basis.10
HAEMATOLOGY ANALYZERS
Nowadays an increasing number of clinical laboratories replace the microscopic tech-
nique by haematology analyzers (HA) for cell counting and differential in CSF.8,10,11 HA 
may provide fast, low-cost and standardized cell counting of CSF and other body fluids 
such as ascites or pleural fluid. However, special attention is needed regarding back-
ground signal, carry-over and interference in view of the low cell concentrations in 
these fluids. Two dedicated, FDA-approved, applications for CSF counting and differen-
tial on HA are available, i.e., the ADVIA® 120/2120 CSF assay (Siemens AG, München, 
Germany) and the Body Fluid mode on a XE-5000TM analyzer (Sysmex, Kobe, Japan).8,11 
ADVIA® CSF assay uses light scatter and absorbance measurement for counting and 
differential, after mixing the sample with CSF reagent to sphere and fix the cells. 
Not only RBC, WBC and PMN/MNC are reported, but also lymphocytes, monocytes 
and eosinophils. XE-5000TM Body Fluid mode uses sheath flow impedance for counting 
RBC, while light scatter and fluorescence intensity after DNA/RNA staining is used 
to analyse WBC. The application reports WBC, PMN/MNC and high-fluorescent cells. 
For CSF WBC counting, comparison of the Fuchs-Rosenthal counting chamber with 
both the XE-5000TM analyzer and the ADVIA® 120/2120 CSF assay showed linearity 
between 1 and 10,000 cells per µL.8,11,12 Automatic MNC counts also correlated well 
with manual counts, but PMN counts showed poor agreement being almost two-fold 
higher using the XE-5000 analyzer.12 Especially in low WBC counts (<20 cells per µL) 
high imprecision was observed in both techniques compared to manual counting.8,11 
The detection limit of the XE-5000 is 10 cells per µL. When the WBC count is below 
that limit, differential into MNC and PMN cannot be made.12 In these cases, manual 
counting or evaluation of stained cytospin slides should be performed. In automatic 
cell counting of low-cellular samples the same problem arises as in flow cytometry 
(see Rapid decline of leukocyte counts upon lumbar puncture section): due to high impreci-
sion, under- or overestimation of CSF WBC counts may lead to erroneous results. In 
clinical practice, HA are more widely available and have lower material costs than 
flow cytometers.
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CYTOMORPHOLOGY
Morphologic examination of CSF cells is performed on cytospin preparations stained 
with May-Grunwald-Giemsa.6 Whilst highly specific (>95%), conventional cytomorpho-
logical analysis is associated with only a limited sensitivity with up to 20% to 60% 
false-negative results.6,13 Interpretation of cytological findings may be difficult because 
of paucity of cells in CSF and possible morphological similarities between benign and 
malignant cells.14 Cytomorphological examination is used in patients with suspected 
leptomeningeal dissemination of solid tumours or haematological malignancies. 
Typically, only 50% of patients have malignant cells identified by cytomorphological 
examination on the first lumbar puncture.15 This yield is increased to 80% with a 
second CSF examination5, but even three lumbar punctures will still miss tumour cells 
in approximately 10% of patients.16 Despite its low sensitivity, CSF cytologic examina-
tion has been the gold standard for leptomeningeal metastasis because of its 100% 
specificity.16 If clinical suspicion is high, gadolinium-enhanced MRI of the brain and 
spine can provide definitive evidence of leptomeningeal metastasis, even without a 
positive CSF cytology.17,18
IMMUNOCYTOCHEMISTRY
Immunocytochemistry allows the detection of cell surface antigens on CSF cells by 
cytospins. For detection of leptomeningeal localization of haematological malignan-
cies a sensitivity of 89% to 95% and a specificity of 89% to 100% was shown by this 
technique.19 For CSF samples with low cell counts, immunocytochemistry should be 
used subsequent to cytomorphology and the selection of the antibodies should be 
determined by the cytological findings in combination with the patients history.20,21 
Alternatively, it is stated that this technique should only be used when CSF cytomor-
phology fails in patients with a strong suspicion of leptomeningeal metastases.22 
Compared to flow cytometry, immunocytochemistry gave similar results in detection 
of high-density surface markers, whereas in analysis of antigens that are expressed 
at low density immunocytochemistry may be more reliable in some applications.23 
Since flow cytometry is used in the detection of CNS involvement of haematological 
malignancies besides cytomorphological analysis, as discussed in the Applications of 
flow cytometry to study CSF section, immunocytochemistry has no major role anymore. 
In contrast, immunohistochemistry is still used in combination with cytology in the 
detection of leptomeningeal metastases of solid tumours.
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POLYMERASE CHAIN REACTION (PCR)
PCR requires the selection of primers specific for tumour cell-derived DNA. In 
haematological B-cell malignancies, analysis of immunoglobulin heavy chain gene 
rearrangements in the third complementarity determining region (CDR3) by PCR in 
blood and bone marrow cells is a state-of-the-art technique for diagnosis, monitor-
ing response to treatment and detection of minimal residual disease.24,25 Presence of 
clonally rearranged CDR3 is the molecular signature of malignant B lymphocytes and 
is present in 80-95% of B-cell lymphomas and leukaemias.26 Until now this technique 
has not been generally applied to CSF samples. PCR can also be used for detection of 
leptomeningeal metastasis in solid malignancies. Although it would be ideal to use 
primers for DNA sequences common to all metastatic cells, the use of sequences for 
specific primary cancer histopathologies might provide a more practical option, as 
many are known already.13,27-29 Additional molecular tumour markers or oncogenes 
can be used for other types of cancer and might eliminate the need for biopsy in 
selected patients.29
FLOW CYTOMETRY
In patients with suspected leptomeningeal metastases of haematological tumours, 
flow cytometry of CSF samples is used in addition to cell counting and cytomorphol-
ogy. In this review we will focus on the applications and recent developments of CSF 
flow cytometry. Although this procedure has only a narrow clinical indication, it has 
significant prognostic and therapeutic implications in individual patients.
Use of polychromatic flow cytometry
The advent of polychromatic flow cytometry, i.e. advanced instrumentation and re-
agent development30, allows detection of a large spectrum of cellular characteristics, 
even in samples with small amounts of cells like CSF. Apart from differentiating 
between major leukocyte subsets by assessing granularity and volume of cells, a 
wide range of cell populations can be specified by immunophenotyping using surface 
membrane, cytoplasmatic and nuclear antigens.7,14,31 However, intracellular staining 
should be limited to those cases in which it is essential to reach the immunological 
conclusion, because its use is associated with relatively pronounced cell loss.31 The 
number of characteristics on one single cell that can be determined in a single tube, 
depends on the number of fluorescent colours available on the flow cytometer used 
and the number of monoclonal antibodies per tube. The applicability of the assay can 
even be further enhanced by combining two antigens expressed by non-overlapping 
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cell subsets on a single fluorochrome (e.g., CD4 present on T lymphocytes and CD19 
present on B lymphocytes).14 In CSF, the simultaneous assessment of 13 parameters (11 
colours plus forward and sideward scatter) has been reported in this way.14 However, 
problems with spectral overlap and colour compensation increase when more than 6 
colours are used, but these problems can be reduced if markers and fluorochromes are 
combined judiciously.32
Absolute cell counts
Frequencies of different WBC populations in CSF are most widely investigated. How-
ever, knowledge of absolute numbers of the major cell populations can be of great 
help to evaluate the sample.33 Due to possible cell loss during concentration and cen-
trifugation steps31,34, absolute cell counts may be an underestimation of the real CSF 
cell number. Addition of counting beads to the monoclonal antibody-stained CSF cell 
suspension allows accurate enumeration of absolute numbers of cell subsets.31 By using 
this technique, we showed that PNS patients stood out by highly increased absolute 
counts of the major lymphocyte subsets in CSF, but above all, by B-lymphocyte counts 
that had increased more than 20-fold as compared to controls without neurological 
disease.35 In these patients, the frequency of B lymphocytes (expressed as fraction of 
lymphocytes) had increased only three-fold.35 When merely frequencies would have 
been studied, this enormous B-lymphocyte expansion suggesting an important role 
for these cells in PNS, would have remained unnoticed. This result indicates that as-
sessment of absolute counts besides frequencies is also important in CSF.
Cellular composition of normal CSF
To use CSF flow cytometry in research of neuro-inflammatory diseases, knowledge of 
the composition of cells in normal CSF is needed. Because CSF of healthy controls is 
usually not available due to ethical considerations36, NIND controls are often included 
instead.37 However, Svenningsson et al.38,39 did study normal CSF by assessing the 
percentages of lymphocyte subsets in CSF of 34 healthy individuals, after informed 
consent, with 2- or 3-colour flowcytometry. In addition, we studied both absolute 
numbers and percentages of leukocyte, lymphocyte, T lymphocyte and dendritic cell 
subsets by 6-colour flow cytometry in 84 individuals without neurological disease 
undergoing spinal anaesthesia (Table 1).40 The two published studies38,39, as well as our 
data40, showed that normal CSF is predominantly composed of CD4+ T lymphocytes, 
mostly with a central memory phenotype, and in addition contains very low frequen-
cies of B lymphocytes, NK cells and NKT lymphocytes (Table 1). Dendritic cells, both 
myeloid as well as plasmacytoid, were also present in normal CSF, although in very 
low frequencies (Table 1).40,41
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Sensitivity and specificity
Flow cytometry is a sensitive method capable of detecting abnormal monoclonal B 
lymphocytes, which comprise as little as 0.01% of total lymphocytes.42,43 The detection 
rate of CSF involvement in hematological malignancies is up to 86% higher in flow 
cytometry than in conventional cytomorphological analysis6,14,42-48 (Table 2). Although 
it was previously suggested that this method may not be suitable in the evaluation 
of samples with low cellularity23, it has been shown that CSF T lymphocytes, the pre-
dominant lymphocyte subset in CSF, can be reliably detected in samples with a cell 
count lower than 5 leukocytes/µL.46 Kleine et al.49 showed that precision of lymphocyte 
flow cytometry is high (coefficient of variance [CV] ≤10%) provided that a sufficient 
number of events has been acquired.50 However, the CV may increase to values up to 
30% for the minor subsets in CSF, e.g. NK cells and NKT lymphocytes.49
Several studies comparing flow cytometry and conventional cytomorphology to detect 
CSF involvement in haematological malignancies (Table 2) describe samples in which 
flow cytometry is positive whilst cytology is negative.6,14,43,51 Presence of neurologi-
cal symptoms compatible with leptomeningeal disease is highly suggestive for CNS 
involvement in such patients, whereas absence of symptoms and lack of recurrence 
of CNS disease during clinical follow-up indicate a false-positive flow cytometric 
result.6,14 Results of clinical follow-up were documented in three studies. Sancho et 
al.51 suggest that a flow cytometry-positive/cytology-negative result is associated with 
a poor clinical outcome in aggressive B-cell lymphomas, as compared to samples with 
Table 1. Reference values of WBC subsets in CSF (adapted from de Graaf et al. 40)
Subset Absolute numberA
Leukocytes 1.12 (0.40 – 3.17)
Granulocytes 0.08 (0.02 – 0.43)
Monocytes 0.23 (0.08 – 1.11)
Lymphocytes 0.66 (0.16 – 1.88)
T cells 0.62 (0.15 – 1.83)
CD4+ T cells 0.44 (0.08 – 1.43)
CD8+ T cells 0.13 (0.04 – 0.40)
NKT cells 0.01 (0.00 – 0.06)
B cells 0.00 (0.00 – 0.03)
NK cells 0.01 (0.00 – 0.05)
Dendritic cells 0.04 (0.01 – 0.18)
Myeloid 0.02 (0.00 – 0.13)
Plasmacytoid 0.01 (0.00 – 0.03)
AMedians (5th-95th percentiles) of absolute numbers x106/L are given.
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absence of neoplastic cells by both methods. In addition, Bromberg et al.6 described 
the absence of CNS recurrence in only 1/24 flow cytometry-positive, cytology-negative 
patients. Hegde et al.43 found that 3/40 patients at increased risk for central nervous 
system involvement but with negative cerebrospinal fluid by flow cytometry on initial 
staging relapsed in the central nervous system and died. These follow-up data indicate 
that flow cytometric analysis of CSF samples has a low risk of being both false-positive 
and false-negative in patients with haematological malignancies.
Rare event detection
When leptomeningeal localization of a haematologic malignancy is suspected, the 
presence of a pathological (monoclonal) population and phenotypic characterization 
of that population can be assessed by using the proper antibody reagent panel adapted 
to the number of cells and previous histological and immunophenotypical diagnosis 
or suspected diagnosis together with appropriate gating strategies.31 Pathological 
Table 2. Comparison of flow cytometry and conventional cytomorphology in detection of CSF 
involvement in haematological malignancies
Malignancies
 Reference
N CSF 
involvementA
FC+/
CC+
FC+/
CC-
FC-/
CC+
Detection rate
by using CC 
aloneB
Detection rate
by using FC 
aloneC
Lymphoma
Finn, 1998 47 27 10 6 3 1 7/10 (70%) 9/10 (90%)
Hegde, 2005 43 60 14 2 12 0 2/14 (14%) 14/14 (100%)
Quijano, 2009 14 123 25 7 17 1 8/25 (32%) 24/25 (96%)
Sancho, 2010 51 105 22 7 15 0 7/25 (28%) 22/22 (100%)
Acute leukaemia
Subira, 2001 46 168 21 11 7 3 14/21 (67%) 18/21 (86%)
Sayed, 2009 48 45 23 8 13 2 10/23 (43%) 21/23 (91%)
Lymphoma, 
leukaemia
French, 2000 42 35 9 4 3 2 6/9 (67%) 7/9 (78%)
Roma, 2002 45 53 21 12 9 0 12/21 (57%) 21/21 (100%)
Nückel, 2006 44 45 18 12 3 3 15/18 (83%) 15/18 (83%)
Bromberg, 
2007 6
219 43 15 24 4 19/43 (44%) 39/43 (91%)
ACSF involvement was diagnosed when flow cytometry, conventional cytomorphology or both 
were positive.
BDetection rate of CSF involvement by using conventional cytomorphology alone: ([FC+/CC+] + 
[FC-/CC+])/CSF involvement.
CDetection rate of CSF involvement by using flow cytometry alone: ([FC+/CC+] + [FC+/CC-])/CSF 
involvement.
FC = flow cytometry; CC = conventional cytomorphology.
Chapter 3
44
cells usually occur at very low percentages in the order of 0.01% in CSF. In addition, 
CSF samples contain a limited number of cells rendering pathologic cells in CSF very 
rare. To detect low numbers of rare cells, the background fluorescence of the reagents 
should be minimal, and a sufficient cell number is required to analyze lymphocyte 
subsets reproducibly. Therefore, the CSF sample has to be as large as possible and cell 
loss during work up has to be prevented as discussed in the Technical pitfalls section.
APPLICATIONS OF FLOW CYTOMETRY TO STUDY CSF
CNS involvement with lymphoproliferative disorders
Involvement of the central nervous system (CNS) is a relatively uncommon compli-
cation of leukaemia and lymphoma14,46, which is suspected in patients who develop 
neurological symptoms or signs 14 or in patients at high risk of CNS localization.6 It has 
grave prognostic significance and requires important therapeutic decisions includ-
ing the administration of intrathecal chemotherapy.6,46 Leptomeningeal localization 
is diagnosed by conventional cytomorphological analysis through identification of 
malignant lymphocytes in CSF.31,52 However, this technique has a relatively high rate 
of false-negative results in up to 60% of cases.22,53 Recent reports suggest that multipa-
rameter flow cytometric assessment of CSF samples could improve the efficiency of 
detection of CNS involvement, due to its high specificity and greater sensitivity.6,52,54 
Table 2 gives an overview of studies which investigated the value of flow cytometry 
and conventional cytomorphology in detection of CSF involvement in haematological 
malignancies. These studies showed that the use of flow cytometry alone increased the 
detection rate of CSF involvement up to 86% compared to the use of cytomorphology 
alone. Combined use of flow cytometry and cytomorphology increased the detection 
rate with 17%-86% compared to cytomorphology alone. Therefore, the National Com-
prehensive Cancer Network (USA) has recommended the routine use of flow cytometry 
in conjunction with cytomorphological analysis for the diagnosis of CNS lymphoma.55 
CNS involvement is diagnosed if one of these diagnostic procedures is positive. For 
detection of haematological malignancies, flow cytometry depends on the analysis of 
light chain restriction (Figure 1) and/or aberrant antigen expression, which should be 
interpreted within the context of the patient’s histological diagnosis.56 Still, cytomor-
phological examination of CSF has additional diagnostic and possibly prognostic value 
and should still be performed in conjunction with flow cytometry.6
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Inflammatory neurological diseases
Multiple sclerosis
Flow cytometry of CSF is also used as a research tool in various neuro-inflammatory 
diseases. The distribution of lymphocyte subpopulations in the CSF may be a con-
sistent indicator of the type of immune response active in these diseases.57 Several 
studies have reported on flow cytometric analysis of lymphocytes and their subsets 
in CSF of patients with MS. The CSF cell populations in MS patients have been shown 
to consist of approximately 60% CD4+ T lymphocytes58 with a higher frequency of 
the regulatory phenotype59,60 and a higher CD4/CD8 ratio61, while the frequency of 
NKT lymphocytes is lower62 than in control patients with non-inflammatory neuro-
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Figure 1. 6-colour flow cytometric CSF analysis
Example of a 6-colour flow cytometric analysis for B-lymphocyte clonality in CSF. Each dot rep-
resents a single cell. For analysis, debris and non-leukocyte events were excluded by gating on 
forward scatter (FSC) and CD45 (gate 1, panel A). The leukocyte subsets (My = myeloid lineage; 
Imm = immature lineage; Mo = monocytes; Ly = lymphocytes) were defined with CD45 expres-
sion and side scatter (panel B) and show two major subsets: lymphocytes (CD45+, SSClo, FSCim; 
green dots) and monocytes (CD45+, SSCim, FSChi, CD4dim; cyan dots). B lymphocytes were gated 
using the lineage-specific marker CD19 and side scatter (SSC) (purple dots; gate 2, panel C). 
Next, physical properties of B lymphocytes were confirmed by FSC and SSC (gate 3, panel D). 
Analysis of clonality revealed that the purple dots represent a population of B lymphocytes 
with monoclonal expression of sIgK but not sIgL light chains (panel E), compatible with B cell 
lymphoma. The cyan dots that bind both sIgK and sIgL (panel E) are monocytes - as revealed by 
their CD14 reactivity - that have bound cytoplasmic Ig (panel F).
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logical disorders (NIND). Compared to blood, CSF of MS patients showed a relative 
depletion of CD8+ effector memory T lymphocytes.63 In relation to disease activity, 
patients with active MS had higher percentages of activated CD4+ T lymphocytes64-67 
and lower percentages of activated CD8+ T lymphocytes64,65,67 in their CSF than inactive 
MS patients. Moreover, the percentage of naïve CD45RA+, CD50+ (ICAM-3) lymphocytes 
in CSF is significantly increased68, while cell surface expression of CD54 (ICAM-1) on T 
lymphocytes in CSF is significantly decreased69 in patients with relapses compared to 
patients in remission. Both are suggested to be used as markers of MS disease activity 
in CSF as well as blood.68,69 With regard to B lymphocytes in CSF of MS patients, a 
significant accumulation of mature B lymphocytes and plasma blasts is observed.70,71 
Most B lymphocytes have a memory phenotype71-74 and more B lymphocytes express 
CD80 (costimulatory molecule inducing T lymphocyte activation) than in NIND and 
healthy controls.75,76 Furthermore, the number of dendritic cells is elevated in CSF of 
MS patients.41 CSF flow cytometry was also used in evaluation of MS treatment with 
immunosuppressive drugs. Both rituximab (anti-CD20 monoclonal antibody [mAb])77 
and natalizumab (anti-α4 integrin mAb)78 reduced the number of B and T lymphocytes, 
while high-dose methylprednisolone induced changes in the expression of CD25, 
CD26 and HLA-DR on CD4+ T lymphocytes.79
Paraneoplastic neurological syndromes
We and others have reported on CSF lymphocyte subsets in patients with PNS. In 
PNS associated with anti-Hu antibodies, CSF is characterized by (i) a very substantial 
(20-fold) B-lymphocyte expansion and (ii) a 3-fold T-cell expansion (including both 
CD4+ and CD8+ subsets) compared to controls.35 Children with paraneoplastic opsoc-
lonus-myoclonus syndrome had normal CSF cell counts, but higher percentages of B 
lymphocytes80,81, activated T lymphocytes and gd-T lymphocytes, lower percentages of 
CD4+ T lymphocytes and a lower CD4/CD8 ratio80 compared to NIND controls.
TECHNICAL PITFALLS
Low cellularity
The low number of cells in CSF (normal range: <5 leukocytes/µL) hampers the use 
of flow cytometry.82 To analyze lymphocyte subsets reproducibly, measuring a suf-
ficient cell number is required. However, the minimal number of CSF cells required 
is not universally defined. In literature, the minimal CSF cell number varies between 
100 gated lymphocytes in lymphocyte subset characterization49 and 1000 cells in 
suspected CSF localization of lymphoma.54 A subpopulation was reliably identified 
whenever 13 or more clustered events displaying identical features were present, 
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whereas the presence of fewer than 5 clustered events could not be related to the 
presence of a specific cell population.82 In another study, a minimum of 15 events 
is reported to ascribe them to a specific cell population with a high probability.83 In 
leptomeningeal metastasis of haematological malignancies, one study describes the 
presence of at least 10 clustered events with abnormal patterns of antigen expression 
for diagnosis14, while another publication prescribes to classify clusters of more than 
25 events as positive, 10-25 events as suspicious and below 10 events as negative.31 In 
our laboratory, we agree with the latter publication and consider 25 clustered events 
as positive. However, this accounts for the use of three or four-colour flow cytometry. 
When a higher number of colours is used, less clustered events are required to define 
a cell population.
To obtain a maximal number of cells for analysis, CSF samples have to be concentrated 
by low-speed centrifugation. No significant cell loss was observed in hypocellular 
samples (<10 leukocytes/µl) when CSF cells were enriched by centrifuging at 200g for 
15 minutes at 4ºC.49 CSF samples containing >10 leukocytes/µL can be stained and ana-
lyzed without cell enrichment.36 However, in case of rare event detection, e.g. in CNS 
involvement of lymphoproliferative disorders, CSF cells should also be concentrated 
in samples containing >10 leukocytes/µl to increase the sensitivity. Another way to 
deal with the low cell numbers in CSF, is the use of a two step approach.31,46 First, one 
third of the sample is analyzed with a screening tube, which in most cases will answer 
the clinical question. When this first staining is not conclusive, the process should be 
repeated with the remaining CSF and the same reagent combination. Combining the 
list mode data of the first and second staining will increase sensitivity by enabling 
analysis of a larger number of cells. Second, if a pathological population is identified 
in the first step, immunophenotyping may be extended.
Rapid decline of leukocyte counts upon lumbar puncture
Another difficulty of CSF studies is the rapid decay of leukocytes after sampling as 
described in several studies (Table 3). Within 30 minutes after sampling, the CSF cell 
number decreases significantly.9,14,34,84-86 Also, differences in survival rate between dif-
ferent leukocyte subsets were observed: monocytes and granulocytes showed a more 
rapid cell loss than lymphocytes9,34,85 (Table 3). In flow cytometric analysis, selective 
cell losses may cause underestimation of cell counts.23 These errors can affect clinical 
decisions. E.g., in CSF samples with a pleocytosis, underestimation of the cell number 
may result in a normal cell count and pathology, such as a neuro-inflammatory dis-
ease, may be considered ruled out.
Chapter 3
48
Ta
bl
e 
3.
 D
ec
lin
e 
of
 C
SF
 c
el
l y
ie
ld
s 
as
 a
 f
un
ct
io
n 
of
 s
to
ra
ge
 t
im
e
CS
F 
ad
di
ti
ve
 
Re
fe
re
nc
e
Fi
rs
t 
as
se
ss
m
en
t
(h
ou
rs
)
Se
co
nd
 a
ss
es
sm
en
t
(h
ou
rs
)
Te
m
pe
ra
tu
re
Ce
ll 
lo
ss
 r
el
at
iv
e 
to
 fi
rs
t 
as
se
ss
m
en
t 
(%
)
W
BC
Ly
m
ph
oc
yt
es
M
on
oc
yt
es
G
ra
nu
lo
cy
te
s
N
o
C
ho
w
, 1
98
4 
83
0A
2 
an
d 
24
22
ºC
40
 a
nd
 6
0
-
-
-
0A
2 
an
d 
24
4º
C
15
 a
nd
 3
9
-
-
-
St
ee
le
, 1
98
6 
84
0B
2 
an
d 
4
A
m
bi
en
t
27
G
 a
nd
 4
4G
12
 a
nd
 3
4
20
 a
nd
 3
9
50
 a
nd
 5
8
D
ux
, 1
99
4 
34
0C
1.
5
O
n 
ic
e
62
G
35
 9
0
D
e 
G
ra
af
, 2
01
1 
9
0.
5
1
A
m
bi
en
t
26
4
36
34
Sa
lin
e St
ee
le
, 1
98
6 
84
0B
4
A
m
bi
en
t
6G
0
0
18
Se
ru
m
-c
on
ta
in
in
g 
bu
ff
er
Ve
er
m
an
, 1
98
5 
85
0.
5D
24
A
m
bi
en
t
0
-
-
-
D
ux
, 1
99
4 
34
0C
1.
5
O
n 
ic
e
-
10
-
-
D
e 
G
ra
af
, 2
01
1 
11
4
0.
5E
1
A
m
bi
en
t
9
2
18
0
Ch
em
ic
al
 s
ta
bi
liz
at
io
n
Q
ui
ja
no
, 2
00
9 
14
0F
24
 a
nd
 4
8
U
nk
no
w
n
21
 a
nd
 4
0
-
-
-
A
Sp
ik
in
g:
 h
om
ol
og
ou
s 
bl
oo
d 
w
as
 a
dd
ed
 t
o 
ac
ce
llu
la
r 
CS
F 
sa
m
pl
es
.
B S
pi
ki
ng
: 
ly
m
ph
oc
yt
es
, 
m
on
oc
yt
es
 a
nd
 n
eu
tr
op
hi
ls
 w
er
e 
ob
ta
in
ed
 f
ro
m
 p
er
ip
he
ra
l 
bl
oo
d 
an
d 
su
bs
eq
ue
nt
ly
 s
pi
ke
d 
in
to
 C
SF
 s
am
pl
es
 t
ha
t 
ha
d 
be
en
 
ce
nt
ri
fu
ge
d 
to
 r
em
ov
e 
ce
lls
 o
r 
in
to
 s
al
in
e.
C S
pi
ki
ng
: a
ft
er
 C
SF
 w
it
hd
ra
w
al
, c
el
ls
 w
er
e 
pe
lle
te
d 
by
 c
en
tr
if
ug
at
io
n 
an
d 
re
su
sp
en
de
d 
in
 C
SF
 o
r i
n 
PB
S 
co
nt
ai
ni
ng
 5
%
 fe
ta
l c
al
f s
er
um
. T
he
 c
el
l n
um
be
r 
at
 r
es
us
pe
ns
io
n 
w
as
 s
et
 a
t 
10
0%
.
D
CS
F 
in
 s
te
ri
le
 p
hy
si
ol
og
ic
 m
ed
iu
m
 (
on
e 
pa
rt
 E
ar
le
’s 
ba
la
nc
ed
 s
al
t 
so
lu
ti
on
 a
nd
 o
ne
 p
ar
t 
20
%
 h
um
an
 s
er
um
 a
lb
um
in
) 
ad
de
d 
di
re
ct
ly
 a
ft
er
 C
SF
 w
it
h-
dr
aw
al
.
E C
SF
 i
n 
se
ru
m
-c
on
ta
in
in
g 
m
ed
iu
m
 (
RP
M
I-1
64
0 
w
it
h 
H
EP
ES
, 
L-
G
lu
ta
m
in
e,
 P
en
ic
ill
in
/S
tr
ep
to
m
yc
in
, 
he
at
-in
ac
ti
va
te
d 
fe
ta
l 
bo
vi
ne
 s
er
um
 a
nd
 h
ep
ar
in
) 
ad
de
d 
di
re
ct
ly
 a
ft
er
 C
SF
 w
it
hd
ra
w
al
.
F C
SF
 d
ir
ec
tl
y 
co
lle
ct
ed
 in
to
 t
ub
es
 c
on
ta
in
in
g 
ED
TA
 a
nd
 0
.2
 m
l o
f 
Tr
an
sfi
xT
M
.
G
W
BC
 lo
ss
 is
 c
al
cu
la
te
d 
by
 a
dd
in
g 
up
 t
he
 ly
m
ph
oc
yt
e,
 m
on
oc
yt
e 
an
d 
gr
an
ul
oc
yt
e 
lo
ss
.
49
Flow cytometry in cerebrospinal fluid
This cell loss in native CSF can be reduced by addition of medium to CSF directly after 
sampling. In an earlier study, we showed that addition of serum-containing medium 
(RPMI-1640 with HEPES, L-Glutamine, Penicillin/Streptomycin, heat-inactivated fetal 
bovine serum and heparin) preserves CSF cells until at least five hours after sampling.9 
Another study showed that immediate addition of Earle’s balanced salt solution with 
human serum albumin to CSF prevents total WBC loss until at least 24h after sam-
pling.86 Also, addition of TransFixTM (fixative) has been shown to reduce CSF cell loss.14 
Other previous reports that investigated CSF cell preservation methods, were more 
laboratory based than clinical. Spiking of CSF cells into 5% fetal calf serum34 or saline85 
showed no significant cell loss, while spiking into acellular CSF did34,85 (Table 3). In 
addition, immediate cooling of the CSF sample84, a minimum of centrifugation steps34 
and aspiration of the supernatant instead of decanting the sample31 all ameliorate 
the loss of cells. Furthermore, due to lack of serum in CSF washing CSF cells before 
surface immunoglobulin staining is not necessary, which minimizes the wash steps in 
the protocol.31 The function of media, in most studies serum-containing, in preserving 
leukocytes is probably a buffering one. Both increase in pH in CSF after removal from 
the body (due to diffusion of CO2 out of the sample) and hypotonicity of CSF (causing 
movement of water and solutes from the extracellular to the intracellular compart-
ments) have been hypothesized to contribute to cell death85,87,88, although the effect of 
both factors has not been confirmed. It remains to be investigated which medium is 
the most effective in preventing CSF cell loss, being both practical for use in clinical 
settings and inexpensive. Evidently, CSF samples used for cell counting should be 
handled carefully by (i) collection in a buffering medium to prevent the rapid cell loss; 
(ii) a minimum of wash and centrifugation steps; (iii) aspirating instead of decanting; 
and (iv) data acquisition at least within 24h after sampling86, although the maximal 
storage time has not been determined yet.
Nonspecific fluorescence
Nonspecific or ”background” fluorescence may constitute a serious problem, 
especially in rare event detection in CSF samples. Its cause can be categorized into 
three groups.89 First, autofluorescence by excitation of naturally occurring cellular 
components (e.g., granule-associated flavoproteins in granulocytes) other than the 
antibody bound fluorochrome.89 This problem may be reduced by the use of a 532 nm 
laser90 or specific tools like single laser excitation91 and cell-by-cell autofluorescence 
correction.92 Second, spectral overlap which becomes significant when more than four 
colours are used and can be minimized by choosing combination of fluorochromes 
that have no or little overlap with each other.32 Third, non-specific antibody binding 
may occur which can be eliminated by optimizing antibody concentration using titra-
tion assays.93
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Blood contamination
Red cells present in CSF reflect either CNS bleeding or a traumatic lumbar puncture 
in which peripheral blood contaminates the CSF. The possibility of blood contamina-
tion of CSF samples can be ruled out by absence of cell populations which are highly 
represented in blood and most frequently absent in normal CSF, e.g. neutrophils and 
erythrocytes, particularly if these cells are present in blood at normal or high num-
bers and not detected in the CSF sample. In flow cytometric absolute cell counting 
of blood contaminated CSF samples, correction of the number of leukocytes has to 
be performed. We prefer to use the leukocyte/erythrocyte ratio in peripheral blood 
for correction94, because this method accounts for a patient’s individual situation. 
Alternatively, the CSF leukocyte number may be arbitrarily adjusted by correction 
according to the CSF erythrocyte count, which results in a correction of 1 leukocyte 
per 500 erythrocytes present in CSF.95,96 This latter method is widely used in clinical 
practice, because information on peripheral blood is not needed.
In blood contaminated CSF samples, which are investigated for the presence of CNS 
involvement of haematological malignancies, detection of a small population of 
neoplastic cells is only diagnostic of CSF involvement if these cells are not detected 
in a simultaneously obtained blood sample.31 In acute leukaemia, lumbar puncture 
should not be performed in an acute phase of the disease when the frequency of 
circulating malignant cells is high. In case of a traumatic lumbar puncture, malignant 
cells from the blood may become detectable in CSF leading to apparently false-positive 
CSF results. Moreover, iatrogenic contamination of CSF with malignant cells might be 
caused.97
Detection of monoclonal B-cell populations
Detection of a monoclonal B-lymphocyte population in CSF diagnoses CNS localization 
of a B-cell lymphoma in patients with haematological malignancies.6,43 B-lymphocyte 
clonality can be investigated by flow cytometry by assessing surface immunoglobulin 
light chain expression on CD19+ B-lymphocytes and comparison of the “light chain 
ratio (LCR)” or “kappa/lambda ratio”, which is determined by dividing the percent-
age of cells with the dominant light chain by the percentage of cells with the minor 
light chain.52 Normal ranges for the LCR differ between laboratories. A LCR threshold 
of 2 was reported to have a specificity of 92.3% and a sensitivity of 73.1% 98, while 
other studies proposed thresholds ranging from 2 to 6, with highest specificities and 
sensitivities around 70%.99-104 This indicates that if e.g., a threshold of 2 is used, ap-
proximately 10% of patients with a LCR above 2 are reported to have a monoclonal 
B-cell population, but do not have a B-cell lymphoma. Therefore, a LCR shift is only 
suggestive for presence of a monoclonal B-cell population, and further analysis of the 
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CSF has to be performed. Assessment of additional markers may increase specific-
ity as an abnormal forward scatter/sideward scatter/CD19/ CD20 phenotypic pattern 
indicates the presence of a malignant cell population14, although absence of such an 
abnormal pattern does not rule out malignancy. Usually, assessment of monoclonal-
ity and additional markers are combined, e.g. looking for monoclonality in a large 
forward scatter (FSC) or dim CD20 population, as presented in Figure 1. Furthermore, 
detection of clonally identical rearranged DNA sequences in malignant B lymphocytes 
by PCR is suggestive of the presence of B-cell lymphoma25, but only a minority of 
clinical laboratories have this technique operational. Another important point of at-
tention is that not every monoclonal B-cell population in CSF indicates symptomatic 
CNS disease.42 In patients with indolent haematological disorders, including chronic 
lymphatic leukaemia (CLL), malignant B cells in the CSF may represent asymptomatic 
leptomeningeal involvement and may require treatment only when (new) symptoms 
arise.52,105,106 At last, clinical follow-up will aid in diagnosing CNS disease.
PERSPECTIVES
We expect that the expansion of the number of colours amenable to flow cytometry 
will enable the simultaneous study of more parameters within the same sample. Using 
this approach, more refined information on CSF cell subsets will become available and 
cell populations can be defined more accurately.107 An ongoing challenge is the search 
for new fluorochromes that can be used in conjunction with current ones and yet 
do not contribute to significant spectral overlap.108 Even without new fluorochromes 
or lasers, instruments will improve through advances in software for data process-
ing. However, visualizing these data becomes more and more complex and would 
require multiple sequential analyses to provide information about each cell subset. 
Therefore, automated classification systems are being developed.109-112 Additionally, 
optimization of storage conditions to preserve CSF cells should result in higher cell 
yields and thereby increase the detection rate of flow cytometry in CSF samples with 
low cellularity.
Importantly, flow cytometry can be combined with molecular techniques including 
PCR to improve sensitivity in detecting CSF involvement of lymphoma.113,114 Further-
more, broadspectrum tumour cell-specific antigens could be fluorescently labelled and 
used in flow cytometric detection of CNS malignancy.13 In future, DNA clonality of the 
tumour might be identified on biopsy material and then followed by CSF assays along 
the course of the disease. This allows us to detect whether selection and development 
of new malignant clones occur in resistant or relapsing disease and will enable us to 
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appraise the therapeutic and prognostic implications of molecular diagnostic testing 
of CSF.26 However, these future techniques have to be internationally validated and 
standardized to be used in clinical practice.
In summary, these future advances will lead to a higher sensitivity and specificity to 
detect CNS localization of malignancies, while in neuro-inflammatory diseases (e.g., 
MS), CSF flow cytometry might become an important tool in the diagnosis, prognosis 
and follow-up of patients.
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ABSTRACT
Cytomegalovirus (CMV)-carrying individuals have significantly higher levels of 
effector memory and late memory T lymphocytes in their blood than noncarriers. 
To date, it is well recognized that the central nervous system (CNS) is subjected to 
active immunosurveillance, as evidenced by the presence of central memory T cells 
in cerebrospinal fluid (CSF) of healthy individuals. In order to investigate whether 
levels of effector memory and late memory T cells were also increased in the CSF of 
CMV-carrying individuals, we characterized CD4+ and CD8+ T-cell subsets in CSF and 
blood of both groups. Effector memory and late memory T cells were only rarely seen 
in CSF, which was similar in CMV carriers and noncarriers. In conclusion, there was 
no demonstrable difference in the numbers of effector memory and late memory T 
cells between CMV seronegative and CMV seropositive individuals.
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INTRODUCTION
CMV-carrying individuals are known to have higher absolute numbers of effector 
memory and late memory T cells in their blood than non-carriers.1,2 These T cells 
express CD57, do not express CD27 or CD28 and are CD45RA- (effector memory) or 
CD45RA+ (late memory).3 In the blood, CMV-specific T cells targeted against a single 
epitope can make up to 42% of CD8+ T cells, and most CMV-specific T cells are effector 
memory or late memory T cells.3 In contrast to earlier paradigms, it has become clear 
that the central nervous system (CNS) is also subjected to active immunosurveillance.4 
Central memory T cells are found in cerebrospinal fluid (CSF) of healthy individuals, 
and mice models showed trafficking of these cells between the CNS and cervical lymph 
lymph nodes.5-7 Recently, it has been shown that, in contrast to the blood, lymph 
nodes of CMV-carrying individuals have only low numbers of effector memory and 
late memory T cells.3 A possible explanation for this finding is that effector memory 
and late memory T cells do not express the chemokine receptor CCR7 needed for T 
cell-homing to the lymph nodes.8 Other chemokine receptors such as CCR5 andCCR6 
are thought to promote T cell homing to the CNS.9,10 Similar to CCR7, the level of 
expression of these chemokine receptors is higher in central memory T cells than in 
effector memory or late memory T cells.8 Therefore, we hypothesized that the effector 
memory or late memory T cells in the blood of CMV-carrying individuals do not traffic 
to the CNS. To test this hypothesis, we studied absolute numbers of naïve, central 
memory, effector memory and late memory T cells in CSF and blood of CMV-carrying 
individuals and non-carriers.
METHODS
Twenty-five patients were included who underwent lumbar puncture for spinal anaes-
thesia (n=15), or for diagnostic purposes (n= 10; Table 1). The study was approved by 
the local ethical review committee, and written informed consent was obtained. Two 
to 5 mL CSF was collected in 2 mL serum-containing medium, and analyzed by 6-color 
flow cytometry as previously described.5 For enumeration of leukocyte and lympho-
cyte subsets in CSF, we used a single 6-color mixture of monoclonal antibodies (mAb): 
CD3 conjugated with fluorescein isothiocyanate (FITC; clone SK7), CD56 conjugated 
with phycoerythrin (PE; clone C5.9), CD45 conjugated with peridinyl cholorophyllin 
(PerCP; clone 2D1), CD4 conjugated with PE-Cy7 (clone SK3), CD19 conjugated with 
allophycocyanin (APC; clone HIB19) and CD8 conjugated with APC-Cy7 (clone SK1). For 
blood two 4-color mAb mixtures were used: CD3-FITC, CD56-PE, CD45-PerCP and CD19-
APC and CD4-FITC (clone HP2/6), CD8-PE (clone SK1), CD45-PerCP and CD3-APC (clone 
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SK7). T cell subsets in both compartments were assessed with a 6-colorpanel: CD45RA-
FITC (clone L48), CD127-PE (clone hIL-7R-M21), CD4-PerCP (clone SK3), CD25-PE-Cy7 
(clone 2A3), CD27/28-APC (clone L128/CD28.2) and CD3-APCeFluor780 (clone UCHT1). 
All mAb were obtained from BD Biosciences (San Jose, CA) with the exception of CD56-
PE (Dako, Glostrup, Denmark), and CD3-APC-eFluor780 and CD19-APC (eBioscience, 
San Diego, CA). CD4+ and CD8+ T cells were further classified according to CD45RA 
expression and CD27 and CD28 expression in naïve T cells (CD45RA+, 27/28+), central 
memory T cells (CD45RA-, CD27/28+), effector memory T cells (CD45RA-, CD27/28-) 
and late memory T cells (CD45RA+, CD27/28-) as previously described.5 Samples were 
acquired on a FACSCanto flow cytometer (BD Biosciences) and analyzed using FCS 
Express software (De Novo Software, Los Angeles, CA). For absolute numbers of total T 
lymphocytes in blood, we used a stain, lyse, no-wash method based on counting beads. 
For further characterization of T cell subsets, we used a lyse, stain and wash technique. 
CSF cells were concentrated by centrifugation and resuspended in 400 µL PBS. Of 
this suspension, 100 µL was stained for each panel, washed, and resuspended in 100 
µL PBS. For absolute cell counts, 100 µL of counting beads were added 5. Individuals 
were excluded from the study if their CSF sample contained less than 25 leukocytes 
per staining.11 Since absolute cell numbers in CSF of patients that underwent spinal 
anesthesia were not significantly different from those of patients that underwent a 
diagnostic lumbar puncture but were not diagnosed with a neuroinflammatory dis-
ease (e.g. tension headache, data not shown), these patient groups were pooled for 
analysis. The absolute cell numbers of each subset were stratified according to CMV 
serostatus, and cell numbers in CMV seropositive versus CMV seronegative individuals 
were compared with the Mann-Whitney test using SPSS version 20 (IBM, Chicago, IL). 
Figure 2 was made with Prism version 5 (GraphPad, San Diego, CA).
Table 1. Patient characteristics
  CMV- CMV+ Pc
N 12 13
Gender (M/F) 6/6 4/9 0.43
Age (years)A 61 (32-88) 57 (19-76) 0.32
Spinal aneasthesia / diagnosticB 9/3 6/7 0.23
CSF leukocyte counts (×106/L)A 3 (1-7) 2 (1-5) 0.71
CSF protein concentration (g/L)A 0.34 (0.18-0.49) 0.33 (0.20-0.44) 0.37
A median, range
B Included were patients without neurological disease who underwent lumbar puncture for spinal anaesthesia 
(usually for orthopaedic surgery) and patients who had a diagnostic lumbar puncture for suspected 
neurological disease (none of these patients turned out to suffer from a neuro-inflammatory disorder).
C P-values were calculated with the Mann-Whitney or Fisher exact test.
Abbreviations: CMV, cytomegalovirus; N, number of patients; M, male; F, female; CNS, central nervous 
system; CSF, cerebrospinal fluid.
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RESULTS
Patient characteristics are shown in table 1. Because all CSF samples contained a 
statistically sufficient number of leukocytes (we measured a median of 498 leukocytes 
per panel, while more than 25 leukocytes per panel are required), no patients were 
excluded from analysis. Both groups (CMV seronegative patients and CMV seropositive 
patients) did not differ significantly with respect to gender, age and reason for lum-
bar puncture. Also, total CSF leukocyte counts and CSF protein concentrations were 
similar in both groups. Figure 2 shows absolute numbers of naïve, central memory, 
effector memory and late memory CD4+ and CD8+ T cells in CSF (panel A and B) and 
blood (panel C and D) of CMV seronegative and CMV seropositive individuals. In the 
blood, a trend was seen towards higher numbers of CD4+ effector memory and CD4+ 
late memory T cells in CMV seropositive individuals as compared to CMV seronegative 
individuals, but these differences did not reach statistical significance (p=0.17 and 
p=0.19, respectively). The numbers of CD4+ effector memory and CD4+ late memory T 
cells in CSF were uniformly low in CMV carriers and non-carriers.
The numbers of CD8+ effector memory and late memory T cells in the blood were 
significantly higher in CMV seropositive individuals. Within the CD8+ T lymphocytes, 
effector memory and late memory cells were only rarely seen in CSF (median, 0.02; 
Figure 1.
Representative example of the expression of CD45RA and CD27/28 on CD4+ and CD8+ T cells in CSF 
of a CMV seropositive patient. The vast majority of CD4+ and CD8+ T cells are CD45RA-CD27/28+ 
central memory T cells. CD45RA-CD27/28- effector memory T cells and CD45RA+CD27/28- late 
memory T cells were only sporadically detected, similar to CMV seronegative patients (data not 
shown).
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range, 0.00-0.11 cells/µL and 0.02; 0.00-0.06 cells/µL respectively) and did not differ 
significantly between CMV seronegative and CMV seropositive individuals.
DISCUSSION
In this study, we found no demonstrable difference between the numbers of effector 
memory and late memory T cells in CSF of CMV seronegative patients and those of 
CMV seropositive individuals, despite significant differences in the numbers of these 
subsets in the blood. These changes in the blood were most prominent and significant 
within the CD8+ T cells, and to a lesser extend seen in CD4+ T cells (not reaching 
significance). The numbers of circulating effector memory and late memory T cells in 
the blood were shown to increase with age, and are strongly correlated with latent 
Figure 2.
Absolute numbers of naïve, central memory, effector memory and late memory CD4+ and CD8+ 
T cells in CSF (panel A and B) and blood (panel C and D) of CMV seronegative and CMV se-
ropositive individuals. Data are shown on logarithmic scales in order to compress the figure. 
Horizontal lines represent medians. For graphic representation, cell numbers <0.01 cells/µL (cor-
responding to < 5 measured events) were assigned a value of 0.005 cells/µL. P-values represent 
the results of the Mann-Whitney test. Abbreviations: CSF, cerebrospinal fluid; PB, peripheral 
blood; CMV, cytomegalovirus; CMV+, seropositive for CMV; CMV-, seronegative for CMV; CM, 
central memory; EM, effector memory; LM, late memory.
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CMV infection.12 Their presence is thought to at least partly result from antigenic 
stimulation of T cells by latently CMV-infected endothelial and myeloid cells. CMV-
specific T cells are thought to prevent viral reactivation by cytolysis of infected cells.3,12 
Interestingly, the lymph nodes of CMV-carrying individuals contain only few effector 
memory and late memory T cells, and the few CMV-specific T cells present have a 
central memory phenotype.3 Our findings in CSF support the hypothesis that CD8+ ef-
fector memory and late memory T cells under normal circumstances do not enter the 
CNS. This situation may be due to a low level of expression of chemokine receptors 
such as CCR5 and CCR6 that are needed for T cell homing to the CNS.8,10 In addition, 
lack of expression of molecules such as CD162 (selectin P ligand) and CD49D (α 4 
subunit of very late antigen 4 receptor) by T lymphocytes or selectin P and very late 
antigen 4 by endothelial cells may prevent migration of T lymphocytes across vascular 
endothelium.4 In this study, we did neither assess the expression of these molecules 
nor the specificity of the CSF T cells. For this moment, we hypothesize that effector 
memory and late memory T cells only enter the CNS under exceptional circumstances 
(for example in case of CMV encephalitis), while under normal conditions, central 
memory T cells enter and leave the CNS in the context of CNS immunosurveillance.
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ABSTRACT
Multi-parametric flow cytometry was used to study lymphocyte subsets and dendritic 
cells in paired blood and CSF samples from 11 newly diagnosed patients with progres-
sive anti-Hu antibody associated paraneoplastic neurological syndromes (Hu-PNS), 9 
patients with other inflammatory neurologic disorders (IND), and 12 patients with 
other non-inflammatory neurologic disorders (OND). Hu-PNS patients had elevated 
numbers of regulatory T cells, central memory T cells, class-switched B cells and 
dendritic cells in their CSF. These findings support the hypothesis that the immune 
system is locally activated in Hu-PNS, and suggests common etiological pathways 
between Hu-PNS and other inflammatory central nervous system disorders.
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INTRODUCTION
Anti-Hu antibody associated paraneoplastic neurological syndromes (Hu-PNS) cause 
severe neurological symptoms and carry a poor prognosis.1 In Hu-PNS, Hu-antigens ex-
pressed by cancer cells are thought to trigger an immune response which cross-reacts 
with neurons that express the same Hu antigens. Evidence for this immune response 
is provided by high titers of anti-Hu antibodies (Hu-Ab) in blood and cerebrospinal fluid 
(CSF) of Hu-PNS patients.1 Because Hu-proteins are intracellular proteins and because 
a direct pathogenic role of Hu-Ab could never be proven2, it has been hypothesized 
that neuronal destruction in Hu-PNS is mediated by cytotoxic T cells.3 A pathogenic 
role for cytotoxic T cells is supported by autopsy studies showing cytotoxic T cells in 
close proximity to damaged neurons.4,5 However, studies to identify cytotoxic T cells 
specific for Hu-proteins have shown conflicting results.6-11 Therefore, the possible role 
of the immune system in Hu-PNS remains incompletely understood.
Previously, we have reported that blood of Hu-PNS patients contained higher numbers 
of regulatory T cells (Tregs) and higher proportions of activated T cells than blood 
of small-cell lung cancer patients and healthy controls.12 These findings supported 
the hypothesis that Hu-PNS is an immune-mediated disease in which CD4+ T cells – 
including Tregs – and CD8+ T cells are involved. In CSF of Hu-PNS patients, we showed 
that, next to approximately five times higher numbers of CD4+ T cells and CD8+ T 
cells, B cell numbers were 20 times higher than in non-cancer controls and cancer 
patients without PNS.13 The high B cell numbers in CSF are in line with the intrathecal 
antibody-production found in these patients.14
In other neurological inflammatory diseases, it has been shown that lymphocytes in 
CSF might search for their specific antigen, and  –  if they encounter their specific an-
tigen – migrate to the nervous tissue to fulfil their effector functions.15,16 Additionally, 
dendritic cells (DC) were shown to be present in CSF and might play a role by trans-
porting antigens from the CNS to deep cervical lymph nodes, but may also stimulate 
lymphocytes within the CNS compartment.17,18
In the present study, we used multi-parametric flow-cytometry to further investigate 
the CSF in recently diagnosed Hu-PNS patients with progressive neurological disease, 
focussing on (i) Tregs, (ii) the differentiation stages of T cells and B cells, and (iii) DCs. 
These findings were compared with paired blood and CSF samples from patients with 
other inflammatory neurological disorders (IND) of non-paraneoplastic origin and 
patients with non-inflammatory neurological disorders (OND).
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MATERIALS AND METHODS
Specimen collection
All Hu-PNS patients had a definite diagnosis of Hu-PNS19 and progressive neurological 
symptoms over the last 4 weeks. Neurological controls included patients with other 
inflammatory neurological disorders (IND) and patients with other (non-inflammatory) 
neurological disorders (OND). The IND control group consisted of three patients with 
meningitis (two patients treated for bacterial meningitis [one of them had an intra-
cranial mycotic aneurysm], and one treated for cryptococcal meningitis), two patients 
with transverse myelitis, and one each with optic neuritis, cranial neuritis (n. VII 
caused by VZV reactivation), PML and cerebral vasculitis. The OND patients consisted 
of three patients with metabolic encephalopathy (toxic in one), two with headache 
(one with tension type headache and the other with analgesia induced headache), two 
with hydrocephalus (one with normal pressure hydrocephalus and one with commu-
nicating hydrocephalus) and one each with polyneuropathy, steroid myopathy, benign 
paroxysmal positional vertigo, carpal tunnel syndrome and radiation myelopathy. Pa-
tients who received intrathecal or systemic chemotherapy in the last 12 months were 
excluded. All but three patients had not received any immunomodulatory medication 
prior to CSF withdrawal. One Hu-PNS patient received intravenous immunoglobulins 
3 weeks prior to CSF withdrawal. In one IND patient (with optic neuritis) CSF was 
drawn immediately after her first infusion with intravenous methylprednisolone, 
another IND patient (with cranial neuritis) received tacrolimus 2mg/day (after heart 
transplantation) and prednisone 5 mg/day. Paired blood and CSF samples were drawn. 
Blood was collected in EDTA tubes. Three to 5 mL CSF was obtained by lumbar punc-
ture with a 20 Gauge atraumatic Sprotte needle, and collected in serum-containing 
medium 20 to reduce decay of leukocytes. Methods of sample collection and reference 
values from NNC have been previously published.20 The study was approved by the 
local ethical review committee, and written informed consent was obtained.
Staining procedures
We used fluorochrome-conjugated antibody panels for leukocyte subsets, T cell 
subsets and DC subsets as we described before.20 The 6-color antibody panel for B 
cell subsets was: IgD-FITC (clone IA6-2), IgM-PE, CD38-PerCP-Cy5.5 (clone HIT2), CD27 
PE-Cy7 (clone O323), CD138-APC (clone MI15) and CD19-APC-Cy7 (clone SJ25C1). All 
antibodies were obtained from BD Biosciences (San Jose, CA) with exception of CD56-
PE (Dako, Glostrup, Denmark), IgD-FITC (Nordic, Taby, Sweden), IgM-PE (Southern 
Biotech, Birmingham, USA) and CD3-APC-eFluor780, CD19-APC, CD27-PE-Cy7 and 
CD123-PE-Cy7 (eBioscience, San Diego, CA). Staining procedures have been described 
before.20 Briefly, for absolute numbers of leukocyte subsets in blood, we used a stain, 
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lyse, no-wash method based on counting beads (Flowcount, Beckman Coulter, Miami, 
FL). For T cell, B cell and DC subsets in blood, we used a lyse, stain and wash tech-
nique. CSF cells were concentrated by centrifugation, resuspended in PBS, stained and 
washed. For absolute cell counts, 100 µL of counting beads were added (Cyto-Cal Count 
Control, Duke Scientific Corporation, Palo Alto, CA).
Data analysis
List mode data were acquired on a 6-color FACSCanto flow cytometer (BD Biosciences) 
and analysed with FCS express (De Novo Software, Los Angeles, CA). Definitions of T 
cell and DC subsets were described before.20 Immunological definitions of the B cell 
subsets were adapted from Caraux et al.21 and included naïve B cells (CD19+, CD27-, 
CD38-/+), IgD/M memory B cells (CD19+, CD27+, CD38-/+, IgD/M+), class-switched memory 
B cells (CD19+, CD27+, CD38-/+, IgD/M-) and plasma blasts (CD19+, CD27+, CD38high). Gat-
ing strategies for T cell subsets, B cell subsets and dendritic cells are shown in figure 
1. Absolute cell numbers are expressed as medians and 5th-95th percentiles. We used 
Fisher’s test to compare the distribution of gender, and the Mann-Whitney U test 
to compare age, CSF protein content and cell numbers in Hu-PNS patients with the 
control groups (as indicated in Table 1 and 2). Prism version 4 (GraphPad, San Diego, 
CA) and SPSS version 17.0.2 (IBM, Chicago, IL) were used for the statistical analyses. 
Two-sided p-values <0.05 were considered significant.
RESULTS
Clinical characteristics
Table 1 shows the clinical characteristics of the 11 Hu-PNS patients and the IND and 
OND control groups. Four of the 11 Hu-PNS patients presented with an encephalomy-
elitis, three of them also had a sensory neuronopathy; four patients presented with 
sensory neuronopathy; one patient with subacute cerebellar ataxia; and one patient 
with limbic encephalitis. The median score on the modified Rankin scale22 at the time 
of study entry was 3 (range 2-4). The median duration of neurological symptoms was 
5 months (range 1-12) and the median Hu-Ab titer was 1,600 (range 400-12,800). A 
tumor was found in 10 of the 11 Hu-PNS patients: Five patients had a small-cell lung 
cancer, three patients had radiographic evidence for a lung tumor, one patient had a 
myxoid chondrosarcoma, and one patient had a small cell tumor of the parotid gland. 
Hu-PNS patients were significantly older than IND patients and Hu-PNS patients had a 
significantly higher CSF protein level than the OND patients (Table 1).
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Figure 1.
Gating strategies for the enumeration of major lymphocyte subsets (panel A), CD4+ T cell subsets 
(panel B), B cell subsets (panel C) and dendritic cells (panel D). CD8+ T cell subsets were gated 
similarly to the ‘CD4+ non-Tregs’ in the right plot of panel B. For absolute counting, microspheres 
were used and defined as FSClow, FLhigh (upper left plot panel A). We used a hierarchical gating 
strategy, the applied gates are indicated in boldface above each plot and refer to similarly named 
gates in the previous plots. ‘CD4+ Non-Tregs’ refers to all (CD3+CD4+) events except those in the 
‘Tregs’ gate (panel B). Dendritic cells were defined as (CD45+HLADR+) events that were negative 
for expression of CD3, CD14, CD16, CD19, CD20 and CD56 (Lin1-). To confirm that these events 
represented dendritic cells, we additionally stained for CD11c (marker for myeloid dendritic cells) 
and CD123 (marker for plasmacytoid dendritic cells; panel D).
Abbreviations: Tregs, regulatory T cells; CM, central memory T cells; EM, effector memory T cells; 
LM, late memory T cells; Lin1, cocktail composed of CD3, CD14, CD16, CD19, CD20 and CD56 
monoclonal antibodies; DC, dendritic cells; mDC, myeloid dendritic cells; pDC, plasmacytoid den-
dritic cells.
75
Cellular composition of CSF in Hu-PNS
T cell subsets
The CSF of Hu-PNS patients showed higher absolute T cell numbers than CSF of OND 
patients (Table 2). Both major T cell subsets, CD4+ T cells and CD8+ T cells, were elevated 
(3.5 and 2.6 fold, respectively). Of the CD4+ T cells, Tregs showed the largest increase 
in absolute cell numbers (8-fold, Table 2). The proportion of Tregs was also increased: 
Tregs made up 10.0% of CD4+ T cells (5.7-25.9) in Hu-PNS patients versus 5.5% (0.0-30.3) 
in OND patients (P=0.014). In Hu-PNS patients, 99.5% (94.6-100.0) of these Tregs did not 
express CD45RA, indicating that these Tregs were antigen-experienced.
In CSF of Hu-PNS patients, most CD4+ and CD8+ T cells had a central memory pheno-
type (Table 2 and Figure 2). The absolute number of CD4+ central memory T cells was 
2.9 times higher, the number of CD8+ central memory T cells 4.3 times higher than 
in OND patients (Table 2). The proportions of CD4+ and CD8+ central memory T cells 
were also increased in Hu-PNS as compared to OND patients (P<0.001 and P=0.014 
respectively, Figure 2). The absolute numbers of the further differentiated CD4+ and 
CD8+ T cell subsets (with effector memory and late memory phenotype) did not differ 
from OND patients (Table 2).
B cell and DC subsets
The absolute numbers of B cells in CSF of Hu-PNS patients were clearly higher than 
in CSF of OND patients (Table 2). The largest subsets were class-switched memory 
B cells, followed by plasma blasts and non-class switched memory B cells. Also the 
proportion of B cells was elevated in Hu-PNS patients: B cells made up 3.7% (1.0-19.9) of 
lymphocytes vs. 0.5% (0.0-7.6) in OND patients (P=0.003). The absolute numbers of DCs 
in CSF of Hu-PNS patients were significantly higher than in OND patients (Table 2). In 
Table 1. Clinical characteristics
  Hu-PNS   IND   OND
      Range       Range PB       Range PC
n 11 9 12
Male 2 5 ns 4 ns
Age (years)A 65 45-76 44 29-76 0.009 65 32-88 ns
CSF
Leukocytes (cells/µL)A 4.0 1.0-49.0 7.0 0.0-172.0 ns 3.5 1.0-7.0 ns
Protein (g/L)A 0.59 0.28-2.47 0.37 0.21-1.77 ns 0.30 0.18-0.67 0.021
A median 
B Hu-PNS vs. IND
C Hu-PNS vs. OND
Groups were compared with a Mann-Whitney U test or Fisher’s exact test, ns= not significant (p>0.05).
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Hu-PNS patients, 50.9% (20.4-100.0%) of DCs were CD11c+ myeloid DCs, the remaining 
DCs were CD123+ plasmacytoid DCs.
Cell numbers in CSF of IND patients
The median absolute cell numbers in IND patients were generally in-between those of 
Hu-PNS patients and OND patients (Table 2, and data not shown). Compared to Hu-PNS 
patients, IND patients had lower proportions of CD4+ central memory T cells (P=0.028, 
Figure 2). Compared to OND patients, IND patients had higher absolute numbers of B 
cells (P=0.032), especially IgD/M memory B cells (P=0.037, Table 2).
Absolute cell numbers in blood
We additionally compared the absolute cell numbers of the investigated subsets in the 
blood of Hu-PNS patients with IND and OND patients, and did not find any significant 
differences between these groups (data not shown).
Figure 2.
Percentage of central memory T cells within the non-regulatory CD4+ T cells (panel A) and CD8+ 
T cells (panel B) in CSF of Hu-PNS patients, IND patients and OND patients. For both subsets 
(CD4+ and CD8+), central memory T cells were the main differentiation stage, and their percent-
ages were higher in Hu-PNS patients than in OND patients. In Hu-PNS patients, the median 
percentage of CD4+ central memory cells was 97.7% (5th-95th percentile: 91.2 – 100.0%) of 
CD4+ T cells, versus 89.4% (66.4-93.1%) in OND patients (P<0.001). The median percentage of 
CD8+ T cells was 72.6% (20.22-83.8%) in Hu-PNS patients versus 49.3 (0.0-63.3%) in OND pa-
tients (p=0.014). One IND had no detectable CD8+ T cells and is therefore not shown in panel B 
of this figure. The median percentages of central memory T cells in IND controls were generally 
in-between those of Hu-PNS patients and OND controls (93.2% [45.5-95.8%] of CD4+ T cells, 
and 61.3% [0.0-73.3%] of CD8+ T cells). Abbreviations: Hu-PNS, patients with anti-Hu antibody 
associated paraneoplastic neurological syndromes, IND, inflammatory neurological disorders; 
OND, other (non-inflammatory) neurological disorders.
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DISCUSSION
In this study, we confirmed our previous observations that CSF of Hu-PNS patients 
contained higher numbers of CD4+ T cells, CD8+ T cells and B cells than CSF of patients 
with non-inflammatory neurological disorders.13 In addition, we characterized these 
cells further and found higher numbers of Tregs, CD4+ and CD8+ central memory 
T cells and class-switched memory B cells in CSF of Hu-PNS patients than in OND 
patients. Finally we also found higher numbers of DCs in Hu-PNS patients than in 
OND patients. Median cell numbers in IND patients were generally in-between those 
of Hu-PNS patients and OND patients, while the cell numbers of OND patients were 
generally similar to previously published non-neurological patients.20
The pronounced expansion of antigen-experienced Tregs in CSF of Hu-PNS patients 
in the absence of similar changes in the blood suggests that these cells are not just 
a result of the underlying cancer,23 but are part of the local immune response in 
the CNS. A similar increase of Tregs has been described in CSF of multiple sclerosis 
(MS) patients.24 Antigen-experienced Tregs are known to suppress immune responses 
against self-antigens by secretion of cytokines such as IL-10.25 The progressive disease 
in our Hu-PNS patients, however, questions the effectiveness of these Tregs in Hu-PNS. 
This is in line with previous studies that suggested that Treg function is compromised 
in two ways in immune-mediated diseases of the CNS. First, intrinsic factors in Tregs, 
such as reduced expression or function of the forkhead/winged helix transcription 
factor (FoxP3), may compromise suppressive function, as supported by the impaired 
suppressive function of Tregs in peripheral blood of Hu-PNS patients26 and MS pa-
tients.27 Second, the local inflammation in the CNS might results in a cytokine milieu 
(high levels of IL-6 and TNF) that might interfere with effective suppression of effector 
T cells by Tregs, as shown in experimental autoimmune encephalitis.28
The expansion of CD4+ and CD8+ central memory T cells in CSF of Hu-PNS patients 
supports the hypothesized role of T helper cells and cytotoxic T cells in neuronal 
destruction in Hu-PNS. Central memory T cells have encountered their antigen in the 
lymph nodes, and are able to cross the blood-CSF barrier to search for their antigen.15 
Especially in the initiation phase of immune-mediated CNS disease, central memory 
T cells in CSF are thought to play a key role in disease pathogenesis.15,16,29 Expansion 
of CD4+ and CD8+ central memory T cells is also found in CSF of patients with MS.15,30 
Upon a second antigen encounter, central memory T cells quickly differentiate into 
effector cells that invade the CNS tissue, as supported by autopsy studies showing T 
cell infiltrates in the CNS of Hu-PNS patients.4,5
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As we previously described, a pronounced expansion of B cells in CSF of Hu-PNS 
patients, and to a lesser extend IND patients, was found. Since antibodies were not 
shown pathogenic in animal models2 and Hu-proteins are intracellular antigens, the 
role of B cells in Hu-PNS is long considered of minor importance.3 B cells could, how-
ever, contribute to Hu-PNS in many ways.29,31 First, like DCs, memory B cells are potent 
antigen-presenting cells that could contribute to differentiation of central memory T 
cells in CSF to the effector cells that invade CNS tissue.29 Interesting is the presence 
of class-switched B cells. Class-switched CD27+ memory B cells have received help of 
CD4+ T cells32 and are more efficient antigen-presenting cells than non-class switched 
B cells.33 Second, B cells might contribute to CNS inflammation by the production of 
pro-inflammatory cytokines.29,31 Finally, the plasma blasts in CSF may, together with 
plasma cells in CNS tissue, be responsible for the intrathecal Hu-Ab production found 
in Hu-PNS patients.14
The median cell number in patients with IND were generally in-between those of Hu-
PNS patients and patients with OND. These findings are consistent with other studies 
on inflammatory CNS disease.16,34 The overlap in cell numbers between Hu-PNS and 
IND supports the hypothesis that Hu-PNS is an immune-mediated disease. In addi-
tion, our results are reminiscent of findings reported in multiple sclerosis. Hence, 
we speculate that newly developed therapies for MS that interfere with lymphocyte 
trafficking from the lymph nodes to the CNS, such as fingolimod or natalizumab, may 
also be effective in Hu-PNS.35,36
In the current study, Tregs were defined as (CD3+, CD4+, CD25high, CD127dim) because 
it has been shown these cells represents the large majority of FoxP3+ Tregs.24,37,38 We 
choose this definition instead of the ‘gold standard’ (CD3+, CD4+, CD25high, FoxP3+), 
because the fixation and the many washing steps needed for this staining were an-
ticipated to result in too much cell loss in the already paucicellular CSF samples. 
Indeed, other studies also used immunological definitions limited to surface antigens 
to overcome this problem.24,27
To conclude, we found higher numbers of Tregs, central memory T cells, class-switched 
memory B cells and DCs in CSF of Hu-PNS patients than in OND patients. The absence 
of similar changes in the blood of Hu-PNS patients supports the hypothesis that their 
immune system is locally activated. Besides supporting a role for cytotoxic T cells, T 
helper cells and B cells, the results of this study suggest that Tregs and DCs are also 
involved in the pathogenesis of Hu-PNS. Our findings are similar to those reported in 
MS, and indicate that future studies are needed to study these neuro-inflammatory 
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diseases side-by-side. We speculate that these studies may identify common targets 
for therapies.
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Supplementary Figure 1.
Percentages of T cell subsets within the non-regulatory T cells (panel A), percentages of CD8+ T 
cell subsets within the CD8+ T cells (panel B), and percentages of B cell subsets within the B cells 
(panel C) in CSF of Hu-PNS patients, IND patients and OND patients. One IND had no detectable 
CD8+ T cells and is therefore not shown in panel B of this figure. The vast majority of CD4+ and 
CD8+ T cells were central memory T cells. The percentages of effector and late memory CD4+ 
and CD8+ T cells were very low. B cells were virtually absent in CSF of other (non-inflammatory) 
neurological disorders, and therefore no percentages could be calculated for this patient group 
(indicated with not applicable, NA). Abbreviations: NA, not applicable; Hu-PNS, patients with 
anti-Hu antibody associated paraneoplastic neurological syndromes, IND, inflammatory neuro-
logical disorders; OND, other (non-inflammatory) neurological disorders.
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ABSTRACT
Flow cytometry is a sensitive method for detection of leptomeningeal localizations of 
hematological malignancies (LHM) in cerebrospinal fluid (CSF). Rapid processing of 
CSF is needed, as leukocyte numbers appear to decline quickly after lumbar puncture. 
The cell-stabilizing agent TransFix™ may enhance the detection of LHM in CSF by 
preventing cellular loss. To study the effects of TransFix™ on leukocyte numbers and 
the detection of LHM, we prospectively collected 99 CSF samples from patients with 
suspected or proven LHM in tubes with (i) TransFix™; (ii) serum-containing medium; 
and (iii) no cell-stabilizing agents (native CSF). Presence of LHM and absolute leukocyte 
numbers were determined by flow cytometry after 30 minutes and 18 hours of storage. 
Leukocyte numbers in TransFix™- stabilized CSF were higher than in the correspond-
ing native samples at both time points (1.4× and 2.3× respectively, P<0.0001 on each 
occasion). After 18 hours of storage, TransFix™ enhanced the detection of LHM in CSF. 
In all discordant paired observations (13/99, P=0.005), the level of suspicion (classified 
as positive, suspicious or negative) in CSF with TransFix™ was higher than in native 
CSF. We conclude that the use of TransFix™-containing CSF storage tubes prevents 
cellular loss, and enhances flow cytometric detection of LHM after 18 hours of storage.
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INTRODUCTION
The use of flow cytometric analysis of cerebrospinal fluid (CSF) in addition to morpho-
logic CSF examination greatly increases the detection rate of leptomeningeal localiza-
tions of hematological malignancies (LHM), as compared to the use of morphology 
alone.1-9 Therefore, flow cytometric CSF analysis is recommended in all patients with 
suspected primary central nervous system lymphomas (PCNSL), patients with other 
hematological malignancies complicated by neurological signs and symptoms sug-
gestive of LHM, and patients with aggressive non-Hodgkin lymphomas (NHL) who by 
themselves have an increased risk of developing LHM.10,11
Since cell numbers in CSF are low (normally <5 cells/µL) and appear to decrease rapidly 
ex-vivo,12,13 CSF samples for flow cytometric analysis should be processed immediately 
after withdrawal.14,15 Thus, in order to obtain optimal results, immediate availability 
of this technique is needed, as any delay in sample transportation or processing will 
lead to decreased CSF cell numbers and will likely reduce the sensitivity of analysis.
To address this problem, various cell stabilizing methods have been employed to reduce 
cellular loss in CSF samples prior to flow cytometric analysis, as recently reviewed.14 
However, only two of these methods have been used in large clinical studies aimed 
at the detection of LHM: (i) CSF withdrawal in tubes with 2 mL serum-containing 
medium;1 and (ii) CSF withdrawal in tubes with 0.2 mL of the commercially available 
fixative agent TransFix™.4
Addition of serum-containing medium to CSF prevents cellular loss up to at least 5 
hours of storage.12 However, CSF storage tubes with serum-containing medium are not 
commercially available and have a limited shelf life of around 3 months. The use of 
TransFix™ CSF storage tubes may be an attractive alternative for cell stabilization in 
CSF because of their commercial availability and longer shelf life, i.e. one year.
TransFix™ is a cellular stabilization reagent that contains a buffer, an aliphatic al-
dehyde, and heavy metal salts.16 It was originally designed to stabilize whole blood 
samples for flow cytometric counting of lymphocytes and their subsets such as CD4+ 
and CD8+ T cells, and was first used by the United Kingdom National External Quality 
Assessment Service (UK NEQAS) for leukocyte immunophenotyping.17 Later, TransFix™ 
became commercially available, and was shown to stabilize whole blood samples for 
up to 10 days.18 TransFix™ in combination with EDTA has also been used to stabilize 
CSF samples to enable overnight shipping to a central flow cytometry facility.4
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Although the above studies suggest that cell stabilization with serum-containing 
medium or TransFix™ may enhance the flow cytometric detection of LHM in CSF,1,4 
no studies have been published that directly compare CSF stabilization with Trans-
Fix™ with the use of serum-containing medium or native CSF. Therefore, the clinical 
significance of the use of TransFix™ or serum-containing medium for flow cytometric 
CSF analysis is unknown.
In this study, we prospectively investigated the effects of TransFix™ on the detection 
of LHM in CSF and CSF cell numbers by flow cytometry. CSF samples were processed 
immediately (i.e. 30 minutes after withdrawal), and after overnight storage (i.e. after 
18 hours). Results were compared with those of simultaneously collected CSF samples 
that were stabilized with serum-containing medium, and simultaneously collected 
CSF samples without cell stabilizing agents (native CSF).
MATERIALS AND METHODS
Sample collection and storage
From January 2011 onwards, 99 diagnostic and follow-up CSF samples were obtained 
at the Erasmus University Medical Center/ Daniel den Hoed Cancer Center from 43 pa-
tients who (i) underwent lumbar puncture for flow cytometric CSF analysis to test for 
LHM; and (ii) provided written informed consent. This study was performed according 
to the Declaration of Helsinki, and its procedures were approved by the local ethics 
committee. In addition to the CSF drawn for conventional tests and procedures, a total 
of approximately 3 mL extra CSF was directly collected in three polypropylene tubes: 
~1 mL in a tube with 0.2 mL TransFix™/EDTA (Caltag Medsystems, Towcester, UK); ~ 1 
mL in a tube with 2 mL serum-containing medium (RPMI-1640 with 35mM HEPES, 1 
mM L-Glutamine, 2% penicillin/streptomycin, 5% heat-inactivated fetal bovine serum 
and 2,500 IU heparin); and ~1 mL in a tube without cell-stabilizing agent (native CSF). 
CSF was drawn in these three tubes in alternating order to avoid a possible influence 
of the order in which the tubes were filled. Each of the three tubes was equally split 
into an additional 2 sterile polypropylene tubes: one of these tubes was processed 30 
minutes after withdrawal; the other was stored at 4oC overnight (18 hours). Before 
and after splitting of the samples, the weight of the tubes was recorded to verify CSF 
volumes.
Flow cytometry
Detailed procedures for CSF processing,15 determination of absolute cell numbers,12,19 
and to test for LHM1,14 have been published elsewhere. Briefly, CSF cells were con-
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centrated by centrifugation (8 minutes, 450 g), and resuspended in 100 µL phosphate 
buffered saline (PBS). In cases where surface immunoglobulins (sIg) had to be detected, 
cells were washed with PBS. Six-color antibody panels were chosen based on clinical 
information, and –if available– results of previous histological or flow cytometric 
analyses. All panels included anti-CD45 peridinin chlorophyll protein (PerCP; clone 
2D1, Dako, Glostrup, Denmark) to distinguish leukocytes from debris and other cells. 
In addition, we used anti-CD4 fluorescein (FITC; clones SK3+SK4), anti-CD8 FITC (clone 
SK1), anti-CD5 R-phycoerythrin (PE; clone L17F12), anti-CD13 PE (clone L138), anti-
CD34 PE (clone 8G12), anti-CD10 PE (clone HI10a), anti-CD19 PE (clone 4G7), anti-CD4 
PE-Cy5 (clone SK3), anti-CD19 allophycocyanin (APC; clone SJ25C1), anti-CD14 APC-H7 
(clone MΦP9), anti-CD19 APC-Cy7 (clone SJ5C1), and anti-CD20 APC-Cy7 (clone L27; all 
from BD Biosciences); anti-sIg κ PE (clone R0436; Dako), anti-sIgκ FITC (clone HP6156; 
Lucracon, Stuttgart, Germany); anti-sIgλ FITC (clones HP6062/6054; both from Invit-
rogen, Carlsbad, CA); anti-sIgλ PE (cat. 2072-09) and anti-sIgM PE (cat. 2020-09; both 
from SouthernBiotech, Birmingham, AL); anti-CD5 PE-Cy7 (clone BL1a) and anti-CD10 
PE-Cy7 (clone ALB1; both from Beckman Coulter, Fullerton, CA); and anti-CD7 APC 
(clone 124-1D1) and anti-CD3 APC-eFluor780 (clone UCHT1; both from eBioscience, 
San Diego, CA). Fluorochrome-conjugated antibodies were added to 100 µL of the cell 
suspension, incubated for 15 minutes in the dark, washed, and resuspended in 100 µL 
PBS. To determine absolute cell numbers, 100 µL of Cyto-Cal Count Control counting 
beads (Duke Scientific Corporation, Palo Alto, CA) were added. Listmode data were 
acquired on a FACSCanto flow cytometer (BD Biosciences).
Data analysis
An example of our gating strategy to detect LHM and determine absolute numbers of 
leukocytes and their subsets is shown in figure 1. To detect LHM, listmode data were 
analyzed with FACSDiva software (BD Biosciences). Clusters of >25 events fulfilling cri-
teria for malignant populations were classified as positive, clusters of 10 to 25 events 
as suspicious, and below 10 events as negative, as described before.1,15 Absolute cell 
numbers and fluorescence intensities were determined with FCS express software (De 
Novo Software, Los Angeles, CA). Relative cell numbers were calculated by dividing 
the absolute cell number of a particular subset, time point and storage condition by 
the absolute cell number of the same subset in CSF with serum-containing medium 
at 30 minutes. Discordances in the detection of LHM in CSF with TransFix™ versus 
the simultaneously collected control CSF samples were compared with the McNemar 
test using SPSS version 17.0.2 (IBM, Chicago, IL). Cell numbers as well as fluorescence 
intensities of TransFix™-treated CSF cells versus CSF cells from the paired control 
samples were compared with the Wilcoxon signed rank test using Prism version 5 
(GraphPad, San Diego, CA). The effects of TransFix™ or serum-containing medium on 
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the detection of LHM, cell numbers, and fluorescence intensities in follow-up samples 
were assumed to be independent of those in the initially obtained samples of the same 
patients. Results of continuous variables were expressed as median and range, unless 
otherwise specified. Two-sided P-values <0.05 were considered significant.
RESULTS
Samples and patients
A total of 99 CSF samples were obtained, 43 diagnostic samples and 56 follow-up 
samples from 43 patients (24 male patients, 19 female patients), all tested for the oc-
Figure 1.
Gating strategy to detect B lymphocyte clonality and enumerate leukocyte subsets in CSF by 
6-color flow cytometry. Leukocytes were distinguished from non-leukocyte events and debris 
by gating on forward scatter (FSC) and CD45; microspheres were used for absolute counting 
and defined as FSClow, FLhigh (panel A). Panels B-F show further analysis of the events selected 
in the leukocyte gate in panel A. Leukocyte subsets were defined with high CD45 expression 
and side scatter (panel B) and show three subsets: lymphocytes (Ly; CD45+, SSClow; green dots), 
monocytes (Mo; CD45+, SSCintermediate; cyan dots) and granulocytes (My [myeloid cells]; 
CD45+, SSChigh; orange dots). B cells were gated using the lineage-specific marker CD19 and 
side scatter (SSC) (purple dots, panel C). The B cells in this analysis were monoclonal sIgL+ (panel 
D) and expressed CD20 (panel E) and CD5 (panel F). Data are shown of an 18-hours old CSF 
sample in TransFix™ from a patient with a B cell non-Hodgkin lymphoma (small lymphocytic 
lymphoma).
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currence of LHM. The median age of these patients was 60 years (range 22-77 years). Of 
the 43 patients, 26 patients had a systemic localization of a hematological malignancy 
while 17 patients had a PCNSL. In most cases (30/43, 70%), a B cell NHL was present, 
usually a diffuse large B cell lymphoma (23/30, 77%). Other cases included patients 
with acute myeloid leukemia (n=5), T lymphoblastic leukemia/lymphoma (n=3), T 
cell NHL (n=2), plasma cell myeloma (n=1) and B lymphoblastic leukemia (n=2). The 
median volumes of CSF drawn were: 1.14 mL (0.48-2.45) CSF in TransFix™/EDTA; 1.28 
mL (0.47-2.66) CSF in serum-containing medium; and 1.25 mL (0.45-2.33) of native CSF. 
The median leukocyte count of the CSF samples was 5 cells/µL (range <1-552 cells/µL); 
the median protein content was 0.38 g/L (range 0.15-2.42 g/L).
Qualitative detection of hematological malignancies
Thirty minutes from CSF withdrawal, we compared the flow-cytometric detection 
of LHM in TransFix™-treated CSF samples with CSF samples with serum-containing 
medium (Table 1), and native CSF samples (Table 2). Compared to CSF with serum-
containing medium and native CSF, CSF with TransFix™ showed concordant results 
in 86/99 (87%) and 83/99 (84%) of cases, respectively. Discordant results included 
paired observations in which the level of suspicion was higher (i.e. positive vs. sus-
picious, positive vs. negative and suspicious vs. negative) in CSF with TransFix™, as 
well as paired observations in which the level of suspicion was higher in CSF with 
serum-containing medium or native CSF. Hence, 30 minutes after withdrawal, use 
of TransFix™ had neither a significant beneficial nor significant unfavorable effect 
on the detection of LHM, as compared to serum-containing medium or native CSF. 
The flow-cytometric detection of LHM after 18 hours in CSF samples with TransFix™ 
versus CSF samples with serum-containing medium and native CSF samples is shown 
in tables 3 and 4. Compared to CSF with serum-containing medium and native CSF, 
CSF with TransFix™ showed concordant results in 92/99 (93%) and 86/99 (87%) of cases, 
respectively. In all discordant pairs of observations, the level of suspicion was higher 
in CSF with TransFix™ than in CSF with serum-containing medium (7/99 [7%], P=0.07) 
or native CSF (13/99 [13%], P=0.005). To exclude that the asymmetrical distribution of 
the discordances seen between TransFix™-treated CSF and native CSF was due to a 
higher volume of TransFix™-stabilized CSF than that of native CSF, we analyzed the 
CSF volumes of the discordant pairs of samples separately, and found no significant 
difference (0.56 mL [0.31-0.81] vs. 0.56 mL [0.23-0.92] respectively, P=0.80). All samples 
that scored positive in CSF with TransFix™ were derived from patients that were also 
diagnosed with LHM by our conventional diagnostic procedure involving flow cyto-
metric analysis of >2 mL CSF with serum-containing medium.1
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Table 2. Detection of LHM after 30 minutes: TransFix vs. native CSF
t= 30 min 
Native
Totalpositive suspicious negative
TransFix™ positive 21 3 4 28
suspicious 2 0 4 6
negative 0 3 62 65
Total 23 6 70 99
P=0.23
(McNemar test)
Table 3. Detection of LHM after 18 hours: TransFix vs. medium
t= 18 hours 
Medium
Totalpositive suspicious negative
TransFix™ positive 28 3 3 34
suspicious 0 1 1 2
negative 0 0 63 63
Total 28 4 67 99
P=0.07
(McNemar test)
Table 4. Detection of LHM after 18 hours: TransFix vs. native CSF
t= 18 hours 
Native
Totalpositive suspicious negative
TransFix™ positive 23 6 5 34
suspicious 0 0 2 2
negative 0 0 63 63
Total 23 6 70 99
P=0.005
(McNemar test)
Table 1. Detection of LHM after 30 minutes: TransFix vs. medium
t= 30 min 
Medium
Totalpositive suspicious negative
TransFix™ positive 25 3 0 28
suspicious 3 1 2 6
negative 1 4 60 65
Total 29 8 62 99
P=0.64
(McNemar test)
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Cell numbers
Thirty minutes after withdrawal in CSF with medium, lymphocytes showed the high-
est absolute cell numbers (0.50 cells/µL [0.01-110.3]), while numbers of monocytes 
and granulocytes were generally very low (0.27 cells/µL [0.01-9.65] and 0.27 cells/µL 
[0.04-8.95], respectively). Figure 2 shows the cell numbers of leukocytes, lymphocytes, 
monocytes and granulocytes after 30 minutes and 18 hours of storage, relative to 
their cell numbers in CSF with serum-containing medium after 30 minutes. Thirty 
minutes from withdrawal, the median number of leukocytes in CSF with TransFix™ 
was similar to those in CSF with serum-containing medium, and 1.4 times higher than 
in native CSF. After 18 hours of storage, the median leukocyte number in CSF with 
TransFix™ was 1.8 times higher than in CSF with serum-containing medium, and 2.3 
times higher than in native CSF (Figure 2A). These higher total leukocyte numbers 
in CSF with TransFix™ as compared to medium (after 18 hours) and native CSF (both 
time points) were mainly due to higher lymphocyte numbers (Figure 2B). Monocytes 
numbers in CSF with TransFix™ were similar to those in serum-containing medium, 
Figure 2.
Relative numbers of leukocytes (A), and their subsets (B, C, D) after 30 minutes and 18 hours 
of storage in CSF with TransFix™, CSF with serum-containing medium and native CSF. Relative 
numbers were calculated by dividing the absolute numbers (in cells/µL) by those in CSF with 
serum-containing medium at 30 minutes. A reference line is drawn at a relative cell number 
of 1, to indicate the cell number in serum-containing medium at 30 minutes. Boxes represent 
medians and quartiles, whiskers 5th-and 95-th percentiles. P-values were calculated with the 
Wilcoxon signed rank test. ns, not significant.
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and higher than those in native CSF after 18 hours of storage (Figure 2C), while no sig-
nificant differences in granulocyte numbers were found between CSF with TransFix™, 
CSF with serum-containing medium, and native CSF (Figure 2D).
Surface antigen labeling and light scatter
Figure 3 shows the measured fluorescence intensities after staining with fluorochrome-
conjugated antibodies against the leukocyte marker CD45, B cell markers (CD19 and 
CD20), and surface immunoglobulins (sIgκ and sIgM). Thirty minutes after withdrawal, 
a small but significant decrease in fluorescence intensity is seen for CD45-PerCP in CSF 
treated with TransFix™ (panel A). At both time points (30 minutes and 18 hours), the 
fluorescence intensities of B cells labeled with anti-CD19 APC and anti-CD20 APC-Cy7 
were significantly lower in TransFix™-treated CSF samples than in CSF samples with 
serum-containing medium (panels B and C). Similarly, lower fluorescence intensities 
were seen in CSF with TransFix™ after staining for surface immunoglobulin kappa 
(panel D). We did not observe any significant increase in background fluorescence in 
Figure 3.
Fluorescence intensities after staining for the leukocyte marker CD45 (A), the B cell markers 
CD19 and CD20 (B, C), and the surface immunoglobulins kappa and M (D, E) in CSF with Trans-
Fix™, CSF with serum-containing medium, and native CSF after 30 minutes and 18 hours of 
storage. A reference line is drawn to indicate the median fluorescence intensity in serum-con-
taining medium at 30 minutes. Boxes represent medians and quartiles, whiskers 5th-and 95-th 
percentiles. P-values were calculated with the Wilcoxon signed rank test. ns, not significant.
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CSF with TransFix or serum-containing medium (data not shown). Figure 4 shows the 
light scatter properties of diffuse large B cell lymphoma cells and other lymphocytes 
in CSF with TransFix™ (panels A en D), CSF with serum-containing medium (panels B 
and E) and native CSF (panels C and F) in a representative sample. Allthough forward 
and sideward scatter signals of the depicted cells tended to be lower after stabilisation 
with TransFix™, diffuse large B cell lymphoma cells could still be discriminated from 
other lymphocytes based on their higher forward light scatter signal.
DISCUSSION
In this study, we compared the detection of LHM by flow cytometry using TransFix™-
stabilized CSF with the detection of LHM using CSF stabilized with serum-containing 
medium and native CSF. We found that, after 18 hours of storage, use of TransFix™ 
significantly enhanced the detection of LHM as compared to native CSF and CSF with 
serum-containing medium, while 30 minutes after withdrawal, detection rates under 
the 3 conditions were similar.
Figure 4.
Light scatter properties of CD19+ diffuse large B cell lymphoma cells (black dots) and CD19- non-
malignant lymphocytes (grey dots) derived from CSF with TransFix™ (A, D), CSF with serum-
containing medium (B, E) and native CSF (C, F) after 30 minutes (A, B, C) and 18 hours (D, E, F) of 
storage. All CD19+ cells (black dots) also expressed CD10 and were monoclonal sIgK+, consistent 
with the diagnosis diffuse large B cell lymphoma. In all six conditions, diffuse large B cell lym-
phoma cells could be discriminated from other lymphocytes based on their higher forward light 
scatter. SSC-A, sideward scatter (area); FSC-H, forward scatter (height).
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Currently, it is recommended to immediately process CSF samples for flow cytometric 
detection of LHM, preferably within 60 minutes after withdrawal.15,20 This implies 
immediate availability of a staffed flow-cytometry facility, which is not within the 
reach of many institutions. A method that enables storage of CSF for later analysis 
with diagnostic accuracy similar to immediately processed native CSF is therefore 
highly desirable. Cell-stabilizing agents such as TransFix™ and serum-containing 
medium have been tested by some laboratories.1,4 In this study, we tested the use of 
TransFix™, serum-containing medium and native CSF side-by-side, in order to enable 
direct comparison of these methods.
Quijano et al.4 used TransFix™ to stabilize CSF samples of patients with aggressive 
B cell NHL for overnight shipment to a central flow cytometry facility, and detected 
LHM in 22% of cases, the same percentage as found in a previous study on fresh native 
CSF.3 However, they did not directly compare their results with those of immediately 
processed native CSF, and hence, a possible negative influence of CSF storage in Trans-
Fix™ on the detection of LHM can not be excluded. Our study shows that the diagnostic 
accuracy of the flow cytometric detection of LHM in 18-hours old TransFix™-stabilized 
CSF is similar to that of immediately processed CSF.
TransFix™ may stabilize leukocytes in different ways: a buffer may prevent cell death 
due to an increase in pH,21 while an aliphatic aldehyde would fixate the cells by 
cross-linking of amino-acid residues.16 TransFix™ also contains heavy metal salts that, 
according to the inventors, further stabilize leukocytes, and reduce excessive autofluo-
rescence caused by aliphatic aldehydes.22 TransFix™ was originally designed for the 
stabilization of whole blood samples. In blood, TransFix™ has shown to reduce cellular 
loss of lymphocytes up to 10 days of storage.18 In addition, light scatter properties of 
lymphocytes were well maintained, autofluorescence levels were low, and fixation did 
not interfere with surface antigen labeling for CD45, CD3 and other markers, enabling 
reliable enumeration of major lymphocyte subsets.17,18 However, TransFix™ was less 
effective in preventing granulocyte and monocyte loss over time. In these leukocyte 
subsets, it caused a decrease in forward and sideward scatter signals, and negatively 
affected surface antigen labeling.18 The effects of TransFix™ on leukocytes in CSF and 
malignant hematological cells have not been studied in detail so far. Here, we have 
shown that, similar to blood, TransFix™ potently reduced cellular loss of lymphocytes. 
In addition, the effects of TransFix™ on light scatter signals seemed not to interfere 
with the identification of diffuse large B cell lymphoma cells based on their higher 
forward scatter signal than other lymphocytes. Also the slightly negative effect on 
surface antigen labeling did not interfere with proper identification of cellular subsets 
or malignant cells.
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The acquired CSF volumes are potential limitations of this study. First, the average vol-
ume of CSF studied per condition and time point was ~ 0.5 mL, since it was considered 
unethical to collect more than 3 mL of extra CSF in addition to the CSF needed for con-
ventional tests and procedures. Normally, it is recommended to analyze a minimum of 
2 mL of CSF, in order to obtain sufficient sensitivity.15 Theoretically, the discrepancies 
in test results found in this study might not apply to higher CSF volumes. However, 
we believe that it is reasonable to assume that CSF-stabilizing reagents that enable 
more sensitive detection of LHM in 0.5 mL of CSF will also have a beneficial effect on 
larger CSF volumes.
Second, we chose to directly collect CSF in TransFix™ CSF storage tubes, since previous 
data suggested that significant cellular loss may occur directly after withdrawal.12 As a 
consequence, some variation in the acquired CSF volumes was seen between samples 
with TransFix™, and paired samples with serum-containing medium or native CSF. 
However, we do not believe that the higher detection rates of LHM in CSF with Trans-
Fix™ were caused by a larger test volume, because median CSF volumes in TransFix™ 
were not higher than in the paired control samples, and in particular in discordant 
pairs of CSF samples, CSF volumes did not differ significantly.
To conclude, we showed that TransFix™ enables flow-cytometric detection in 18-hours 
old CSF samples with a similar or higher detection rate than in rapidly processed CSF 
with serum-containing medium or native CSF. We propose that the use of TransFix™ 
may facilitate flow cytometric analysis of CSF samples that were collected outside 
office hours, and enable the use of external flow cytometry facilities in institutions 
without a flow cytometry facility of their own. In addition, TransFix™ may save costs, 
since it allows storage and batch-processing of CSF samples instead of immediate 
processing that requires continuous availability of a flow cytometry facility.
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ABSTRACT
Introduction
Paraneoplastic neurological syndromes (PNS) are severely disabling conditions that 
are associated with cancer. Well characterized onconeural antibodies (Abs) are, by 
definition, virtually exclusively present in patients with cancer and include anti-Hu, 
Yo, CV2, Ri, Ma2, amphiphysin and DNER (anti-Tr). More recently a second group of 
antineuronal antibodies has been described that occur both in patients with and 
without cancer.
Areas covered
This review is focused on putative T cell mediated immunopathogenetic mechanisms 
and treatment of PNS associated with well characterized onconeural Abs. As of De-
cember 2013, only uncontrolled open-label clinical trials, retrospective case series and 
case reports were detected in the literature. Six clinical studies in Hu-PNS reported the 
effect of immunotherapy on functional outcome.
Expert opinion
When taken together, these 6 studies showed an improvement of one point or more 
on the modified Rankin scale (mRS) in 11% (7/61) of patients. In Yo-PNS, 8% (2/26) of 
patients improved on the mRS. PNS with other well characterized onconeural Abs 
also responded poorly to immunotherapies. Potential new immunotherapies include 
natalizumab, fingolimod, alemtuzumab and combination of rituximab with cyclo-
phosphamide.
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INTRODUCTION
Paraneoplastic neurological syndromes (PNS) are severely disabling conditions that 
are associated with cancer, but not caused by invasion of the tumor or its metastases.1 
In patients with PNS, various antibodies (Abs) have been found directed at neuronal 
antigens that are also expressed by the associated tumors in most cases (Table 1). 
These Abs can be directed at intracellular or cell surface proteins.2,3
In 2004, the term ‘well characterized onconeural Abs’ was defined based on (1) Abs for 
which there are recognizable reactivity patterns on routine immunohistochemistry, 
confirmed by immunoblotting on recombinant proteins; (2) the number of cases re-
ported associated with tumors; (3) the description of well characterized neurological 
syndromes associated with the antibodies; (4) the unambiguous identification of the 
Abs among independent studies, and (5) the (virtual) absence of these Abs in patients 
without cancer.4 These ‘well characterized onconeural Abs’ are by definition almost 
exclusively found in patients with cancer and include anti-Hu, Yo, CV2, Ri, Ma2 and 
amphiphysin.4 Since the recent identification of the transmembrane protein Delta/
Notch-like epidermal growth factor-related receptor (DNER) as the Tr-antigen, anti-Tr 
(anti-DNER) can also be considered a well characterized onconeural Ab due to its close 
association with Hodgkin lymphoma.5
Patients with any neurological syndrome with unknown cause who harbor these 
well characterized onconeural Abs fulfill the diagnostic criteria of a ‘definite PNS’ 
and should be screened for the presence of a tumor.4,6 In 2006, a European task force 
evaluated the management of PNS and concluded that immune therapies such as 
steroids, plasma exchange or intravenous immunglobulins had generally no or only 
modest effects on PNS associated with well characterized onconeural Abs.7 The main 
recommendations of the task force included treatment of the underlying tumor, if 
histologically proven, and symptomatic therapies. In 2012, a Cochrane review con-
cluded that there is only class IV evidence of the effect of immunomodulation on 
paraneoplastic neuropathy.8
The prognosis of PNS patients with well characterized onconeural Abs is poor: 
improvement of the neurological disability is rare, and median survival is 12 to 22 
months.9-11 Apart from anti-DNER, all well characterized onconeural antibodies are 
directed against intracellular proteins. Since intracellular antigens are not directly ac-
cessible to Abs, the majority of these well characterized onconeural Abs are probably 
not pathogenic but are considered disease markers of a concurrent T cell-mediated 
immune response targeted against the same proteins.12-15
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A second group of antineuronal Abs is found in patients with PNS that can also be 
detected in non-paraneoplastic neurological autoimmune syndromes (Table 1).16 These 
Abs can therefore not be categorized as ‘well characterized onconeural Abs’ according 
to the criteria of Graus et al.4 Examples include anti-N-methyl-D-aspartate (NMDA) 
receptor Abs and anti-voltage gated calcium channels (VGCC) Abs.16-18 Most of these 
Abs are potentially pathogenic as they are directed against easily accessible neuronal 
surface antigens.16 The associated PNS often respond much better to tumor treatment 
and immunotherapies than PNS with well characterized onconeural Abs.3,16,17
In this review, we provide an update on the available evidence on the immunopatho-
genesis and immunotherapy of PNS associated with well characterized onconeural 
Abs.
METHODS
The PubMed (MEDLINE; 1946 - December 2013) and Cochrane Libraries (The Cochrane 
Library; December 2013) were searched for published articles on the pathogenesis and 
treatment of paraneoplastic neurological syndromes. Search terms included the medi-
cal subject headings “paraneoplastic syndromes, nervous system” or “paraneoplastic 
neurological syndromes”, in combination with either (i) “etiology.fs.” or “pathogen-
esis”, or (ii) “drug therapy.fs” or “treatment”. In addition, we searched for specific 
PNS using the following search terms: (1) “Hu” or “ANNA-1” or “anti-neuronal nuclear 
antibody 1” or “HuD” or “HuC” or “Hel-N1”; (2) “Yo” or “PCA-1” or “type 1 Purkinje cell 
cytoplasmic autoantibodies” or “CDR62”; (3) “CV2” or “CRMP5” or “collapsin response 
mediator protein 5”; (4) “Ri” or “ANNA-2” or “anti-neuronal nuclear antibody 2” or 
“Nova-1” or “Nova-2”; (5) “Ma2” or “Ta”; (6) “amphiphysin”; (7) “recoverin”, and (8) 
“Tr” or “DNER”; any of these 8 in combination with “paraneoplastic” or “treatment”.
To systematically evaluate the effectiveness of immunotherapy in patients with PNS 
associated with antibodies against intracellular proteins, we selected prospective 
clinical trials, and case series that (i) included patients with PNS associated with 
well characterized onconeural Abs, (ii) were aimed at evaluating the effects of im-
munotherapy and (iii) reported functional outcome using a well-defined clinical scale 
such as the modified Rankin scale (mRS).19 Patients with mRS ≤3 are ambulatory 
patients, while patients with mRS ≥4 are bedridden or wheelchair-bound. Functional 
improvement or deterioration were defined as a change of at least 1 point on the 
mRS. Treatment was considered successful when a patient with mRS ≤3 improved or 
stabilized and when a patient with mRS ≥4 (bed- or wheelchair-bound) improved one 
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Table 1. Paraneoplastic antibodies and their associations with neurological syndromes and tu-
mors
Antibody Neurological syndromes Tumors (prevalence)
Well characterized onconeural antibodies
Anti-Hu (ANNA-1) EM, LE, SSN, PCD, AN SCLC, neuroblastoma, prostate (84-88%) A 
9,11,84,85
Anti-Yo (PCA-1) PCD Ovary, breast (79-95%)10,52,86
Anti-CV2 (CRMP5) SSN, AN, PCD, EM, LE, ON, 
Chorea
SCLC, thymoma (86-91%)64,87
Anti-Ri (ANNA-2) OMS, BE, PCD SCLC, breast (86-100%)65,88
Anti-Ma2 (Ta) EM, LE, PCD, BE Testicle, lung (63%-89%)66,67
Anti-Amphiphysin SPS, EM, SSN, SMN SCLC, breast (79-100%)69,70,89
Anti-DNER (Tr) PCD Hodgkin’s lymphoma (89%)5,51
Partially characterized onconeural antibodies
Anti-ANNA-3 SMN, PCD, AN, LE, BE SCLC (82%)90
Anti-Recoverin Cancer-associated retinopathy SCLC (100%)91,92
Antibodies associated with paraneoplastic and non-paraneoplastic (i.e. autoimmune) neurological syndromes
Anti-GAD SPS, PCD, LE Lung, neuroendocrine tumors (1-9%)69,93
Anti-VGCC LEMS, PCD SCLC (57%)18
Anti-AchR Myasthenia gravis Thymoma (19%)94
Anti-gAchR AN SCLC, thymoma (11%)95
Anti-NMDAR Anti-NMDAR-associated 
encephalitis
Ovarian teratoma (38%)96
Anti-LGI1 LE Rarely paraneoplastic (8%)97-100
Anti-Caspr2 Morvan syndrome or 
neuromyotonia
Thymoma (22%)98,101-103
Anti-AMPAR LE Lung, breast, thymus (66%)104,105
Anti-GABABR LE SCLC (60%)106-109
Anti-mGluR1 PCD Hodgkin lymphoma, prostate carcinoma 
(60%)110-113
Anti-mGluR5 Ophelia syndrome Hodgkin lymphoma (100%)112,114
Anti-GlyR SPS, PERM Hodgkin lymphoma, thymoma, breast, lung 
(19%)115,116
A In children younger than 18 years, anti-Hu was associated with neuroblastoma (or any other 
tumor) in only 2 of 8 (25%) patients.117
Abbreviations: prop, proportion (patients with detectable tumor/total) used to calculate preva-
lence; ANNA, anti-neuronal nuclear antibody; EM, encephalomyelitis; LE, limbic encephalitis; SSN, 
subacute sensory neuronopathy; PCD, paraneoplastic cerebellar degeneration; AN, autonomic 
neuropathy; SCLC, small-cell lung cancer; PCA, Purkinje cell cytoplasmatic autoantibodies; CRMP, 
collapsin response mediator protein; ON, optic neuritis; BE, brainstem encephalitis; SPS, stiff per-
son syndrome; SMN, sensory motor neuropathy; DNER, delta/notch-like epidermal growth factor-
related receptor; GAD, glutamic acid decarboxylase; VGCC, voltage-gated calcium channel; LEMS, 
Lambert-Eaton myasthenic syndrome; AchR, acetylcholine receptor; g, ganglionic; NMDAR, N-
methyl-D-aspartate receptor; yrs, age in years; VGKC, voltage gated potassium channel; Ag, anti-
gen; AMPAR, α-amino-3-hydroxy-5-methyl-4-osixazolepropionic acid receptor; GABABR, gamma-
aminobutyric acid B receptor; mGluR, metabotropic glutamate receptor.
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point or more.20 For PNS with onconeural antibodies for which no prospective clinical 
trials or case series were available, we reviewed the available case reports. To identify 
possible predictors for functional outcome after immunotherapy in patients with PNS 
with anti-Hu Abs (Hu-PNS), we pooled data from the available therapeutic studies. 
Prism version 5 (GraphPad, San Diego, CA) was used for univariate statistical analyses 
(Fisher’s exact test or Mann-Whitney test), SPSS version 20 (IBM, Chicago, IL) was used 
for multivariate analysis (logistic regression; using successful functional outcome as 
dependent variable and age, CNS involvement, initial mRS, detectable tumor and anti-
tumor therapy as independent variables; no correction for ‘study’). Two-sided P-values 
<0.05 were considered significant.
IMMUNOPATHOGENESIS
Anti-Hu is the most frequent well characterized onconeural Ab and is usually associ-
ated with paraneoplastic encephalomyelitis and sensory neuronopathy.9,21 Anti-Hu Abs 
are directed at a family of RNA-binding proteins (HuD, HuC, Hel-N1 and HuR).22 Three 
of these proteins (HuD, HuC and Hel-N1) are neuronal specific while HuR is ubiqui-
tously expressed. In an ELISA assay, anti-Hu Ab titers against HuR were much lower 
than against HuD, HuC and Hel-N1 indicating that the immunoreactivity against HuR 
represents cross-reactive antibody specificities directed against conserved sequences 
in this family.23 In addition, only HuD and Hel-N1 are expressed by SCLC and SCLC-
derived tumor cell lines.22,24
The presence of high titers of anti-Hu Abs in the blood and cerebrospinal fluid of 
Hu-PNS patients led to the hypothesis that Hu-PNS are caused by an immune response 
triggered by Hu expression in tumor cells that also reacts with Hu-expressing neu-
rons.25 Supporting evidence for a putative immunopathogenetic mechanism is found 
in HLA-associations,26 intrathecal antibody production,27 cerebrospinal fluid (CSF) 
pleocytosis,28,29 and infiltrates of oligoclonal cytotoxic T cells around damaged neurons 
at autopsy.30-33 Since immunization of animals against HuD did result in high-titered 
anti-Hu Abs but no disease, it was hypothesized that the anti-Hu Abs themselves were 
not pathogenic.14,34 In addition, these studies showed that anti-Hu Abs did not enter 
neurons and bind the intracellular Hu-proteins, suggesting that the observed intra-
neuronal IgG accumulation in autopsy studies in humans may have resulted from a 
postmortem artefact.14 Finally, autopsy studies showed only weak complement reac-
tivity and absence of natural killer (NK) cells, suggesting that complement-mediated 
and antibody-dependent cell cytotoxicity were not pathogenic.35 In view of this lack 
of support for Ab-mediated pathogenesis of PNS, cytotoxic CD8+ T cells were proposed 
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to be responsible for neuronal destruction in Hu-PNS, as supported by the CD8+ T cell 
infiltrates around damaged neurons found at autopsy.15,31 Based on this hypothesized 
CD8+ T cell response, several studies have been performed to detect HuD-specific 
cytotoxic CD8+ T cells, but initial positive results36-38 could not be reproduced.39,40 
More recently, CD8+ HuD-specific T cells were described with an abnormal ‘type 2’ 
phenotype41, but these data could not be reproduced either.42 In summary, cumulative 
evidence suggests that neuronal destruction in Hu-PNS is caused by a T cell-mediated 
immune response, but the specificity, phenotype and function of these autoreactive T 
cells remain largely unknown.
Similar to Hu-PNS, also PNS with Abs against other intracellular antigens are probably 
T cell-mediated. Animal models failed to demonstrate a pathogenic effect of anti-Yo 
Abs.12,13 Postmortem studies of patients with paraneoplastic cerebellar degeneration 
and anti-Yo Abs (Yo-PNS) showed CD8+ T cell infiltration in the cerebellum and loss of 
Purkinje cells.43,44 Yo-specific T cells have been described, but these results could not 
be reproduced.45,46 Immunopathological studies in PNS with anti-CV2, anti-Ma2 and 
anti-Ri Abs also showed cytotoxic T cells infiltrates and neuronal loss supporting the 
hypothesis that these PNS may also be T cell-mediated.33,47-49
An exception is PNS with anti-amphiphysin Abs, as autoantibodies against intracel-
lular amphiphysin are probably pathogenic. Amphiphysin is an intracellular neuronal 
protein involved in synaptic vesicle endocytosis. Intrathecal passive transfer of af-
finity purified anti-amphiphysin IgG into rats caused stiffness and muscle spasms 
resembling stiff-person syndrome (SPS).50 Electrophysiological studies identified 
reduced presynaptic GABA-ergic inhibition as an underlying mechanism while im-
munofluorescence studies provided evidence that anti-amphiphysin IgGs can enter 
the synapses of neurons.50 How the Abs get taken up into the nerve terminals remains 
unclear although one may speculate that epitopes of amphiphysin are exposed during 
GABA release when synaptic vesicles transiently fuse with the neuronal membrane.
Contrary to anti-amphiphysin Abs that are directed at an intracellular antigen and 
may still be pathogenic, anti-DNER Abs are directed at the extracellular domain of 
DNER, but may not be pathogenic. Anti-DNER Abs did not change the morphology of 
neurons in vitro, suggesting that the Abs did not directly interfere with DNER func-
tion.5 Anti-Tr/DNER PNS patients have a poor prognosis and an autopsy study showed 
loss of Purkinje cells.51,52 These findings may indicate that complement-mediated 
toxicity or antibody-dependent cytotoxicity play a role, although anti-DNER PNS may 
also be caused by a T cell-mediated immune response despite the accessability of the 
target antigen to the Abs.53
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IMMUNOTHERAPY
Rationale for the use of immunotherapy
In patients with PNS and well characterized onconeural antibodies, detection and 
treatment of underlying tumors offers the best chance to stabilize their PNS.54 How-
ever, even after tumor treatment, only 3-6% (5/164; 3/51) of Hu-PNS patients improve, 
while 30% (15/51) deteriorate.9,54 Median survival for Hu-PNS patients is 12 months, 
and most patients die from progression of their PNS (60%, 76/126), not their tumor.9 In 
PNS patients with anti-Yo Abs, 73% (14/19) further deteriorate after diagnosis of their 
PNS, 78% (15/17) of patients become bedridden, 36% (8/22) die from their PNS, and 
median survival is 13-22 months.10,52 Hence, there is a clear need for immunotherapies 
that can effectively suppress the harmful auto-immune response in PNS and prevent 
further deterioration, morbidity and death.
A possible negative effect of immunotherapy might be the suppression of a concur-
rent beneficial immune response against the associated tumor. There is conflicting 
evidence that SCLC patients with low titers of anti-Hu Abs without PNS may have a 
better tumor prognosis,55,56 and spontaneous tumor regressions have been reported in 
Hu-PNS patients indicating that the immune response against Hu may control tumor 
growth.57 However, in a series of 51 Hu-PNS patients, no negative effect was seen of 
immunotherapy (i.e., intravenous IgG, plasma exchange or cytoreductive therapy and 
immunosuppression) on the outcome of anti-tumor therapy,54 and complete cancer 
remissions after chemotherapy were frequently reported in studies on immunothera-
pies in PNS.58-60 In conclusion, the severity of PNS and the poor functional outcome 
after tumor treatment alone indicate that there is a need for effective immunotherapy 
in PNS. There is no substantial evidence that such a treatment would negatively affect 
tumor outcome.
Functional outcome and survival after immunotherapy in Hu-PNS
Most studies on immunotherapy in PNS involve patients with Hu-PNS, reflecting the 
relatively high frequency of anti-Hu Abs.21 Six studies evaluated functional outcome 
after immunotherapy using the mRS (Table 2).20,58-62 A seventh study on the effect 
of tacrolimus + prednisone included 6 Hu-PNS patients but did not formally asses 
functional outcome.63 All studies were uncontrolled open-label studies, the included 
numbers of Hu-PNS patients were small (range 7-18 patients), and only three studies 
reported a prospective design.58-60 Taken together, these studies reported functional 
improvement, defined as an improvement of one point or more on the mRS, in 11% 
(7/61) of patients, which is slightly, and not significantly higher than in the largest 
published case series on Hu-PNS thus far (i.e. 5% (10/200), Fisher’s exact test: p= 0.08).9
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In this setting, a therapeutic benefit can be considered as either at least stabilization 
in patients who are still ambulatory (mRS≤3) or improvement (decrease of ≥1 on the 
mRS) in bedridden patients (RS≥4).20 According to these criteria, immunotherapy was 
considered successful in 36% of cases, which is within the range of previous clinical 
series (14-53%) (Table 2).11 In the study investigating tacrolimus + prednisone, subjec-
tive improvement was reported in 3/6 Hu-PNS patients. Median survival from the start 
of immunotherapy was 10 months (range 0 to >48) in the studies shown in Table 
2. In the study with tacrolimus + prednisone, the median survival from the start of 
immunotherapy was 57 months (range, 2 - 61; n=6).63
Functional outcome and survival after immunotherapy in Yo-PNS
Four of the 6 clinical studies described in Table 2 also included four or more Yo-PNS 
patients (Table 3).20,60-62 Taken together, these studies reported an improvement of one 
point or more on the mRS in 8% (2/26) of patients. Immunotherapy was considered suc-
cessful in 6 patients (23%). Survival from the start of immunotherapy was 18 months 
(range, 2 to >53), similar to larger clinical series that also included patients who did 
not receive immunotherapy (13-22 months).10,52 In another study that investigated the 
effect of tacrolimus + prednisone in 19 Yo-PNS patients who all had ovarian cancer and 
received tumor treatment, subjective improvement occurred in 11 patients (58%) and 
a median survival from start of immunotherapy of 48 months was reported.63
Functional outcome and survival after immunotherapy in other subgroups 
of PNS
Patients with PNS with anti-CV2/CRMP5 Abs are on average less disabled and survive 
longer than Hu-PNS patients (mean mRS 2.5 vs. 3.1; median survival times 47.7 vs. 
11.5 months, respectively).64 The longer survival in CV2/CRMP5-PNS could partly be 
explained by the fact that CV2/CRMP5-PNS are not only associated with SCLC but 
also with thymoma. Tumor type is, however, not the only factor that causes a better 
prognosis in CV2/CRMP5-PNS, since CV2/CRMP5-PNS patients with SCLC seem to have 
a better prognosis than Hu-PNS patient with SCLC as well.64 Only two cases of CV2/
CRMP5-PNS have been described in studies aimed at evaluating the effects of immu-
notherapy. One female patient with ataxia and optic neuritis and no tumor remained 
ambulatory (mRS 3) after treatment with plasma exchange and cyclophosphamide 
and survived for at least 31 months.60 Another female encephalopathic patient with a 
small cell carcinoma was severely disabled (mRS 5), did not respond to tacrolimus and 
prednisone, and died one month after treatment.63
Pittock et al. reported clinical outcome of 17 patients with PNS with anti-Ri Abs after 
tumor and/or immunotherapy, 14 of them had a tumor.65 In this series, subjective 
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clinical improvement was reported by the treating physician in 5 out of 7 patients 
who received only anti-tumor therapy (radiation, chemotherapy and/or surgery); in 4 
out of 6 patients who received only immunotherapy (intravenous immunoglobulins 
[ivIg], or plasma exchange, and/or methylprednisolone or dexamethasone); and in 3 
out of 4 patients that received both therapies. Interestingly, the 2 patients that did 
not improve upon immunotherapy both had no detectable cancer. Shams’ili et al. 
reported 6 patients with anti-Ri antibodies and paraneoplastic cerebellar degenera-
tion, 5 of them had a tumor.52 In this series, the mRS was used to assess functional 
status and outcome after therapy. Four out of these 6 patients were ambulatory (mRS 
≤ 3); 1 patient received anti-tumor treatment but progressed; 2 out of 3 patients who 
received immunotherapy remained stable or improved; and 2 out of 2 patients that 
received both therapies remained stable or improved. The median survival of these 6 
patients was >69 months.52
Dalmau et al. presented clinical outcome of 33 patients with PNS with anti-Ma2 Abs, 30 
of them had a tumor.66 Eight patients received only anti-cancer treatment, 4 of them 
improved, 3 stabilized and 1 progressed. Ten patients received only immunotherapy 
(steroids, ivIg, and/or plasma exchange), 3 of them improved, 1 of them stabilized 
and 6 progressed. Nine patients received anti-tumor therapy and immunotherapy 
(steroids, ivIg, plasma exchange, IgG adsorption and/or cyclophosphamide), 4 of them 
improved, 3 stabilized and 2 progressed. All 6 patients who did not receive anti-tumor 
or immunotherapy progressed. Interestingly, the three patients who improved upon 
immunotherapy alone did very well, two of them even completely recovered.66 The 
chance of neurological stabilization or improvement in patients with anti-Ma2 Abs 
(reacting solely to Ma2; also called anti-Ta) seems better than that of patients with 
anti-Ma Abs (reacting to Ma1 and Ma2): 69% vs. 24%, respectively.67,68
Clinical improvements have been reported in patients with PNS with anti-amphiphy-
sin Abs after treatment of the tumor and following immunomodulation with steroids, 
ivIg or plasma exchange.69-71 In a series of 63 amphiphysin-PNS patients, neurological 
improvement was reported in 4 patients who received methylprednisolone, while at 
least one patient did not respond to methylprednisolone.70 In the same study, two 
out of four patients who received ivIg improved neurologically. Four patients who 
received plasma exchange showed no neurological improvement. In this study, neuro-
logical improvement was not quantified. Survival did not differ significantly between 
patients with cancer who received immunotherapy and/or anti-tumor therapy and 
those who did not receive therapy.70 In another study on 11 patients with stiff-person 
syndrome associated with anti-amphiphysin Abs, all patients were female; 10 of them 
had breast cancer. Nine patients were described as benzodiazepine responsive and 
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three were described as dramatically better following tumor excision and chemo-
therapy. Four patients responded to methylprednisolone, while ivIg efficacy was not 
reported.69 Efficacy of plasma exchange in patients with paraneoplastic SPS is limited 
to case reports.71
Paraneoplastic cerebellar degeneration (PCD) with anti-DNER Abs and Hodgkin 
lymphoma responds poorly to therapy, similar to PCD with other well characterized 
onconeural Abs.51,52 In a series of 7 anti-DNER PNS patients, 6 patients had a Hodgkin 
lymphoma.52 One of these patients, who received anti-tumor therapy resulting in com-
plete remission, showed objective functional improvement (≥ 1 point on the mRS). 
In a larger series of 28 PCD patients with anti-DNER Abs, 4 patients (14%) showed 
complete (3) or partial (1) remission of ataxia, while the majority of patients remained 
with a bad functional status.51 In comparison to patients with PCD with anti-Hu and 
anti-Yo Abs, patients with PCD with anti-Tr/DNER Abs survived longer (median >113 
months).52
Choice of immunotherapy
Based on the evidence for a T cell-mediated immunopathogenesis in Hu-PNS, it has 
been hypothesized that therapies aimed at depletion of B cells (rituximab) or removal 
of circulating antibodies (plasma exchange) would be less effective than therapies 
that include suppression of T cell-mediated immune responses such as methylpred-
nisolone, cyclophosphamide and tacrolimus.1 However, a small prospective study on 
the effect of rituximab also showed functional improvement in 2 out of 8 Hu-PNS pa-
tients (25%).52 A possible explanation of the functional improvement after rituximab 
treatment could be that B cells might contribute to the pathogenesis of Hu-PNS by 
antigen-presentation to T cells and production of pro-inflammatory cytokines.72 Simi-
lar to rituximab, also ivIg may theoretically be effective in PNS. The main effects of 
administration of ivIg are thought to be modulation of pathogenic antibodies, interac-
tion with Fc receptors on phagocytic cells and inhibition of complement activation.73 
However, ivIg may also suppress T cell responses by downregulation of cytokines, 
suppression of T cell functions and interference with antigen recognition. Hence, ivIg 
have been suggested as second-line immunotherapy in PNS with antibodies against 
intracellular proteins when corticosteroids are not effective or contra-indicated.73
Patient characteristics, tumor treatment and functional outcome
Previously, several factors have been suggested to be associated with better functional 
outcome including younger age,60 absence of CNS involvement,20,62 moderate disabil-
ity (e.g. mRS ≤3),9,20,60,62 and tumor treatment.9 Analysis of pooled data of the studies 
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shown in Table 2 showed that only functional disability was significantly associated 
with ‘succesful functional outcome’ after immunotherapy (Table 4).
Among the 22 patients with ‘successful functional outcome’, 7 patients improved 
in functional status. Among the patients with detectable tumors (n=55), those who 
received tumor treatment improved more frequently than patients with an untreated 
tumor (5/27 vs. 0/28; P=0.02 [Fisher exact test]). Four of these 5 patients who showed 
functional improvement reached complete tumor remission, while in the fifth tumor 
response was not reported. These trends between improvement in functional status, 
anti-tumor treatment and complete tumor remission underline the importance of 
tumor screening and anti-tumor treatment in patients with Hu-PNS. In 2 out of the 
7 patients who improved, no tumor was detected when immunotherapy was admin-
istered. One patient improved during immunotherapy from a mRS of 3 to a mRS of 
2, while it took 20 months before SCLC was detected and successfully treated.59 The 
other patient improved from a mRS of 2 to a mRS of 1, while NSCLC was detected 
and successfully treated after 26 months.60 This patient survived for more than 41 
months. These cases indicate that immunotherapy can be helpful in patients without 
detectable tumor and does not seem to accelerate tumor growth.
Adverse events
Treatment with ivIg was generally well tolerated. Uchuya et al. reported adverse 
events in 3 out of 22 PNS patients, two of them could continue treatment (one with 
Table 4. Possible predictors for functional outcome after immunotherapy for Hu-PNS
Therapeutic studies on Hu-PNS 
20,58-62
Functional outcome
  Succesful Not successful OR A 95% CI (OR) P A P B
N of patients 22 39
Age (years; median, range) 63 (41-78) 61 (35-80) 1.04 0.97-1.11 0.32 0.54
CNS involvement (n, %) 7 (32%) 18 (46%) 0.35 0.09-1.37 0.13 0.30
Initial mRS (median, range) 3 (1-5) 4 (1-5) 0.53 0.30-0.94 0.03 0.003
Detectable tumor C (n, %) 18 (82%) 37 (95%) 0.16 0.02-1.37 0.10 0.10
Anti-tumor therapy D (n, %) 12 (55%) 15 (39%) NT NT NT 0.09
A Odds ratios and P-values derived from multivariate analysis (Logistic regression). Anti-tumor therapy was only 
considered relevant within patients with detectable tumor, and hence not included in multivariate analysis.
B P-values derived from univariate analyses (Fisher exact test or Mann-Whitney test).
C At time of first tumor screening.
D Chemotherapy and/or radiotherapy and/or surgery simultaneously with immunotherapy. Percentages 
calculated within patients with detectable tumors.
Abbreviations: OR, odds ratio; CI, confidence interval; N, number of patients; n, number of patients positive 
for predictor; CNS, central nervous system; mRS, modified Rankin score; NT, not tested.
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transient headache and one with transient fever, malaise and cyanosis), the third 
had severe hemolytic anemia.62 Also treatment with rituximab was well tolerated. 
Shams’ili et al. treated 9 PNS patients with rituximab, and 3 of them additionally 
received chemotherapy.58 Complete B cell-depletion was achieved in 8 of the 9 PNS 
patients, and none of them had significant adverse events, notably no infections.58 
Treatment with plasma exchange and chemotherapy was tolerated by 16 out of 20 
patients. Of the 4 patients with (severe) adverse events, one died from progressive 
PNS, one developed a central line infection and two had significant hypotension 
without long-term complications.60 Adverse events may be more common in patients 
treated with cyclophosphamide. Keime-Guibert et al. treated 17 PNS patients with 
600 mg/m2 cyclophosphamide i.v. every three weeks in combination with ivIg and 
methylprednisolone and reported no severe side-effects; only one patient experienced 
transient feeling of discomfort (shivering and agitation).20 However, in 9 other PNS 
patients treated with cyclophosphamide (oral dose of 2 mg/kg/day for 3 months, 
combined with plasma exchange) all developed grade 1 or 2 anemia (according to the 
Common Toxicity Criteria)74, 3 developed grade 3 lymphopenia, 3 developed severe 
neutropenia (grade 3 or 4) and 1 developed mild hemorrhagic cystitis.60 In 5 out of 
9 patients, treatment with cyclophosphamide had to be discontinued because of 
hematologic toxicity (n=4) or nausea and vomiting that persisted after dose reduction 
(n=1).60 Adverse events were also common after combined treatment with tacrolimus 
and prednisone.63 In a series of 26 PNS patients treated with this combination, 23 
patients (88%) experienced one or more adverse events.63 Three of these 23 adverse 
events were serious and required transfer to an acute care hospital: progressive ataxia, 
pneumonia, and a progressive encephalopathy in a patient with pneumonia and me-
tastasized small-cell lung cancer.63
Quality of evidence
All evidence on immunotherapies for PNS with well characterized onconeural Abs is 
based on observational studies and uncontrolled open-label trials. Several factors other 
than immunotherapy may have contributed to the reported clinical outcomes. Patient 
selection bias may play a role since in the retrospective case series, it is unclear why 
some patients received immunotherapy and others did not,9,52 while in some stud-
ies on immunotherapy, inclusion criteria (other than PNS) were not defined,20,61,62 or 
patients with stabilized PNS and/or severe disabilities were excluded.58-60 Furthermore, 
the reviewed studies were hampered by the heterogeneity of included PNS patients 
and low patient numbers. Hence, according to the criteria of the European Federation 
of Neurological Societies, the quality of all the evidence presented here should be 
considered ‘very low’.75
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CONCLUSIONS
Neurological syndromes of unknown cause are ‘definite’ paraneoplastic neurological 
syndromes (PNS) when associated with a well characterized onconeural Ab.4 These 
‘well characterized onconeural Abs’ are by definition almost exclusively found in 
patients with cancer and include anti-Hu, Yo, CV2, Ri, Ma2, amphiphysin, and DNER 
(formerly anti-Tr). Apart from anti-DNER, all well-characterized onconeural antibodies 
are directed against intracellular proteins. Since intracellular antigens are usually not 
directly accessible to Abs, the majority of these well characterized onconeural Abs 
are probably not pathogenic but are considered disease markers of a concurrent T 
cell-mediated immune response targeted against the same proteins.12-15
Anti-Hu is the most frequent onconeural Ab and six studies evaluated the functional 
outcome after various forms of immunotherapy using the mRS. Overall, improvement 
defined as decrease of one point or more on the mRS occurred in 11% of the patients. 
When a successful outcome of immunotherapy was defined as improvement by one 
point or more in bedridden patients and stabilization or improvement in ambulatory 
patients, immunotherapy was overall successful in 36% of the patients. Four of these 
six studies also included anti-Yo patients and improvement of one point or more was 
noted in 8% of the patients with Yo-PNS.
Pooled analysis also showed that in these studies only functional status was associated 
with ‘successful functional outcome’. Trends were observed between improvement in 
functional status, antitumor treatment and complete tumor remission.
Treatment with ivIg, rituximab (also in combination with chemotherapy), plasma 
exchange and steroids was generally well tolerated. Adverse events were more com-
mon following treatment with cyclophosphamide and combination treatment with 
tacrolimus and prednisone.
Case series of patients with anti-CV2/CRMP5, Ma, Ri, amphiphysin and DNER are sum-
marized.
EXPERT OPINION
Paraneoplastic neurological syndromes with well characterized onconeural Abs are 
immune-mediated and, by definition, tightly associated with cancer. When the term 
‘well characterized onconeural Ab’ was introduced, all such Abs were directed at 
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intracellular neuronal antigens that were also expressed by the associated tumors.4 
Based on the intracellular localization of these neuronal antigens, postmortem stud-
ies and animal experiments, it was hypothesized that these PNS were caused by a T 
cell-mediated immune response against onconeural antigens expressed by neurons 
and tumor cells.15
In the last decade, however, evidence has become available that challenges the hypoth-
esis that intracellular onconeural antigens are targeted by a T cell-mediated immune 
response, and extracellular onconeural antigens by an antibody-mediated immune 
response. First, PNS with Abs against the intracellular neuronal antigen amphiphysin 
may be antibody-mediated, since animal models and in-vitro models showed that anti-
amphiphysin immunoglobulin G can enter the nerve terminals, reduce presynaptic 
GABA-ergic inhibition and cause disease resembling stiff person syndrome.50 Second, 
the target of anti-Tr was recently identified as the Delta/Notch-like epidermal growth 
factor-related receptor (DNER).5 Given the tight association between PNS with anti-
DNER Abs and Hodgkin lymphoma,51 anti-DNER should now be considered a well char-
acterized onconeural Ab. Anti-DNER Abs are targeted against the extracellular domain 
of DNER,5 and hence these Abs could, in theory, directly access their target in the brain 
and interfere with DNER function. However, anti-DNER Abs did not change neuron 
morphology in cell cultures.5 Furthermore, a single autopsy case showed severe loss 
of Purkinje cells, and DNER-PNS patients respond poorly to therapy.51 Based on these 
observations, we suggest that DNER-PNS is most likely either caused by complement 
dependent toxicity or antibody dependent cellular toxicity; also, a T cell-mediated 
disease, despite the extracellular target of anti-DNER Abs, remains possible.
The tight association between well characterized onconeural Abs and associated 
cancers does not necessarily implicate that the targets of these onconeural Abs are 
expressed by the associated cancers. Immunohistochemical studies using anti-Tr 
could hardly detect expression of the target antigen in Hodgkin lymphoma tissues 
of DNER-PNS patients, and normal CRMP proteins could not be detected in thymoma 
tissue of a CV2-PNS patient (while CRMP5 is highly expressed in SCLC).51,76 Therefore, 
we suggest that well characterized onconeural Abs may be better defined as ‘tightly 
associated with the presence of an underlying malignancy’ than as ‘targeted against 
neural antigens expressed by the tumor’.4
To improve the functional outcome in PNS with well characterized onconeural Abs, 
various immunotherapies have been used including plasma exchange, ivIg, rituximab, 
steroids and cyclophosphamide.20,58-62 There is some evidence that these immuno-
therapies might improve functional outcome in a few patients. However, within PNS 
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patients with the most frequent well characterized onconeural (Hu-PNS), only 11% 
showed objective functional improvement after immunotherapy. The quality of the 
evidence is classified as ‘very low’ due to the uncontrolled design of the studies, the 
low number of patients and the heterogeneity of neurological syndromes and underly-
ing tumor types.
To determine whether some patients respond better to immunotherapy than others, 
we investigated whether patient characteristics were associated with functional out-
come after immunotherapy in Hu-PNS patients. In contrast to previously suggested 
associations,9,20,60,62 we could only find a significant relation between prior disability 
and successful functional outcome (Table 4). Another possible factor may be the dis-
ease stage (progressive or stable). We did not include disease stage in this analysis, 
since data on disease stage were not reported on an individual basis in three of the 6 
studies.20,61,62 However, it must be noted that in these three studies, only one patient 
improved, and this patient had progressive PNS at the time of treatment.62 The other 
studies exclusively included patients with progressive PNS.58-60 Hence, progressive 
patients may respond better to immunotherapy than patients who already reached a 
plateau phase.
In addition, we found that in patients with detectable tumor, concurrent tumor 
treatment resulted significantly more often in functional improvement. This finding 
underlines the importance of tumor screening and anti-tumor treatment in patients 
with Hu-PNS. In these patients, we cannot determine the differential effects of the 
immunotherapy and anti-tumor therapy. However, also two patients improved after 
immunotherapy alone while a tumor could only be detected after 20-26 months.59,60 
Thus, tumor treatment seems important, but not obligatory, for functional improve-
ment in Hu-PNS patients who receive immunotherapy.
More effective immunotherapies are clearly needed. Based on the hypothesized im-
munopathogenesis (Figure 1), several newly available immunotherapies should be 
investigated.15,77,78 Examples are fingolimod, a drug that prevents egress of T cells from 
the lymph nodes by down regulation of the sphingosine 1-phosphate receptor,79 and 
natalizumab, a drug that prevents adhesion of T cells and other leukocytes to endothe-
lial cells by binding to very late activation antigen 4 (VLA-4) thereby preventing their 
extravasation and migration to the central nervous system.80 Alternatively, one could 
argue that combined suppression of T and B lymphocyte-mediated immune responses 
might be more effective than suppression of T lymphocyte-mediated immune respons-
es alone. An example of a single agent that suppresses both, T lymphocytes and B 
lymphocytes, is alemtuzumab (anti-CD52). Alemtuzumab leads to reduced numbers of 
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circulating T lymphocytes and B lymphocytes and is effective in multiple sclerosis.81,82 
Another strategy to suppress both B and T lymphocytes would be the combination of T 
cell-targeted therapy and CD20 monoclonal Abs such as rituximab or ofatumumab.58,83
To conclude, there is still insufficient evidence to recommend immunotherapy for all 
patients with PNS associated with well characterized onconeural Abs. In patients with 
Figure 1.
Schematic representation of the hypothetical immunopathogenesis of Hu-PNS. In the lung, 
expression of Hu-proteins (red dots) by cancer cells triggers an immune response against Hu 
proteins. Antigen presenting cells (APCs) present the Hu-proteins to naïve CD4+ and CD8+ T 
lymphocytes in the lymph nodes, while naïve B lymphocytes undergo an antigen-driven ger-
minal center reaction. These antigen-experienced ‘memory’ T and B lymphocytes enter the 
circulation, and travel to the lung. In the lung, the T lymphocytes are re-stimulated by APCs and 
produce pro-inflammatory cytokines that stimulate CD8+ T cells and B cells (CD4+ T cells, dashed 
arrows), or kill cancer cells by release of cytotoxic granules (CD8+ T cells, dashed red arrows). 
Additionally, some of these T and B lymphocytes enter the CSF via the choroid plexus (route 1, 
at disease initiation), or by adhesion to inflamed endothelium (route 2). The T cells in CSF are 
re-stimulated by APCs, migrate to the brain parenchyma and kill neurons that express the same 
Hu proteins. Simultaneously, B cells may contribute to the immunopathogenesis of Hu-PNS by 
antigen presentation (not shown) and production of pro-inflammatory cytokines (dashed ar-
rows). After stimulation by CD4+ T cells (dashed arrows), B cells can differentiate into plasma 
cells that produce anti-Hu antibodies. Not shown are the spleen (common place for the B cell 
germinal center reaction), and bone marrow (common place for antibody-producing plasma 
cells). Mechanisms involving natural killer (NK) cells are not depicted as these cells were absent 
in autopsy studies.35
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an identified tumor, immediate antitumor therapy is probably the most import factor 
contributing to stabilization or improvement of functional outcome. Immunotherapy 
may be considered in individual patients, especially patients with progressive PNS 
despite tumor treatment and patients without detectable tumor. In those patients, 
steroids and ivIg are well tolerated while cyclophosphamide or rituximab could be 
used as a second-line therapy.58,73 Available evidence underlines the need for more 
effective immunotherapies for PNS and the need for larger, controlled clinical trials. 
This will be a formidable challenge given the rarity and heterogeneity of PNS.
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LIST OF ABBREVIATIONS
(g)AchR acetylcholine receptor; g, ganglionic;
AMPAR α-amino-3-hydroxy-5-methyl-4-osixazolepropionic acid receptor
AN autonomic neuropathy
ANNA anti-neuronal nuclear antibody
APC antigen presenting cells
BE brainstem encephalitis
CNS central nervous system
CRMP collapsin response mediator protein
CSF cerebrospinal fluid
CTX cyclophosphamide
DNER delta/notch-like epidermal growth factor-related receptor
EM encephalomyelitis
GABABR gamma-aminobutyric acid B receptor
GAD glutamic acid decarboxylase
hCG human chorionic gonadotropin
ivIg intravenous immunoglobulins
LE limbic encephalitis
LEMS Lambert-Eaton myasthenic syndrome
mGluR metabotropic glutamate receptor.
MP methylprednisolone
mRS modified Rankin scale
NK cells natural killer cells
NMDAR N-methyl-D-aspartate receptor
ON ptic neuritis
PCA Purkinje cell cytoplasmatic autoantibodies
PCD paraneoplastic cerebellar degeneration
PE plasma exchange
PNS paraneoplastic neurological syndromes
SCLC small-cell lung cancer
SMN sensory motor neuropathy
SPS stiff-person syndrome
SSN subacute sensory neuronopathy
VGCC voltage-gated calcium channel
VGKC voltage gated potassium channel
VLA-4 very late activation antigen 4
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ABSTRACT
Background
Several lines of evidence suggest a T cell-mediated immune response in paraneoplas-
tic neurological syndromes with anti-Hu antibodies (Hu-PNS). In order to investigate 
whether suppression of T cell-mediated immune responses in Hu-PNS patients im-
proved their neurological outcome, we performed a prospective open-label, single-
arm study on sirolimus.
Methods
Seventeen progressive Hu-PNS patients were treated with sirolimus with an intended 
treatment duration of 8 weeks. Primary outcome measures were (i) functional im-
provement defined as a decrease of one or more points on the modified Rankin Scale 
(mRS), and (ii) improvement of neurological impairment defined as an increase of one 
or more points on the Edinburgh Functional Impairment Tests (EFIT).
Results
One patient showed improvement on both clinical scales (mRS and EFIT). This patient 
presented with limbic encephalitis and improved dramatically from an mRS score of 
3 to mRS 1. Another patient with subacute sensory neuronopathy remained stable 
at mRS 2, and improved one point on the EFIT scale. The other patients showed no 
improvement on the primary outcome measures. Median survival was 21 months.
Conclusion
We conclude that treatment of Hu-PNS patients with sirolimus may improve or 
stabilize their functional disabilities and neurological impairments. However, the 
effects of this T cell-targeted therapy were not better than reported in trials on other 
immunotherapies for Hu-PNS.
Trial Registration https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000793- 
20/NL
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INTRODUCTION
Among paraneoplastic neurological syndromes (PNS) with well-characterized onco-
neural antibodies, anti-Hu antibody-associated PNS (Hu-PNS) are the most frequent.1,2 
Hu-PNS have a very poor prognosis: more than half of the patients become bedridden 
(modified Rankin scale [mRS] score ≥4), only 2%-6% of patients improve, and median 
survival is < 12 months.3,4 Hu-PNS are thought to result from an immune response 
against Hu-expressing tumor cells that additionally destroys Hu-expressing neurons.5 
There are several reasons why neuronal destruction in Hu-PNS is more likely caused 
by T cells than anti-Hu antibodies (Hu-Ab): Hu proteins are intracellular proteins,6 
animal models failed to demonstrate Hu-Ab -induced neurological disease,7 and au-
topsy studies showed T cell infiltrates with frequent appositions of cytotoxic T cells to 
neurons with associated neuronal loss.8-10
Sirolimus (Rapamune ®) is an immunosuppressive drug that specifically inhibits 
activated T cells.11 Sirolimus binds to FKBP-12, an intracellular protein, to form an 
immunosuppressive complex that inhibits the regulatory kinase mammalian target 
of rapamycin (mTOR).11 This inhibition suppresses cytokine-mediated T cell prolif-
eration. As a result, T cells cannot proliferate following antigenic stimulation, and T 
cell-mediated immune responses are strongly suppressed. In addition, sirolimus has 
anti-oncogenic and anti-angiogenic effects that may prevent growth of the underlying 
tumor.12
We hypothesized that cellular immune suppression with sirolimus could stop neuro-
nal damage by the presumed T cell-mediated immune response in Hu-PNS, and may 
improve neurological outcome. To test this hypothesis, we prospectively treated 17 
progressive Hu-PNS patients with sirolimus, and recorded neurological function and 
impairment using well-defined clinical scales in a prospective open-label, single-arm 
study.
METHODS
Eligibility Criteria
Inclusion criteria included high serum titers of Hu-Ab (≥400 by indirect immunofluores-
cence, confirmed by Western blotting) and progression of neurological symptoms defined 
as neurological deterioration over the last four weeks. From May 2008 to October 2012, 
we identified 68 patients with high-titer Hu-Ab. Four of these patients died before test 
results became available. Eighteen patients did not meet the inclusion criteria according 
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to their treating physician: 12 had no progressive disease over the last 4 weeks, while 6 
patients had other potential causes for their neurological symptoms (toxic neuropathy 
or brain metastasis). Of the remaining 46 patients who were invited to participate in 
this study, 29 declined participation (mainly because of severe illness or unwillingness 
to travel to our institution) or did not respond to our invitation. Seventeen patients gave 
written informed consent and participated in this trial. Clinical characteristics of the 17 
included patients are summarized in Table 1. All patients were evaluated throughout 
the study by one of two clinical investigators (JEB, PASS). The study was approved by the 
Erasmus University Medical Center Institutional Review Board.
Treatment Plan
Sirolimus treatment was initiated with an oral loading dose of 6 mg sirolimus per day 
for 3 consecutive days, followed by oral maintenance dosing of 3 mg/day. The dosing 
was adjusted weekly to maintain trough concentrations of 8-12 ng/mL. If the patient was 
under co-therapy with drugs that induce or inhibit the activity of CYP3A4, the sirolimus 
dose was adjusted accordingly, under the guidance of the clinical pharmacologist. Pa-
tients were informed that any planned change in co-medication needed to be reported 
to the treating physician, in order to avoid adverse events due to drug-drug interactions.
Laboratory Tests
Serum and CSF were sampled at baseline and after 4 weeks of sirolimus treatment. 
Serum was additionally sampled at weeks 8 and 16. Sirolimus blood trough levels 
were determined in the clinical chemistry laboratory (target level 8-12 ng/ml) using a 
chromatographic assay. IgG titers of the Hu-Ab were determined, as described.3
Assessment of Efficacy
The primary endpoints of the study were the functional and neurological improve-
ment after 8 weeks of sirolimus. Functional improvement was defined as an decrease 
of one point or more on the modified Rankin scale (mRS) as compared with the 
baseline evaluation. Improvement of neurological impairment was assessed with the 
Edinburgh Functional Impairment Tests (EFIT), which incorporate objective measures 
of upper and lower limb function, memory and a rating scale for dysphasia.13 Overall 
EFIT = 0 indicates no change, EFIT > 0 indicates significant neurological improvement 
and EFIT < 0 indicates significant neurological deterioration.
Secondary endpoints included reduction of CSF protein and white blood cells (WBCs), 
decrease in Hu-Ab titers in serum and CSF, and improvement in activities of daily 
living (ADL) as evaluated by means of the Barthel index (BI).14 We additionally added a 
post-hoc analysis to enable comparison with previous studies. In this post-hoc analysis, 
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outcome was considered ‘successful’ when a patient with an mRS score ≤ 3 improved 
or stabilized (i. e. remained ambulatory) and when a patient with an mRS score ≥ 4 
(bedridden patient) improved to ≤ 3 (ambulatory), after the 8th week of sirolimus 
treatment as compared with baseline, as defined by Keime-Guibert et al.15
Statistical Methods
We compared WBC, total protein concentration and Hu-Ab titers in baseline CSF and 
CSF obtained after 4 weeks of treatment by means of the Wilcoxon matched pairs test. 
We used the same test to compare Hu-Ab serum titers at baseline and end of study. 
P-values were 2-sided and a significance level a = 0.05 was used. All statistical analyses 
were performed using GraphPad Prism version 5 software (GraphPad Software, Inc., 
San Diego, CA).
RESULTS
Patient Flow and Treatment
A total of 17 patients started treatment with sirolimus, 11 of whom completed the 
full 8 weeks of treatment (Table 2). Six patients of these 11 patients received sirolimus 
for 9-11 weeks because of low sirolimus blood levels during the titration phase. In 6 
patients, sirolimus treatment was terminated before 8 weeks. In 2 of these patients 
serious adverse events (SAE) related to sirolimus were reported (patients 8 and 15; 
see below). In 2 patients, withdrawal was requested for fear of increased hemato-
logical toxicity by oncologists in other hospitals who wanted to start treatment with 
chemotherapy. In 1 patient, sirolimus was withdrawn after 4 weeks because of obvi-
ous neurological deterioration and 1 patient died after 1 week of treatment of the 
neurological disorder. The range of the average daily sirolimus dose was 2.3 – 5.3 mg/
day resulting in average trough levels of 3.0 – 11.7 µg/L (Table 2).
Toxicity
As stated above, 2 patients were unable to complete the treatment because of serious 
adverse events. Patient 8 developed severe epistaxis that caused a drop in hemoglobin 
levels (from 5.3 to 4.8 mmol/l) requiring hospitalization and transfusion of 2 units of 
packed red cells. Sirolimus was stopped and the patient recovered completely (hemo-
globin 6.0 mmol/L). Patient 15 developed a generalized erythrodermia for which the 
consultation of a dermatologist was necessary. Sirolimus was withdrawn and topical 
corticosteroids were prescribed. Two weeks later, the patient was seen again by the 
dermatologist and the skin was recovering. One week later, the patient was admitted 
to the hospital because of a Staphylococcus aureus bacteriemia with the skin as possible 
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porte d’entrée. The patient recovered completely from the erythrodermia and the 
bacteriemia. Patient 1 developed oral mucositis, thrombocytopenia and hypokalemia 
from which he recovered completely.
Primary Endpoints
Only in patient 14 did the mRS score improve (from 3 to 1) with concomitant im-
provement of one point on the EFIT score (Table 3). This patient suffered from limbic 
encephalitis (memory deficits, sexual disinhibition and visual hallucinations) and 
received concomitant treatment with chemotherapy for the underlying small-cell 
lung cancer. After treatment, his memory and behaviour had improved dramatically, 
and he had no more hallucinations. Patient 5, with subacute sensory neuronopathy, 
improved one point on the EFIT scale while remaining stable at an mRS score of 2. 
Overall, 10 patients had stable mRS scores (59%), while 6 patients (35%) showed further 
functional deterioration. The neurological outcome (EFIT) was stable in 7 of 14 evalu-
able patients (50%) and deteriorated in 5 (36%).
Table 2. Sirolimus treatment duration and intensity
No. Sirolimus Reason Early Termination Concurrent
Weeks Average Daily 
Dose (mg)
Average Trough 
Level (µg/L)
Chemotherapy
1 8 3.0 7.1 NA Yes
2 3 3.0 3.1 Initiation chemotherapy No
3 9 3.0 4.8 NA No
4 8 5.0 3.4 NA No
5 9 3.0 5.2 NA Yes
6 5 3.8 3.9 Neurological deterioration No
7 1 3.0 Died of PNS No
8 4 3.8 4.1 SAE, severe epistaxis No
9 9 2.3 11.5 NA No
10 3 4.7 5.5 Initiation chemotherapy No
11 9 5.3 7.4 NA No
12 11 4.8 6.1 NA No
13 8 4.1 10.2 NA No
14 10 4.7 8.0 NA Yes
15 2 3.0 4.2 SAE, severe erythrodermia Yes
16 8 2.3 8.9 NA No
17 8 3.4 11.6 NA Yes
Abbreviations: SEA, serious adverse event; NA, not applicable.
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Secondary Endpoints
Improvement in activities of daily living (a rise of 5 points or more on the Barthel 
index) was seen in patients 11 (+15) and 13 (+20). Both patients had a stable mRS score 
of 4 and unchanged EFIT score. Laboratory evaluations showed in CSF a median of 5 
WBC/µL at baseline versus 5 WBC/µL after 4 weeks of treatment (P=0.38, n=12). The 
median CSF protein concentration was 0.42 g/L at baseline and 0.35 g/L after 4 weeks 
(P=0.12). The median CSF Hu-Ab titer changed from 32 at baseline to 64 at week 4 
(P=0.47). In serum, the median Hu-Ab titer at baseline was 3200, at 4 weeks 2400 
(P=0.16 vs baseline, n=12), at 8 weeks 1600 (P=0.03 vs baseline, n=11) and at 16 weeks 
800 (P=0.50 vs baseline, n=5).
Table 3. Primary outcome measures
No.
Sirolimus
(weeks)
Concurrent
Chemotherapy
Functional 
Outcome
mRS 
Baseline
mRS 
Change
Neurological 
Outcome
EFIT 
Baseline
EFIT 
Overall
1 8 Yes Stable 3 0 Stable 2 0
2 3 No Worse 2 1 Worse 0 -1
3 9 No Worse 3 2 Worse 3 -1
4 8 No Stable 3 0 Worse 4 -1
5 9 Yes Stable 2 0 Improved 2 1
6 5 No Worse 3 1 Worse 2 -1
7 1 No Worse 3 3 NEA 2
8 4 No Stable 3 0 StableB 2 0
9 9 No Stable 4 0 Stable 2 0
10 3 No Stable 3 0 NEC 1
11 9 No Stable 4 0 Stable 2 0
12 11 No Worse 3 1 Stable 2 0
13 8 No Stable 4 0 Stable 3 0
14 10 Yes Improved 3 -2 Improved 2 1
15 2 Yes Stable 3 0 NEC 1
16 8 No Worse 4 1 Worse 4 -2
17 8 Yes Stable 5 0 Stable 2 0
Abbreviations: NE, not evaluable.
A Patient died because of progressive PNS
B Patient’s PNS remained stable on sirolimus. After discontinuation because of side effects, her PNS 
progressed.
C EFIT score was not determined, mRS was determined by contacting patient and treating physician.
Functional and neurological outcome after up to 8 weeks of treatment with sirolimus. Abbrevia-
tions: mRS, modified Rankin scale; EFIT, Edinburgh Functional Impairment Tests; NE, not evaluable. 
An mRS change <0 indicated functional improvement; an mRS change of 0 indicated stable func-
tional outcome, an mRS change >0 indicated functional deterioration. An overall EFIT of > 0 indi-
cated neurological improvement, an overall EFIT of 0 indicated stable neurological function, while 
an overall EFIT < 0 indicated neurological progression.
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Post-hoc Analyses
According to the criteria of Keime-Guibert and colleagues, treatment response would 
be classified as ‘successful’ in 7 patients (41%; patients 1, 4, 5, 8, 10, 14 and 15).15 
Median survival was 21 months.
DISCUSSION
One patient showed a dramatic clinical improvement during sirolimus treatment with 
a decrease of 2 points on the mRS (from 3 to 1) and concomitant improvement on the 
overall EFIT of +1. Of the remaining patients, 59% had a stable functional outcome, 
while 35% showed further deterioration. Treatment response was ‘successful’ in 7 
patients (41%).15
Six other studies have reported treatment results in Hu-PNS patients using the mRS 
as the primary outcome measure, and have recently been reviewed elsewhere.16 In 3 
retrospective studies, treatment with plasma exchange and methylprednisolone with 
or without cyclophosphamide was successful in 0 of 6 (0%),17 intravenous immuno-
globulin treatment was successful in 6 of 17 (35%),18 while treatment with intravenous 
immunoglobulin, cyclophosphamide and methylprednisolone was successful in 2 of 
9 (22%)15 evaluable Hu-PNS patients. In a prospective study, treatment with plasma 
exchange combined with either cyclophosphamide or chemotherapy (in patients with 
a tumor) was successful in 3 of 5 (60%) Hu-PNS patients.19 In two prospective studies, 
rituximab was successful in 4 of 8 (50%)20 and human chorionic gonadotropin in 7 of 
15 (47%)21 Hu-PNS patients. The rate of success in the current study is within the range 
of the success rates of previous studies.
The current study suggests that immunosuppressive and immuomodulatory therapy 
may modify the course of Hu-PNS. However, several confounding factors may have 
contributed to these results. The patient who showed improvement on both primary 
outcome measures (patient 14) suffered limbic encephalitis, a syndrome that appears 
most responsive to treatment and can rarely spontaneously resolve, even in the pres-
ence of Hu-Abs.3 In addition, this patient received concomitant chemotherapy, and 
several studies have demonstrated that effective treatment of the tumor is important 
to at least stabilize Hu-PNS. 3,4 Four of the other 6 patients with a ‘successful’ outcome 
received chemotherapy with a complete response in 3 of them. Patient 5 had a long 
interval from symptom onset to diagnosis (11 months), which is also associated with 
a more favorable outcome.3
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During sirolimus treatment, we did not find significant changes in the CSF WBC count, 
protein concentration, nor Hu-Ab titers. Also, serum titers were not significantly af-
fected by sirolimus. The significant decrease in the serum titer at 8 weeks (P=0.03) 
probably reflects multiple testing.
To summarize, this study and other studies suggest that immunomodulation may 
modify the course of Hu-PNS. However, we can currently not conclude that T cell-
targeted therapies should be preferred above other immunotherapies, and more 
effective treatments are clearly needed.
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Summary and discussion
This thesis aimed to unravel the immunopathogenesis of paraneoplastic neurological 
syndromes with anti-Hu antibodies (Hu-PNS), and to contribute to the development of 
effective immunotherapy.
DETECTION OF HUD-SPECIFIC T LYMPHOCYTES
Since passive immunization of animals resulted in high titers of anti-Hu antibod-
ies but no disease and because of the intracellular localization of the Hu-antigens, 
it was hypothesized that anti-Hu antibodies are not pathogenic.1 Instead, neuronal 
destruction in Hu-PNS seems more likely caused by cytotoxic CD8+ T lymphocytes, 
as supported by the CD8+ T lymphocyte infiltrates around damaged neurons found 
at autopsy.1,2 Based on this hypothetical CD8+ T lymphocyte response, others and we 
have performed several studies to detect HuD-specific cytotoxic CD8+ T lymphocytes, 
but these studies often showed conflicting results.3-10 More recently, Roberts et al. 
described in three patients T lymphocyte responses to the HuD-derived T lymphocyte 
epitopes Hu133 and Hu157, and reported ‘type 2’ CD8+ T lymphocytes that secreted 
the type 2 cytokines IL-4, IL-5 and IL-13.6 The detection and further characterization 
of any HuD-specific T lymphocytes is of potential relevance to patients with Hu-PNS, 
since these lymphocytes could serve as a target for specific therapies. Therefore we 
aimed to confirm the presence of HuD-specific T lymphocytes in a relatively large 
group of 17 Hu-PNS patients in chapter 2. We used three highly sensitive assays to de-
tect classical ‘type 1’ cytotoxic T lymphocytes and ‘type 2’ CD8+ T lymphocytes. To gain 
maximal sensitivity, all procedures included the use of dendritic cells (DCs) to expand 
the number of any HuD-specific T lymphocytes. Despite using these 3 highly sensitive 
assays, we did not detect any HuD-specific T lymphocytes. The discrepancies between 
our results and those of Roberts et al.6 could be caused by methodological differ-
ences or differences in patient characteristics (especially a delay in patients inclusion). 
However, since our methods and patient characteristics were very similar to those of 
Roberts et al., we consider it unlikely that these factors would have accounted for our 
negative results. There are several possible explanations for our negative results. First, 
HuD-specific T lymphocytes may be preferentially found in or around target tissues 
such as CNS, dorsal roots or SCLC rather than in peripheral blood. As a consequence, 
the numbers of HuD-specific T cells in the blood might be extremely low and not 
detectable with even the most sensitive techniques. Second, HuD itself might not be 
the target of the hypothetical auto-aggressive T lymphocytes in Hu-PNS. Although the 
high expression of HuD in both neurons and SCLC lymphocytes makes HuD the most 
likely candidate, other proteins, such as the Hu-protein Hel-N1 which is also expressed 
by neurons and SCLC cells, may be involved.11 Even proteins that do not belong to the 
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family of Hu proteins may be involved, despite the presence of high titers of Hu-Ab 
in Hu-PNS patients. An example is celiac disease, in which a B lymphocyte response 
is seen that is targeted against the enzyme tissue transglutaminase itself, while T 
lymphocyte responses are targeted at the products of this enzyme.12 In summary, we 
propose that auto-aggressive T lymphocytes in Hu-PNS either do not target HuD, or are 
extremely rare in the blood which makes their detection extremely demanding and 
certainly not feasible for clinical application. Finally, Hu-PNS might not be caused by 
auto-reactive T cells at all.
CELLULAR COMPOSITION OF CEREBROSPINAL FLUID IN HU-PNS
In chapter 3, we reviewed the use of flow cytometry to study the cellular components 
of cerebrospinal fluid (CSF). In the clinic, CSF flow cytometry is used for detection 
of leptomeningeal localizations of hematological malignancies. In research settings, 
flow cytometry is used to study the cellular composition of CSF in neuro-inflammatory 
diseases such as multiple sclerosis and PNS. In order to reliably compare the cellular 
composition of CSF of Hu-PNS patients with the cellular composition of control pa-
tients, we first investigated the effect CMV carrier status on T lymphocyte subsets in 
the CSF of patients with non-inflammatory disorders in chapter 4. In the blood, CMV 
carrier status is known to significantly increase the numbers of effector memory and 
late memory T lymphocytes.13 We did not find a significant effect of CMV carrier status 
on T lymphocyte subsets in CSF. Hence, there was no need to stratify for CMV carrier 
status when comparing T lymphocyte subsets in CSF of Hu-PNS patients with those of 
(i) patients with other inflammatory neurological disorders (IND) of non-paraneoplastic 
origin and (ii) patients with other non-inflammatory neurological disorders (OND) in 
chapter 5. In this chapter, we found higher numbers of regulatory T lymphocytes, 
central memory T lymphocytes, class-switched memory B lymphocytes and dendritic 
cells in CSF of Hu-PNS patients than in OND patients. These findings in the absence 
of similar findings in the blood of Hu-PNS patients indicate that their immune system 
is locally activated and support a role for cytotoxic T lymphocytes, T helper lympho-
cytes and B lymphocytes as well as regulatory T lymphocytes and dendritic cells in 
the pathogenesis of Hu-PNS. In all studies on CSF described above, we stabilized CSF 
samples with serum-containing medium, since otherwise, rapid cellular decay would 
occur directly after withdrawal of CSF from the body.14 The serum-containing me-
dium we used is not commercially available, and has a limited shelf life of 3 months. 
Recently, a novel CSF-stabilizing agent came on the market that has a shelf life of 12 
months (TransFixTM).15 In chapter 6, we studied the effects of this commercially avail-
able CSF-stabilizing agent on cellular loss in CSF and the detection of leptomeningeal 
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localizations of hematological malignancies as detected by flow cytometry. We found 
that TransFix™ prevented cellular loss, and enhanced the flow-cytometric detection of 
leptomeningeal localizations of hematological malignancies after 18 hours of storage. 
Hence, TransFixTM may be an attractive alternative for our serum-containing medium 
in future studies.
TREATMENT OF HU-PNS
In chapter 7, we reviewed the available evidence on immunotherapy in Hu-PNS and 
other PNS with well characterized onconeural antibodies. To improve the poor func-
tional outcome in these patients, various immunotherapies have been used including 
plasma exchange, ivIg, rituximab, steroids and cyclophosphamide.16-21 In patients with 
Hu-PNS, treatment with immunotherapy resulted in functional improvement, defined 
as an improvement of ≥1 point on the modified rankin scale (mRS), in 11% (7/61) of 
patients,16-21 and median survival from the start of immunotherapy was 10 months 
(range 0 to >48).16-21 In patients with PNS with anti-Yo antibodies (Yo-PNS), 8% (2/26) 
of patients showed functional improvement (of ≥ 1 point on the mRS), and survival 
from the start of immunotherapy was 18 months (range, 2 to >53),16,17,19,21 Also in PNS 
with other well characterized onconeural antibodies, the effects of immunotherapy 
were very limited. In patients with an identified tumor, immediate antitumor therapy 
is probably the most important factor contributing to better functional outcome. 
The available evidence underlined the need for more effective immunotherapies for 
PNS. In chapter 8, we describe the results of a clinical trial in which we treated Hu-
PNS patients with sirolimus, an inhibitor of activated T lymphocytes. In this trail, 1 
patient showed functional improvement (of ≥ 1 point on the mRS) and improvement 
of neurological impairment (as measured with the Edinburgh Functional Impairment 
Tests) while another patient only showed improvement of neurological impairment. 
If we apply the criteria of Keime-Guibert17 and collegues, than treatment response 
would be classified as successful in 41% (7/17) patients, which is within the range 
of previous studies.16-21 Thus, sirolimus may modify the course of Hu-PNS but our 
results might be influenced by several confounding factors, such as the predominant 
paraneoplastic syndrome (i.e. limbic encephalitis versus other PNS such as subacute 
sensory neuronopathy), concomitant chemotherapy and long interval from symptom 
onset to diagnosis.22,23 To conclude, there is still insufficient evidence to recommend 
immunotherapy for all patients with Hu-PNS or other PNS with well characterized 
onconeural antibodies. Immunotherapy may be considered in individual patients, 
especially patients with progressive PNS despite tumor treatment and patients with-
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out detectable tumor. In those patients, steroids and ivIg are well tolerated while 
cyclophosphamide or rituximab could be used as a second-line therapy.18,24
DIRECTIONS FOR FUTURE RESEARCH
Future research should focus on the role of the effector T lymphocytes found in the 
CSF and nervous tissue of Hu-PNS and their interplay with other components of the 
immune system, including regulatory T lymphocytes, B lymphocytes and dendritic 
cells. Hopefully, novel techniques such as single-cell PCR and the ability to isolate 
functionally active lymphocytes at autopsy will help to further elucidate the immune 
response in Hu-PNS.25 Regarding the development of immunotherapy, we propose 
two treatment strategies that should be further investigated. First, therapies should 
be investigated that potently suppress T lymphocyte mediated immune responses 
in the CNS. Examples are fingolimod, a drug that prevents egress of T lymphocytes 
from the lymph nodes by down regulation of the sphingosine 1-phosphate recep-
tor,26 and natalizumab, a drug that prevents adhesion of T lymphocytes and other 
leukocytes to endothelial cells by binding to very late activation antigen 4 (VLA-4) 
thereby preventing their extravasation and migration to the central nervous system.27 
Second, combined suppression of T lymphocyte-mediated immune responses and B 
lymphocyte-mediated immune responses might be more effective than suppression 
of T lymphocyte-mediated immune responses alone. An example of a single agent 
that suppresses both, T lymhocytes and B lymphocytes, is alemtuzumab (anti-CD52). 
Alemtuzumab leads to reduced numbers of circulating T lymphocytes and B lympho-
cytes and has shown effective in multiple sclerosis.28,29 Alternatively, the combination 
of T lymphocyte-targeted therapy and rituximab treatment could be investigated.18 
Finally, there is a need for larger, controlled clinical trials, which will be a formidable 
challenge given the rarity and heterogeneity of Hu-PNS.
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SAMENVATTING
Het onderzoek beschreven in dit proefschrift had tot doel om de onderliggende 
mechanismen die leiden tot paraneoplastische syndromen met anti-Hu antistoffen 
(Hu-PNS) te ontrafelen. Hu-PNS zijn effecten-op-afstand van kanker, die niet direct 
veroorzaakt worden door de tumor of metastasen. Waarschijnlijk worden Hu-PNS 
veroorzaakt door een immuunrespons tegen de tumor, die zich ook richt tegen het 
zenuwweefsel. Een mogelijk doelwit van deze immuunrespons is HuD, een eiwit dat 
zowel in bepaalde kankercellen als in neuronen tot expressie komt.
DETECTIE VAN HUD-SPECIFIEKE T CELLEN
Op basis van de observatie dat passieve immunisatie van proefdieren wel leidde tot 
hoge anti-Hu antistoftiters maar niet tot ziekte, kwam men tot de hypothese dat 
Hu-PNS niet wordt veroorzaakt door anti-Hu antistoffen, maar door HuD-specifieke T 
cellen. In hoofdstuk 2 beschrijven wij ons onderzoek gericht op het detecteren van 
deze hypothetische HuD-specifieke T cellen in het bloed van patiënten met Hu-PNS. 
We gebruikten drie zeer gevoelige detectiemethoden, maar detecteerden desondanks 
geen HuD-specifieke T cellen. Mogelijke verklaringen hiervoor zijn onder andere: (1) 
dat Hu-PNS wel worden veroorzaakt door HuD-specifieke T cellen, maar dat deze zich 
vooral in kanker- en zenuwweefsels bevinden en niet in het bloed; (2) dat Hu-PNS wel 
worden veroorzaakt door T cellen, maar dat deze T cellen niet HuD-specifiek zijn; of 
(3) dat Hu-PNS toch niet worden veroorzaakt door anti-neuronale T cellen.
CELLULAIRE COMPOSITIE VAN LIQUOR CEREBROSPINALIS IN HU-PNS
Hoofdstuk 3 geeft een overzicht van de toepassingen van flowcytometrie van liquor 
cerebrospinalis. Met flowcytometrie kunnen leukocyten in liquor cerebrospinalis wor-
den geteld en getypeerd. Deze techniek wordt gebruikt voor het detecteren van lep-
tomeningeaal gelocaliseerde hematologische maligniteiten en voor wetenschappelijk 
onderzoek naar neurologische ontstekingsziekten zoals multipele sclerose en Hu-PNS. 
In hoofdstuk 4 onderzochten we het effect van cytomegalovirus(CMV)-dragerschap 
op de het aantal effector- T cellen in liquor cerebrospinalis. In de tegenstelling tot in 
het bloed was het aantal effector-T cellen in liquor cerebrospinalis van proefpersonen 
die drager zijn van het CMV virus niet verhoogd. Deze kennis was nodig om een 
betrouwbare vergelijking te kunnen maken van de cellulaire compositie van liquor 
cerebrospinalis van Hu-PNS patiënten met die van controlepatiënten in hoofdstuk 5. 
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Liquor cerebrospinalis van Hu-PNS patiënten bevat verhoogde aantallen van regula-
toire T cellen, central memory-T cellen, memory-B lymfocyten en dendritische cellen. 
Deze cellen spelen mogelijk een rol in de pathogenese van Hu-PNS. In hoofdstuk 4 en 
5 maakten we gebruikt van een mediumvloeistof om ervoor te zorgen dat leukocyten 
intact bleven tijdens transport van de patiënt naar ons laboratorium. In hoofdstuk 6 
onderzochten we een nieuwe commerciele vloeistof om deze leukocyten te stabilise-
ren, genaamd TransFixTM. Het blijkt dat dit middel voordelen heeft om leukocyten te 
stabliseren tijdens transport naar een flowcytometrie laboratorium. De cellen bleven 
langer gestabiliseerd waardoor ze ook na 18 uur bewaren beter onderzocht konden 
worden. Dit is nuttige kennis voor toekomstige onderzoeken naar leukocyten in 
liquor cerebrospinalis.
BEHANDELING VAN HU-PNS
Hoofdstuk 7 is een review van alle studies die met immunotherapie hebben gepro-
beerd om het functioneren van patiënten met Hu-PNS te verbeteren. Helaas is er nog 
geen bewezen werkzame immunotherapie voor Hu-PNS. Slechts 11% van de patiënten 
ging in functioneren vooruit, en de mediane overleving was 10 maanden. In hoofdstuk 
8 beschrijven we de resultaten van onze studie met het middel sirolimus, een remmer 
van geactiveerde T cellen. De resultaten van deze studie suggereerden een beperkt 
effect, vergelijkbaar met effecten die beschreven waren in voorgaande studies. Er is 
dus nog steeds onvoldoende bewijs om standaard immunotherapie toe te passen bij 
patiënten met Hu-PNS, en behandeling van de onderliggende tumor is de aangewezen 
therapie. In individuele gevallen kan wel immunotherapie overwogen worden, met 
name wanneer er progressie is ondanks behandeling van de onderliggende tumor, of 
wanneer er geen tumor kan worden aangetoond.
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PHD PORTFOLIO
Year Workload
(ECTS)
General courses
Basiscursus Regelgeving Klinisch Onderzoek, examen Good Clinical Practice 2010 1.5
Introduction to Data-Analysis, Netherlands Institute for Health Sciences (overall 
mark 8.5)
2010 1.5
English Biomedical Writing and Communication 2010-2011 4
In-depth courses
Geavanceerde beeldvormende technieken voor dokters 2009 0.5
Biomedical research techniques IX, day 1 and 2 2010 0.5
Advanced Course “Molecular Immunology” 2010 1.5
European Association of Neuro Oncology Educational Day 2010 0.5
7th course on Leukemia/lymphoma immunophenotyping, European Society
for Clinical Cell Analysis, Dublin, Ireland
2011 0.5
Cursus Neuro-anatomie en radiologie 2013 1
National conferences
Wetenschappelijke dag, Landelijke Werkgroep Neuro-Oncologie 2010 0.5
Symposium Medische Immunologie 2010 0.5
Landelijke werkgroep Neuro-Oncologie investigators 2011 0.5
Wetenschappelijke vergadering, Nederlandse Vereniging voor Neurologie 2012 0.5
Molecular Medicine Day, Molecular Medicine Postgraduate School 2012 0.5
International conferences
9th meeting of the European Association of Neuro Oncology, Maastricht, the 
Netherlands
2010 21
Measuring Antigen-Specific Immune Responses, Mykonos, Greece 2010 1.5
11th Euroconference, European Society for Clinical Cell Analysis, Dublin, Ireland 2011 1.5
12th Euroconference, European Society for Clinical Cell Analysis, Budapest, 
Hungary
2012 1.5
Oral presentations
Josephine Nefkens Institute meeting 2010 0.5
Wetenschappelijke dag, Landelijke Werkgroep Neuro-Oncologie 2010 0.5
9th meeting of the European Association of Neuro Oncology 2010 0.5
Landelijke werkgroep Neuro-Oncologie investigators 2011 0.5
12th Euroconference, European Society for Clinical Cell Analysis, Budapest, 
Hungary
2012 0.5
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Poster presentations
Measuring Antigen-Specific Immune Responses, Mykonos, Greece 2010 0.5
10th Euroconference, European Society for Clinical Cell Analysis, Valencia, Spain 2010 0.5
11th Euroconference, European Society for Clinical Cell Analysis, Dublin, Ireland 2011 0.5
Molecular Medicine Day, Molecular Medicine Postgraduate School 2012 0.5
Seminars and workshops
Workshop on Photoshop and Illustrator CS5 2011 0.3
Workshop Writing Successful Grant Proposals 2012 0.5
Teaching activities
Teaching nursing staff 2011 0.5
Teaching students MSc Neuroscience 2011-2012 1.0
Teaching students MSc Infection and Immunity 2011-2012 1.0
Reviewing papers for international peer-reviewed journals 2012-2014 1.0
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